[go: up one dir, main page]

US20180194731A1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
US20180194731A1
US20180194731A1 US15/811,490 US201715811490A US2018194731A1 US 20180194731 A1 US20180194731 A1 US 20180194731A1 US 201715811490 A US201715811490 A US 201715811490A US 2018194731 A1 US2018194731 A1 US 2018194731A1
Authority
US
United States
Prior art keywords
compound
nmr
mhz
hrms
calcd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/811,490
Inventor
Liqiang Chen
Teng Ai
Swati More
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Priority to US15/811,490 priority Critical patent/US20180194731A1/en
Publication of US20180194731A1 publication Critical patent/US20180194731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • SIRT2 is a member of the mammalian sirtuin (NAD + -dependent histone deacetylase) family that comprises SIRT1-7 (Houtkooper, R. H., et al., Nat. Rev. Mol. Cell Biol. 2012, 13, 225-238). SIRT2 is the only sirtuin that predominantly resides in the cytosol even though it is localized in the nucleus during mitosis. Interestingly, an alternatively spliced isoform has been reported to permanently reside in the nucleus. As the most abundant sirtuin homolog in the brain (Pandithage, R., et al., J. Cell Biol.
  • SIRT2 has emerged as an important regulator in brain physiology and pathology (Harting, K., et al., Eur. J. Cell Biol. 2010, 89, 262-269).
  • PD Parkinson's disease
  • overexpression of SIRT2 induced neuronal apoptosis Pfister, J. A., et al., PLoS One 2008, 3, e4090.
  • blocking SIRT2 protected cells from the neurotoxicity induced by ⁇ -synuclein, a risk factor associated with the familial PD, in the cellular and fruit fly models of PD (Outeiro, T.
  • SIRT2 exacerbated the nigrostriatal neurotoxicity induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) while genetic deletion (Liu, L., et al., Front. Aging Neurosci. 2014, 6, 184) or pharmacological inhibition (Chen, X., et al., PLoS One 2015, 10, e0116919) of SIRT2 prevented MPTP-induced neurodegeneration in mice. Furthermore, as a major deacetylase of ⁇ -tubulin (North, B. J., et al., Mol.
  • SIRT2 decreased the acetylation level of microtubules, enhancing their association with pathologically mutated leucine-rich kinase 2 (LRRK2) in the Roc-COR domain (R1441C and Y1699C). While this strengthened association impaired axonal transport, genetic knockdown of SIRT2 restored both axonal transport and locomotion in fruit flies (Godena, V. K., et. al., Nat. Commun. 2014, 5, 5245).
  • LRRK2 pathologically mutated leucine-rich kinase 2
  • SIRT2 may also provide protection in other neurodegenerative diseases.
  • inhibition of SIRT2 had a protective effect in a cellular model of multiple system atrophy (Hasegawa, T., et al., Neurochem. Int. 2010, 57, 857-866), which is one form of synucleinopathy like PD.
  • SIRT2 inhibiting SIRT2 offered neuroprotection in the fly, worm, and primary striatal neuron models of Huntington's disease, likely by reducing sterol biosynthesis ((a) Luthi-Carter, R., et al., Proc. Natl. Acad. Sci. U.S.A 2010, 107, 7927-7932; (b) Taylor, D. M., et al., ACS Chem. Biol. 2011, 6, 540-546), even though the therapeutic potential still remains to be unequivocally defined.
  • SIRT2 inhibitors have been explored for their potential therapeutic applications in the mouse models of tauopathies, such as Alzheimer's disease (AD) (Green, K. N., et al., J. Neurosci.
  • SIRT2 has been shown as a key player in the transcription regulation signalling initiated by bacterial infection, suggesting that blocking host SIRT2 may be a viable approach to fight bacterial infection (Eskandarian, H. A., et al., Science 2013, 341, 1238858). Furthermore, there are studies that suggest that SIRT2 inhibitors can be therapeutically useful in the treatment of cancer ((a) Hu, J.; Jing, H.; Lin, H., Future Med. Chem. 2014, 6, 945-966; (b) Soung, Y. H., et al., Sci. Rep.
  • SIRT2 inhibitors can also be useful for the treatment of sepsis (Zhao, T., et al., Curr. Mol. Med. 2015, 15, 634.) and hepatic fibrosis (Arteaga, M., et al., Am. J. Physiol. Gastrointest. Liver Physiol. 2016, 310, G1155), and for the control of platelet function (Moscardó, A., et al., J. Thromb. Haemost. 2015, 13, 1335).
  • agents that are useful for inhibiting SIRT2. Such agents may be useful to treat pathologies associated with SIRT2, such as, for example, Parkinson's disease.
  • the invention provides compounds that are inhibitors of SIRT2. Accordingly, in one embodiment the invention provides a compound of formula (I):
  • X is CH or N
  • Y is CH or N
  • A is selected from the group consisting of: -A′-B′—,
  • A′ is selected from the group consisting of:
  • B′ is phenyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl, 5-membered heteroaryl, and 6-membered heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy;
  • C is selected from the group consisting of:
  • D is selected from the group consisting of (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -C 15 )carbocycle, aryl, and heteroaryl, wherein the (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -C 15 )carbocycle, aryl, and heteroaryl, are optionally substituted with one or more groups R z independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NR a R b , —C( ⁇ O)NR a R b , —N—S(O) 2 R a , —NR a C( ⁇ O)NR a R b , (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C
  • each R a and R b is independently selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, (C 1 -C 4 )alkanoyloxy, aryl, and heteroaryl, wherein any (C 1 -C 4 )alkyl, (C 3 -C 5 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, and (C 1
  • each R c and R d is independently selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )alkoxy, wherein any (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, and (C 1 -C 4 )alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, (C 3 -C 15 )carbocycle, (
  • R e is selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, aryl, and (C 1 -C 4 )alkanoyl, wherein any (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )alkanoyl is optionally substituted with one or more groups independently selected from halo and aryl, and wherein any aryl is optionally substituted with one or more groups independently selected from halo deuterium, nitro, cyano, hydroxy, carboxy, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C
  • R x is (C 1 -C 4 )alkyl that is substituted with one or more (e.g. 1, 2, 3, or 4) groups independently selected from oxo, carboxy, (C 1 -C 4 )alkoxycarbonyl, and amino;
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
  • the invention also provides a method for inhibiting the activity of SIRT2 in vitro or in vivo comprising contacting the SIRT2 with a compound of formula (I) or a salt thereof.
  • the invention also provides a method for inhibiting the activity of SIRT2 in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating Parkinson's disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating neurodegeneration in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating a neurodegenerative disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for promoting neuroprotection in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating Alzheimer's disease (AD) or frontotemporal dementia in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • AD Alzheimer's disease
  • frontotemporal dementia in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating a bacterial infection in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating cancer in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a method for treating kidney disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medical therapy.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a SIRT2 associated disorder.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of Parkinson's.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of neurodegeneration.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a neurodegenerative disease.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for promoting neuroprotection.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of Alzheimer's disease (AD) or frontotemporal dementia.
  • AD Alzheimer's disease
  • frontotemporal dementia a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of Alzheimer's disease (AD) or frontotemporal dementia.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a bacterial infection.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of kidney disease.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of cancer.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for inhibiting the activity of SIRT2 in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1 - 13 to prepare a medicament for treating Parkinson's disease in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating neurodegeneration in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a neurodegenerative disease in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for promoting neuroprotection in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating Alzheimer's disease (AD) or frontotemporal dementia in an animal.
  • AD Alzheimer's disease
  • frontotemporal dementia in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a bacterial infection in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating cancer in an animal.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating kidney disease in an animal.
  • the invention also provides processes and intermediates disclosed herein that are useful for preparing a compound of formula I or a salt thereof.
  • halo is fluoro, chloro, bromo, or iodo.
  • Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to.
  • Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
  • Heteroaryl encompasses a radical of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C 1 -C 4 )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic ring of about eight to ten ring atoms comprising one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X).
  • carrier or “carbocyclyl” refers to a single saturated (i.e., cycloalkyl) or a single partially unsaturated (e.g., cycloalkenyl, cycloalkadienyl, etc.) all carbon ring having 3 to 7 carbon atoms (i.e., (C 3 -C 7 )carbocycle).
  • carrier or “carbocyclyl” also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings).
  • carbocycle includes multicyclic carbocyles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 carbon atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and polycyclic carbocycles (e.g tricyclic and tetracyclic carbocycles with up to about 20 carbon atoms).
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • multicyclic carbocyles can be connected to each other via a single carbon atom to form a spiro connection (e.g., spiropentane, spiro[4,5]decane, etc), via two adjacent carbon atoms to form a fused connection (e.g., carbocycles such as decahydronaphthalene, norsabinane, norcarane) or via two non-adjacent carbon atoms to form a bridged connection (e.g., norbornane, bicyclo[2.2.2]octane, etc).
  • carbocycle includes a 3-15 membered carbocycle.
  • carbocycle includes a 3-8 membered carbocycle.
  • carbocycle includes a 3-6 membered carbocycle.
  • carbocycle includes a 3-5 membered carbocycle.
  • the atom to which the bond is attached includes all stereochemical possibilities.
  • a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge)
  • a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge)
  • the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted.
  • the compound may be at least 51% the absolute stereoisomer depicted.
  • the compound may be at least 60% the absolute stereoisomer depicted.
  • the compound may be at least 80% the absolute stereoisomer depicted.
  • the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.
  • (C 1 -C 6 )alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl;
  • (C 3 -C 8 )cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl;
  • (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl;
  • (C 1 -C 6 )alkoxy can be
  • the invention also provides a compound of formula (Ia):
  • the invention also provides a compound of formula (Ib):
  • the invention also provides a compound of formula (Ic):
  • the invention also provides a compound of formula (Id):
  • the invention also provides a compound of formula (Ie):
  • X is CH and Y is N; or X is N and Y is CH; or X is N and Y is N; or a salt thereof.
  • the invention also provides a compound of formula (I), wherein:
  • A is-A′-B′—
  • A′ is selected from the group consisting of:
  • B′ is phenyl wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl is substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • the invention also provides a compound of formula (If):
  • V is CH and W is N; or V is N and W is CH; or V is N and W is N; or a salt thereof.
  • the invention also provides a compound of formula (Ig):
  • R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • the invention also provides a compound of formula (Ih):
  • R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • the invention also provides a compound of formula (Ii):
  • R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • the invention also provides a compound of formula (I), wherein D is selected from the group consisting of methyl, ethyl, vinyl, naphthyl, cyclohexyl, adamantly, cyclohex-1-enyl, thienyl, benzothienyl, benzofuranyl, indolyl, benzothiazolyl, indazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, and pirazinyl, wherein D is optionally substituted with one or more groups R z independently selected from halo, deuterium, nitro, hydroxy, cyano, —NR a R b , —N—S(O) 2 R a , —NR a C( ⁇ O)NR a R b , (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )
  • the invention also provides a compound of formula (I), wherein D is selected from the group consisting of naphthyl, cyclohexyl, adamantly, cyclohex-1-enyl, thienyl, benzothienyl, benzofuranyl, indolyl, benzothiazolyl, indazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, and pirazinyl, wherein D is optionally substituted with one or more groups R z independently selected from halo, deuterium, nitro, hydroxy, cyano, —NR a R b , —N—S(O) 2 R a , —NR a C( ⁇ O)NR a R b , (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -
  • the invention also provides a compound of formula (I), wherein D is substituted with —NR a R b ; or a salt thereof.
  • the invention also provides a compound of formula (I), wherein R a is (C 1 -C 4 )alkanoyl, that is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, (C 3 -C 15 )carbocycle, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxycarbonyl, (C 1 -C 4 )alkanoyloxy, oxo ( ⁇ O), aryl, and heteroaryl, and wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, nitro, cyano, carboxy, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 3 -Cis)carbocycle, —NR c R d , —C( ⁇ O
  • the invention also provides a compound of formula (I), wherein R a and R b together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino and piperidino is optionally substituted with one or more groups independently selected from halo and (C 1 -C 4 )alkyl; or a salt thereof.
  • the invention also provides a compound of formula (I):
  • X is CH or N
  • Y is CH or N
  • A is selected from the group consisting of: -A′-B′—,
  • A′ is selected from the group consisting of:
  • B′ is phenyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl, 5-membered heteroaryl, and 6-membered heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy;
  • C is selected from the group consisting of:
  • D is selected from the group consisting of (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -Cis)carbocycle, aryl, and heteroaryl, wherein the (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -Cis)carbocycle, aryl, and heteroaryl, are optionally substituted with one or more groups R z independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NR a R b , —C( ⁇ O)NR a R b , —N—S(O) 2 R a , —NR a C( ⁇ O)NR a R b , (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4
  • each R a and R b is independently selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, (C 1 -C 4 )alkanoyloxy, aryl, and heteroaryl, wherein any (C 1 -C 4 )alkyl, (C 3 -C 5 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, and (C 1
  • each R c and R d is independently selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )alkoxy, wherein any (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkanoyl, (C 1 -C 4 )alkoxycarbonyl, and (C 1 -C 4 )alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, (C 3 -Cis)carbocycle, (C
  • R e is selected from the group consisting of H, (C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, aryl, and (C 1 -C 4 )alkanoyl, wherein any (C 1 -C 4 )alkyl, (C 3 -C 5 )cycloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, and (C 1 -C 4 )alkanoyl is optionally substituted with one or more groups independently selected from halo and aryl, and wherein any aryl is optionally substituted with one or more groups independently selected from halo deuterium, nitro, cyano, hydroxy, carboxy, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C
  • a salt of a compound of formula I can be useful as an intermediate for isolating or purifying a compound of formula I.
  • administration of a compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate.
  • pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
  • the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
  • a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
  • the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • IC1b (2.50 g, 14.1 mmol) was reduced with NaBH 4 (1.07 g, 28.2 mmol) in MeOH to give IC2d as a light yellow solid (2.40 g, 95%).
  • 1 H NMR (CDCl 3 , 600 MHz) ⁇ 8.26-8.22 (m, 1H), 8.14-8.10 (m, 1H), 7.39-7.35 (m, 1H), 5.34-5.28 (m, 1H), 3.16-3.09 (m, 1H), 2.94-2.86 (m, 1H), 2.63-2.56 (m, 1H), 2.09-2.01 (m, 1H).
  • IC2a (1.28 g, 7.16 mmol), methyl 5-hydroxynicotinate (1.32 g, 8.59 mmol), and Ph3P (2.82 g, 10.7 mmol) in anhydrous THF (45 mL) at rt was added DIAD (2.17 g, 10.7 mmol) dropwise. After the mixture was stirred for 12 h and the solvent removed, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford IC3a as a yellow solid (1.70 g, 76%).
  • IC3d was prepared from IC2d (1.14 g, 6.34 mmol) as a yellow solid (1.30 g, 65%).
  • HRMS ESI + calcd for C 16 H 15 N 2 O 5 (M+H) + 315.0975, found 315.0988.
  • IC1a (1.77 g, 10.0 mmol) was reduced with BH 3 .SMe 2 (1.00 mL, 10.0 mmol) in the presence of (S)—CBS (139 mg, 0.50 mmol) to give IC2c as a white solid (1.61 g, 90%).
  • IC1b (1.00 g, 5.65 mmol) was reduced with BH 3 .SMe 2 (0.57 mL, 5.65 mmol) in the presence of (S)—CBS (78 mg, 0.28 mmol) in DCM to give IC2e (850 mg, 84%) as a light yellow solid.
  • IC1b (1.00 g, 5.65 mmol) was reduced with BH 3 .SMe 2 (0.57 mL, 5.65 mmol) in the presence of (R)—CBS (78 mg, 0.28 mmol) to give IC2f as a light yellow solid (900 mg, 89%).
  • IC2c 500 mg, 2.79 mmol
  • methyl 5-hydroxynicotinate 513 g, 3.35 mmol
  • DIAD DIAD
  • Ph 3 P methyl 5-hydroxynicotinate
  • IC2b 500 mg, 2.79 mmol
  • methyl 5-hydroxynicotinate 513 g, 3.35 mmol
  • DIAD DIAD
  • Ph 3 P methyl 5-hydroxynicotinate
  • IC2f 550 mg, 3.07 mmol
  • methyl 5-hydroxynicotinate 554 g, 3.68 mmol
  • DIAD DIAD
  • Ph 3 P methyl 5-hydroxynicotinate
  • IC2e 700 mg, 3.91 mmol
  • methyl 5-hydroxynicotinate 718 g, 4.69 mmol
  • DIAD DIAD
  • Ph 3 P methyl 5-hydroxynicotinate
  • IC7a (468 mg, 2.42 mmol) and methyl 5-hydroxynicotinate (371 mg, 2.42 mmol) were treated with DIAD and Ph 3 P to afford IC8a as a yellow solid (600 mg, 75%).
  • IC7b (505 mg, 3.30 mmol) and methyl 5-hydroxynicotinate (638 mg, 3.30 mmol) were treated with DIAD and Ph 3 P to afford IC8b as a yellow solid (810 mg, 75%).
  • ID12 200 mg, 0.77 mmol
  • NH 3 /MeOH ca. 7N, 5 mL
  • a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the solution was washed with H 2 O (150 mL) and brine (100 mL). The organic layer was dried over Na 2 SO 4 , concentrated, and the residue was purified by flash column chromatography (5% MeOH/CH 2 Cl 2 ) to afford ID13 as a light brownish solid (56 mg, 30%).
  • ID16 (490 mg, 1.60 mmol) and NiCl 2 .6H 2 O (761 mg, 3.20 mmol) in MeOH (100 mL) was slowly added NaBH 4 (242 mg, 6.40 mmol) and the mixture was allowed to stir at rt for 3 h. The reaction was quenched with saturated NH 4 Cl (50 mL) and the mixture was extracted with EtOAc. The organic phase washed with water and brine, dried over anhydrous K 2 CO 3 , and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID17 as a white solid (120 mg, 27%).
  • ID35 (1.10 g, 7.09 mmol) and CBr 4 (2.82 g, 8.51 mmol) in CH 2 C 12 (100 mL) was added Ph 3 P (2.23 g, 8.51 mmol) and the reaction mixture was allowed to stir at rt for 12 h. After removal of the solvent, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID36 as a yellow oil (1.33 g, 86%).
  • ID37 800 mg, 2.76 mmol
  • NiCl 2 .6H 2 O 1.31 g, 5.52 mmol
  • MeOH 100 mL
  • NaBH 4 420 mg, 11.04 mmol
  • the reaction was quenched with saturated NH 4 Cl (50 mL) and the mixture was extracted with EtOAc.
  • the organic phase was washed with water and brine, dried over anhydrous K 2 CO 3 , and concentrated in vacuo.
  • the residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID38 as a light yellow solid (500 mg, 70%).
  • ID38 500 mg, 1.92 mmol
  • NH 3 /MeOH ca. 7N, 5 mL
  • a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the resulting solution was washed with H 2 O (150 mL) and brine (100 mL). The organic layer was dried over Na 2 SO 4 and concentrated, and the residue was purified by flash column chromatography (5% MeOH/CH 2 Cl 2 ) to afford ID39 as a light brownish solid (430 mg, 91%).
  • Compound D11-2 was prepared from compound ID39 through an amide formation reaction in a manner similar to that described for compound A-1.
  • HRMS (ESI + ) calcd for C 19 H 15 D 2 N 4 O 3 (M+H) + 351.1421, found 351.1428.
  • IF1d (2.35 g, 10.0 mmol) was reduced to alcohol IF2d as a light yellow solid (1.70 g, 77%).
  • IF1g (1.85 g, 10.0 mmol) was reduced to alcohol IF2g as a light yellow oil (1.54 g, 90%).
  • IF1i (2.50 g, 13.5 mmol) was reduced to alcohol IF2i as a yellow oil (1.37 g, 59%).
  • IF1k (1.00 g, 5.40 mmol) was reduced to alcohol IF2k as a yellow oil (346 mg, 37%).
  • IF1l (1.00 g, 5.78 mmol) was reduced to alcohol IF2l as a light yellow oil (700 mg, 76%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides compounds of formula (I):
Figure US20180194731A1-20180712-C00001
wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.

Description

    PRIORITY
  • This application is a continuation of U.S. application Ser. No. 15/192,728, filed on Jun. 24, 2016 and claims the benefit of U.S. Provisional Application Ser. No. 62/185,417, filed on Jun. 26, 2015. The entire content of these applications is hereby incorporated by reference herein.
    • BACKGROUND
  • Sirtuin 2 (SIRT2) is a member of the mammalian sirtuin (NAD+-dependent histone deacetylase) family that comprises SIRT1-7 (Houtkooper, R. H., et al., Nat. Rev. Mol. Cell Biol. 2012, 13, 225-238). SIRT2 is the only sirtuin that predominantly resides in the cytosol even though it is localized in the nucleus during mitosis. Interestingly, an alternatively spliced isoform has been reported to permanently reside in the nucleus. As the most abundant sirtuin homolog in the brain (Pandithage, R., et al., J. Cell Biol. 2008, 180, 915-929), SIRT2 has emerged as an important regulator in brain physiology and pathology (Harting, K., et al., Eur. J. Cell Biol. 2010, 89, 262-269). Several studies have suggested that selective pharmacological inhibition of SIRT2 is a promising therapeutic approach for Parkinson's disease (PD). First, overexpression of SIRT2 induced neuronal apoptosis (Pfister, J. A., et al., PLoS One 2008, 3, e4090). Second, blocking SIRT2 protected cells from the neurotoxicity induced by α-synuclein, a risk factor associated with the familial PD, in the cellular and fruit fly models of PD (Outeiro, T. F., et al., Science 2007, 317, 516-519). Third, SIRT2 exacerbated the nigrostriatal neurotoxicity induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) while genetic deletion (Liu, L., et al., Front. Aging Neurosci. 2014, 6, 184) or pharmacological inhibition (Chen, X., et al., PLoS One 2015, 10, e0116919) of SIRT2 prevented MPTP-induced neurodegeneration in mice. Furthermore, as a major deacetylase of α-tubulin (North, B. J., et al., Mol. Cell 2003, 11, 437-444), SIRT2 decreased the acetylation level of microtubules, enhancing their association with pathologically mutated leucine-rich kinase 2 (LRRK2) in the Roc-COR domain (R1441C and Y1699C). While this strengthened association impaired axonal transport, genetic knockdown of SIRT2 restored both axonal transport and locomotion in fruit flies (Godena, V. K., et. al., Nat. Commun. 2014, 5, 5245).
  • Besides PD, blocking SIRT2 may also provide protection in other neurodegenerative diseases. First, inhibition of SIRT2 had a protective effect in a cellular model of multiple system atrophy (Hasegawa, T., et al., Neurochem. Int. 2010, 57, 857-866), which is one form of synucleinopathy like PD. Second, in the granule cells obtained from slow Wallerian degeneration (Wld(s)) mice, genetic knockdown of SIRT2 enhanced resistance to axonal degeneration while overexpression of SIRT2 abrogated the resistance (Suzuki, K., et al., Neuroscience 2007, 147, 599-612). Third, inhibiting SIRT2 offered neuroprotection in the fly, worm, and primary striatal neuron models of Huntington's disease, likely by reducing sterol biosynthesis ((a) Luthi-Carter, R., et al., Proc. Natl. Acad. Sci. U.S.A 2010, 107, 7927-7932; (b) Taylor, D. M., et al., ACS Chem. Biol. 2011, 6, 540-546), even though the therapeutic potential still remains to be unequivocally defined. Four, SIRT2 inhibitors have been explored for their potential therapeutic applications in the mouse models of tauopathies, such as Alzheimer's disease (AD) (Green, K. N., et al., J. Neurosci. 2008, 28, 11500-11510) and frontotemporal dementia (Spires-Jones, T. L., et al., Front. Pharmacol. 2012, 3, 42). Lastly, a neurotoxic role of SIRT2 in AD has been recently proposed ((a) Theendakara, V., et al., Proc. Natl. Acad. Sci. U.S.A 2013, 110, 18303-18308; (b) Silva, D. F., et al., Mol. Neurobiol. 2016, PMID: 27311773). Taken together, these studies suggest that optimized SIRT2 inhibitors will have a broad impact on the treatment of neurodegenerative diseases.
  • Recently, SIRT2 has been shown as a key player in the transcription regulation signalling initiated by bacterial infection, suggesting that blocking host SIRT2 may be a viable approach to fight bacterial infection (Eskandarian, H. A., et al., Science 2013, 341, 1238858). Furthermore, there are studies that suggest that SIRT2 inhibitors can be therapeutically useful in the treatment of cancer ((a) Hu, J.; Jing, H.; Lin, H., Future Med. Chem. 2014, 6, 945-966; (b) Soung, Y. H., et al., Sci. Rep. 2014, 4, 3846; (c) Jing, H., et al., Cancer Cell 2016, 29, 297; (d) Deng, A., et al., Sci. Rep. 2016, doi: 10.1038/srep27694; (e) Jing, H.; Lin, H., Oncotarget 2016, doi: 10.18632/oncotarget.8502.) and kidney diseases ((a) Zhou, X., et al., Hum. Mol. Genet. 2014, 23, 1644-1655; (b) Ponnusamy, M., et al., J. Pharmacol. Exp. Ther. 2014, 350, 243; (c) Jung, Y. J., et al., J. Am. Soc. Nephrol. 2015, 26, 1549). SIRT2 inhibitors can also be useful for the treatment of sepsis (Zhao, T., et al., Curr. Mol. Med. 2015, 15, 634.) and hepatic fibrosis (Arteaga, M., et al., Am. J. Physiol. Gastrointest. Liver Physiol. 2016, 310, G1155), and for the control of platelet function (Moscardó, A., et al., J. Thromb. Haemost. 2015, 13, 1335).
  • Currently there is a need for agents that are useful for inhibiting SIRT2. Such agents may be useful to treat pathologies associated with SIRT2, such as, for example, Parkinson's disease.
    • SUMMARY
  • The invention provides compounds that are inhibitors of SIRT2. Accordingly, in one embodiment the invention provides a compound of formula (I):
  • Figure US20180194731A1-20180712-C00002
  • wherein:
  • X is CH or N;
  • Y is CH or N;
  • A is selected from the group consisting of: -A′-B′—,
  • Figure US20180194731A1-20180712-C00003
  • A′ is selected from the group consisting of:
  • Figure US20180194731A1-20180712-C00004
  • B′ is phenyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl, 5-membered heteroaryl, and 6-membered heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; C is selected from the group consisting of:
  • Figure US20180194731A1-20180712-C00005
  • D is selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C15)carbocycle, aryl, and heteroaryl, wherein the (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C15)carbocycle, aryl, and heteroaryl, are optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NRaRb, —C(═O)NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C3-C15)carbocycle, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C3-C15)carbocycle, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, aryloxy, and heteroaryl, wherein any aryl, aryloxy, and heteroaryl, of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, Rx, and (C1-C4)haloalkoxy;
  • each Ra and Rb is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any (C1-C4)alkyl, (C3-C5)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, hydroxy, (C3-Cis)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, oxo (═O), aryl, and heteroaryl, and wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, nitro, cyano, carboxy, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C15)carbocycle, —NRcRd, —C(═O)NRcRd, (C1-C4)alkoxycarbonyl, (C1-C4)haloalkyl, aryl, heteroaryl, and ReO—; or Ra and Rb together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino, 1,1-(dioxido)thiomorpholino and piperidino is optionally substituted with one or more groups independently selected from halo, oxo, and (C1-C4)alkyl;
  • each Rc and Rd is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkoxy, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, (C3-C15)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, and oxo (═O); or Rc and Rd together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
  • Re is selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, aryl, and (C1-C4)alkanoyl, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkanoyl is optionally substituted with one or more groups independently selected from halo and aryl, and wherein any aryl is optionally substituted with one or more groups independently selected from halo deuterium, nitro, cyano, hydroxy, carboxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy; and
  • Rx is (C1-C4)alkyl that is substituted with one or more (e.g. 1, 2, 3, or 4) groups independently selected from oxo, carboxy, (C1-C4)alkoxycarbonyl, and amino;
  • or a salt thereof.
  • The invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
  • The invention also provides a method for inhibiting the activity of SIRT2 in vitro or in vivo comprising contacting the SIRT2 with a compound of formula (I) or a salt thereof.
  • The invention also provides a method for inhibiting the activity of SIRT2 in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating Parkinson's disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating neurodegeneration in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating a neurodegenerative disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for promoting neuroprotection in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating Alzheimer's disease (AD) or frontotemporal dementia in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating a bacterial infection in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating cancer in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a method for treating kidney disease in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medical therapy.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a SIRT2 associated disorder.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of Parkinson's.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of neurodegeneration.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a neurodegenerative disease.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for promoting neuroprotection.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of Alzheimer's disease (AD) or frontotemporal dementia.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a bacterial infection.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of kidney disease.
  • The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of cancer.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for inhibiting the activity of SIRT2 in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1-13 to prepare a medicament for treating Parkinson's disease in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating neurodegeneration in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a neurodegenerative disease in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for promoting neuroprotection in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating Alzheimer's disease (AD) or frontotemporal dementia in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a bacterial infection in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating cancer in an animal.
  • The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof to prepare a medicament for treating kidney disease in an animal.
  • The invention also provides processes and intermediates disclosed herein that are useful for preparing a compound of formula I or a salt thereof.
    • DETAILED DESCRIPTION
  • The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl encompasses a radical of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein X is absent or is H, O, (C1-C4)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic ring of about eight to ten ring atoms comprising one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X).
  • The term “carbocycle” or “carbocyclyl” refers to a single saturated (i.e., cycloalkyl) or a single partially unsaturated (e.g., cycloalkenyl, cycloalkadienyl, etc.) all carbon ring having 3 to 7 carbon atoms (i.e., (C3-C7)carbocycle). The term “carbocycle” or “carbocyclyl” also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings). Accordingly, carbocycle includes multicyclic carbocyles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 carbon atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and polycyclic carbocycles (e.g tricyclic and tetracyclic carbocycles with up to about 20 carbon atoms). The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. For example, multicyclic carbocyles can be connected to each other via a single carbon atom to form a spiro connection (e.g., spiropentane, spiro[4,5]decane, etc), via two adjacent carbon atoms to form a fused connection (e.g., carbocycles such as decahydronaphthalene, norsabinane, norcarane) or via two non-adjacent carbon atoms to form a bridged connection (e.g., norbornane, bicyclo[2.2.2]octane, etc). In one embodiment the term carbocycle includes a 3-15 membered carbocycle. In one embodiment the term carbocycle includes a 3-8 membered carbocycle. In one embodiment the term carbocycle includes a 3-6 membered carbocycle. In one embodiment the term carbocycle includes a 3-5 membered carbocycle.
  • It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase.
  • When a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities. When a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted. In one embodiment, the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 60% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.
  • Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents
  • Specifically, (C1-C6)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C3-C8)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; (C3-C8)cycloalkyl(C1-C6)alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl; (C1-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C2-C6)alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C2-C6)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl; (C1-C6)alkanoyl can be acetyl, propanoyl or butanoyl; halo(C1-C6)alkyl can be iodomethyl, bromomethyl, chloromethyl, fluoromethyl, trifluoromethyl, 2-chloroethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, or pentafluoroethyl; hydroxy(C1-C6)alkyl can be hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6-hydroxyhexyl; (C1-C6)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexyloxycarbonyl; (C2-C6)alkanoyloxy can be acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy; aryl can be phenyl, indenyl, or naphthyl; and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide).
  • The invention also provides a compound of formula (Ia):
  • Figure US20180194731A1-20180712-C00006
  • or a salt thereof.
  • The invention also provides a compound of formula (Ib):
  • Figure US20180194731A1-20180712-C00007
  • or salt thereof.
  • The invention also provides a compound of formula (Ic):
  • Figure US20180194731A1-20180712-C00008
  • or a salt thereof.
  • The invention also provides a compound of formula (Id):
  • Figure US20180194731A1-20180712-C00009
  • or a salt thereof.
  • The invention also provides a compound of formula (Ie):
  • Figure US20180194731A1-20180712-C00010
  • wherein: X is CH and Y is N; or X is N and Y is CH; or X is N and Y is N; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein:
  • A is-A′-B′—;
  • A′ is selected from the group consisting of:
  • Figure US20180194731A1-20180712-C00011
  • and
  • B′ is phenyl wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl is substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • The invention also provides a compound of formula (If):
  • Figure US20180194731A1-20180712-C00012
  • wherein: V is CH and W is N; or V is N and W is CH; or V is N and W is N; or a salt thereof.
  • The invention also provides a compound of formula (Ig):
  • Figure US20180194731A1-20180712-C00013
  • wherein: R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • The invention also provides a compound of formula (Ih):
  • Figure US20180194731A1-20180712-C00014
  • wherein: R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • The invention also provides a compound of formula (Ii):
  • Figure US20180194731A1-20180712-C00015
  • wherein: R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein D is selected from the group consisting of methyl, ethyl, vinyl, naphthyl, cyclohexyl, adamantly, cyclohex-1-enyl, thienyl, benzothienyl, benzofuranyl, indolyl, benzothiazolyl, indazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, and pirazinyl, wherein D is optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, —NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any aryl, and heteroaryl, of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, and (C1-C4)haloalkoxy; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein D is selected from the group consisting of naphthyl, cyclohexyl, adamantly, cyclohex-1-enyl, thienyl, benzothienyl, benzofuranyl, indolyl, benzothiazolyl, indazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, and pirazinyl, wherein D is optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, —NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any aryl, and heteroaryl, of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, and (C1-C4)haloalkoxy; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein D is substituted with —NRaRb; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein Ra is (C1-C4)alkanoyl, that is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, (C3-C15)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, oxo (═O), aryl, and heteroaryl, and wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, nitro, cyano, carboxy, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-Cis)carbocycle, —NRcRd, —C(═O)NRcRd, (C1-C4)alkoxycarbonyl, (C1-C4)haloalkyl, aryl, heteroaryl, and ReO—; or a salt thereof.
  • The invention also provides a compound of formula (I), wherein Ra and Rb together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino and piperidino is optionally substituted with one or more groups independently selected from halo and (C1-C4)alkyl; or a salt thereof.
  • The invention also provides a compound of formula (I):
  • Figure US20180194731A1-20180712-C00016
  • wherein:
  • X is CH or N;
  • Y is CH or N;
  • A is selected from the group consisting of: -A′-B′—,
  • Figure US20180194731A1-20180712-C00017
  • A′ is selected from the group consisting of:
  • Figure US20180194731A1-20180712-C00018
  • B′ is phenyl, a 5-membered heteroaryl, or a 6-membered heteroaryl, wherein A′ and C are attached to B′ in a meta-orientation, and the phenyl, 5-membered heteroaryl, and 6-membered heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy;
  • C is selected from the group consisting of:
  • Figure US20180194731A1-20180712-C00019
  • D is selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-Cis)carbocycle, aryl, and heteroaryl, wherein the (C1-C6)alkyl, (C2-C6)alkenyl, (C3-Cis)carbocycle, aryl, and heteroaryl, are optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NRaRb, —C(═O)NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C3-Cis)carbocycle, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C3-C15)carbocycle, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any aryl, and heteroaryl, of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, and (C1-C4)haloalkoxy;
  • each Ra and Rb is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any (C1-C4)alkyl, (C3-C5)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, hydroxy, (C3-Cis)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, oxo (═O), aryl, and heteroaryl, and wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, nitro, cyano, carboxy, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C15)carbocycle, —NRcRd, —C(═O)NRcRd, (C1-C4)alkoxycarbonyl, (C1-C4)haloalkyl, aryl, heteroaryl, and ReO—; or Ra and Rb together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino and piperidino is optionally substituted with one or more groups independently selected from halo and (C1-C4)alkyl;
  • each Rc and Rd is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkoxy, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, (C3-Cis)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, and oxo (═O); or Rc and Rd together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino; and
  • Re is selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, aryl, and (C1-C4)alkanoyl, wherein any (C1-C4)alkyl, (C3-C5)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkanoyl is optionally substituted with one or more groups independently selected from halo and aryl, and wherein any aryl is optionally substituted with one or more groups independently selected from halo deuterium, nitro, cyano, hydroxy, carboxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy;
  • or a salt thereof.
  • Processes for preparing compounds of formula I are provided as further embodiments of the invention and are illustrated by the procedures illustrated in the Examples below.
  • In cases where compounds are sufficiently basic or acidic, a salt of a compound of formula I can be useful as an intermediate for isolating or purifying a compound of formula I. Additionally, administration of a compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
  • Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
  • The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
  • The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • The invention will now be illustrated by the following non-limiting Examples.
    • EXAMPLES Example 1
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00020
    • Methyl 5-((3-Nitrobenzyl)oxy)nicotinate (IA2)
  • To a solution of 3-nitrobenzyl bromide (IA1, 9.50 g, 44 mmol) in DMF (80 mL) were added methyl 5-hydroxynicotinate (6.12 g, 40 mmol) and Cs2CO3 (26.1 g, 80 mmol) and the mixture was allowed to stir at rt for 12 h. After water (200 ml) was added, the precipitate was filtered, washed with hexanes, and dried in vacuo to yield compound IA2 as a light yellow solid (8.64 g, 75%). 1H NMR (CDCl3, 600 MHz) δ 8.89 (d, J=1.2 Hz, 1H), 8.58 (d, J=3.0 Hz, 1H), 8.35 (s, 1H), 8.24 (d, J=8.4 Hz, 1H), 7.87 (dd, J=3.0, 1.8, Hz, 1H), 7.79 (d, J=7.2 Hz, 1H), 6.61 (dd, J=7.8, 7.8 Hz, 1H), 5.25 (s, 2H), 3.97 (s, 3H). HRMS (ESI+) calcd for C14H13N2O5 (M+H)+289.0824, found 289.0820.
    • Methyl 5-((3-Aminobenzyl)oxy)nicotinate (IA3)
  • To a solution of compound IA2 (8.64 g, 30 mmol) and NiCl2.6H2O (14.3 g, 44 mmol) in MeOH (100 mL) was slowly added NaBH4 (4.8 g, 120 mmol) and the mixture was allowed to stir at rt for 3 h. The reaction was quenched with saturated NH4Cl (50 mL) and the mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford compound IA3 as a light yellow solid (6.19 g, 80%). 1H NMR (CDCl3, 600 MHz) δ 8.83 (d, J=1.8 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 8.83 (dd, J=2.4, 1.8, Hz, 1H), 7.18 (d, J=7.8 Hz, 1H), 6.80 (d, J=7.8 Hz, 1H), 6.76 (s, 1H), 6.66 (dd, J=7.8, 1.8 Hz, 1H), 5.30 (s, 2H), 5.06 (s, 2H), 3.95 (s, 3H). HRMS (ESI+) calcd for C14H15N2O3 (M+H)+259.1083, found 259.1080. 5-((3-Aminobenzyl)oxy)nicotinamide (IA4). A solution of methyl ester IA3 (6.19 g, 24 mmol) and CaCl2 (2.66 g, 24 mmol) in NH3/MeOH (ca. 7N, 20 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (150 mL) and the resulting solution was washed with H2O (150 mL) and brine (100 mL). After the organic layer was dried over Na2SO4 and filtered, the filtrate was concentrated and the residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to afford compound IA4 as a light yellow solid (5.25 g, 90%/). 1H NMR (DMSO-d6, 600 MHz) δ 8.63 (s, 1H), 8.44 (d, J=3.0 Hz, 1H), 8.12 (s, 1H), 7.81 (s, 1H), 7.60 (s, 1H), 7.02 (dd, J=7.5, 7.5 Hz, 1H), 6.63 (s, 1H), 6.57 (d, J=7.8 Hz, 1H), 6.52 (d, J=7.8 Hz, 1H), 5.13 (s, 2H), 5.07 (s, 2H). HRMS (ESI+) calcd for C13H14N3O2 (M+H)+244.1081, found 244.1082.
  • Figure US20180194731A1-20180712-C00021
    • 5-((3-(4-Methyl-3-nitrobenzamido)benzyl)oxy)nicotinamide (A-1)
  • To a solution of amine IA4 (52 mg, 0.21 mmol) and DIPEA (80 μL, 0.46 mmol) in anhydrous CH2Cl2 (5 mL) and DMF (1 mL) was added 4-methyl-3-nitrobenzoyl chloride (50 μL, 0.34 mmol) and the mixture was allowed to stir at rt for 24 h. After the solvents were removed, the residue was diluted with EtOAc (30 mL), H2O (10 mL) and saturated NaHCO3 (10 mL). After separation, the organic layer was washed with brine (20 mL) and concentrated. The residue was purified by flash column chromatography to give compound A-1 as a white solid (51 mg, 59%/). 1H NMR (DMSO-d6, 600 MHz) δ 10.54 (s, 1H), 8.65 (s, 1H), 8.58 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.22 (d, J=7.8 Hz, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.77 (d, J=7.8 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 5.26 (s, 2H), 2.60 (s, 3H). HRMS (ESI+) calcd for C21H19N4O5 (M+H)+407.1350, found 407.1353.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for compound A-1.
  • Figure US20180194731A1-20180712-C00022
    • 5-((3-Acetamidobenzyl)oxy)nicotinamide (A-2)
  • White solid (60 mg, 88%). 1H NMR (DMSO-d6, 600 MHz) δ 9.99 (s, 1H), 8.64 (s, 1H), 8.47 (d, J=3.0 Hz, 1H), 8.13 (s, 1H), 7.84-7.82 (m, 1H), 7.70 (s, 1H), 7.61 (s, 1H), 7.54 (d, J=8.1 Hz, 1H), 7.31 (dd, J=7.8, 7.8 Hz, 1H), 7.13 (d, J=7.6 Hz, 1H), 5.20 (s, 2H), 2.03 (s, 3H). HRMS (ESI+) calcd for C15H16N3O3 (M+H)+ 286.1186, found 286.1191.
  • Figure US20180194731A1-20180712-C00023
    • 5-((3-(Cyclohexanecarboxamido)benzyl)oxy)nicotinamide (A-3)
  • White solid (52 mg, 62%). 1H NMR (DMSO-d6, 600 MHz) δ 9.85 (s, 1H), 8.64 (d, J=1.2 Hz, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.84-7.83 (m, 1H), 7.75 (s, 1H), 7.61 (s, 1H), 7.55 (d, J=8.2 Hz, 1H), 7.30 (dd, J=7.8, 7.8 Hz, 1H), 7.11 (d, J=7.5 Hz, 1H), 5.20 (s, 2H), 2.34-2.29 (m, 1H), 1.80-1.73 (m, 4H), 1.64 (d, J=12.3 Hz, 1H), 1.43-1.37 (m, 2H), 1.29-1.16 (m, 3H). HRMS (ESI+) calcd for C20H24N3O3 (M+H)+354.1812, found 354.1818.
  • Figure US20180194731A1-20180712-C00024
    • 5-((3-((3R,5R,7R)-Adamantane-1-carboxamido)benzyl)oxy)nicotinamide (A-4)
  • White solid (40 mg, 41%). 1H NMR (DMSO-d6, 600 MHz) δ 9.18 (s, 1H), 8.64 (s, 1H), 8.48 (d, J=3.0 Hz, 1H), 8.13 (s, 1H), 7.83 (s, 1H), 7.80 (s, 1H), 7.64-7.60 (m, 2H), 7.30 (dd, J=7.9, 7.9 Hz, 1H), 7.13 (d, J=7.5 Hz, 1H), 5.19 (s, 2H), 2.03-1.99 (m, 3H), 1.92-1.88 (m, 6H), 1.72-1.68 (m, 6H). HRMS (ESI+) calcd for C24H28N3O3 (M+H)+406.2125, found 406.2132.
  • Figure US20180194731A1-20180712-C00025
    • 5-((3-(Cyclohex-1-enecarboxamido)benzyl)oxy)nicotinamide (A-5)
  • White solid (120 mg, 84%). 1H NMR (DMSO-d6, 600 MHz) δ 9.65 (s, 1H), 8.64 (s, 1H), 8.47 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.85-7.82 (m, 1H), 7.81 (s, 1H), 7.65-7.57 (m, 2H), 7.32 (dd, J=8.1, 8.1 Hz, 1H), 7.14 (dd, J=7.8, 7.8 Hz, 1H), 6.65 (s, 1H), 5.20 (s, 2H), 2.27-2.22 (m, 2H), 2.20-2.14 (m, 2H), 1.66-1.60 (m, 2H), 1.60-1.54 (m, 2H). HRMS (ESI+) calcd for C20H22N3O3 (M+H)+352.1656, found 352.1669.
  • Figure US20180194731A1-20180712-C00026
    • 5-((3-Benzamidobenzyl)oxy)nicotinamide (A-6)
  • White solid (22 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 7.96 (d, J=7.3 Hz, 2H), 7.93 (s, 1H), 7.88-7.86 (m, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.63-7.58 (m, 2H), 7.52 (dd, J=7.8, 7.8 Hz, 2H), 7.39 (dd, J=7.9, 7.9 Hz, 1H), 7.21 (d, J=7.3 Hz, 2H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H18N3O3 (M+H)+348.1343, found 348.1350.
  • Figure US20180194731A1-20180712-C00027
    • 5-((3-(Thiophene-2-carboxamido)benzyl)oxy)nicotinamide (A-7)
  • White solid (40 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.29 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 8.04 (d, J=3.7 Hz, 1H), 7.88-7.84 (m, 3H), 7.72 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.39 (dd, J=7.9, 7.9 Hz, 1H), 7.24-7.20 (m, 2H), 5.25 (s, 2H). HRMS (ESI+) calcd for C15H16N3O3S (M+H)+354.0907, found 354.0913.
  • Figure US20180194731A1-20180712-C00028
    • 5-((3-(2-Phenylacetamido)benzyl)oxy)nicotinamide (A-8)
  • Yellow solid (41 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.26 (s, 1H), 8.64 (s, 1H), 8.47 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 7.84-7.82 (m, 1H), 7.73 (s, 1H), 7.60 (s, 1H), 7.57 (d, J=7.8 Hz, 1H), 7.35-7.30 (m, 5H), 7.26-7.22 (m, 1H), 7.14 (d, J=7.6 Hz, 1H), 5.20 (s, 2H), 3.63 (s, 2H). HRMS (ESI+) calcd for C21H20N3O3 (M+H)+362.1499, found 362.1510.
  • Figure US20180194731A1-20180712-C00029
    • 5-((3-(3-Phenylpropanamido)benzyl)oxy)nicotinamide (A-9)
  • Yellow solid (47 mg, 60%). 1H NMR (DMSO-d6, 600 MHz) δ 9.97 (s, 1H), 8.65 (d, J=1.6 Hz, 1H), 8.47 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 7.84 (dd, J=2.6, 1.8 Hz, 1H), 7.71 (s, 1H), 7.61 (s, 1H), 7.54 (d, J=8.2 Hz, 1H), 7.33-7.21 (m, 5H), 7.18 (dd, J=7.2, 7.2 Hz, 1H), 7.13 (d, J=7.6 Hz, 1H), 5.21 (s, 2H), 3.91 (t, J=7.5 Hz, 2H), 2.62 (t, J=8.1 Hz, 2H). HRMS (ESI+) calcd for C22H22N3O3 (M+H)+376.1656, found 376.1661.
  • Figure US20180194731A1-20180712-C00030
    • (E)-5-((3-Cinnamamidobenzyl)oxy)nicotinamide (A-10)
  • White solid (35 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.35 (s, 1H), 8.66 (d, J=1.0 Hz, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.16 (s, 1H), 7.87 (s, 1H), 7.84 (s, 1H), 7.69 (d, J=8.8 Hz, 1H), 7.63-7.58 (m, 4H), 7.47-7.36 (m, 4H), 7.18 (d, J=7.6 Hz, 1H), 6.87 (d, J=15.7 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C22H20N3O3 (M+H)+374.1499, found 374.1515.
  • Figure US20180194731A1-20180712-C00031
    • 5-((3-(1-Naphthamido)benzyl)oxy)nicotinamide (A-11)
  • White solid (16 mg, 17%). 1H NMR (DMSO-d6, 600 MHz) δ 10.65 (s, 1H), 8.66 (s, 1H), 8.51 (s, 1H), 8.19 (d, J=7.8 Hz 1H), 8.15 (s, 1H), 8.08 (d, J=8.2 Hz, 1H), 8.03-8.00 (m, 2H), 7.88 (d, J=1.5 Hz, 1H), 7.76 (d, J=6.8 Hz, 2H), 7.63-7.58 (m, 4H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.5 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C24H20N3O3 (M+H)+398.1499, found 398.1503.
  • Figure US20180194731A1-20180712-C00032
    • 5-((3-(2-Naphthamido)benzyl)oxy)nicotinamide (A-12)
  • White solid (60 mg, 63%). 1H NMR (DMSO-d6, 600 MHz) δ 10.50 (s, 1H), 8.66 (s, 1H), 8.59 (s, 1H), 8.51 (d, J=2.6 Hz, 1H), 8.14 (s, 1H), 8.09 (d, J=7.6 Hz, 1H), 8.07-8.00 (m, 3H), 7.97 (s, 1H), 7.87 (s, 1H), 7.82 (d, J=8.1 Hz, 1H), 7.66-7.61 (m, 3H), 7.41 (dd, J=7.6, 7.6 Hz, 1H), 7.24 (d, J=7.5 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C24H20N3O3 (M+H)+398.1499, found 398.1507.
  • Figure US20180194731A1-20180712-C00033
    • 5-((3-(Benzo[b]thiophene-2-carboxamido)benzyl)oxy)nicotinamide (A-13)
  • Pale solid (48 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.58 (s, 1H), 8.66 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.38 (s, 1H), 8.14, (s, 1H), 8.06 (d, J=8.4 Hz, 1H), 8.01 (d, J=7.2 Hz, 1H), 7.91 (s, 1H), 7.87 (s, 1H), 7.76 (d, J=9.6 Hz, 1H), 7.61 (s, 1H), 7.52-7.45 (m, 2H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H) 5.27 (s, 2H). HRMS (ESI+) calcd for C22H18N3O3S (M+H)+404.1069, found 404.1064.
  • Figure US20180194731A1-20180712-C00034
    • 5-((3-(Benzofuran-2-carboxamido)benzyl)oxy)nicotinamide (A-14)
  • Yellowish solid (44 mg, 56%). 1H NMR (DMSO-d6, 600 MHz) δ 10.59 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.83 (d, J=8.4 Hz, 1H), 7.81-7.77 (m, 2H), 7.72 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.51 (dd, J=7.8, 7.8 Hz, 1H), 7.42 (dd, J=7.5, 7.5 Hz, 1H), 7.37 (dd, J=7.5, 7.5 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C22H18N3O4 (M+H)+388.1292, found 388.1295.
  • Figure US20180194731A1-20180712-C00035
    • N-(3-((5-Carbamoyl)oxy)methyl)phenyl)-1H-indole-2-carboxamide (A-15)
  • Yellowish solid (33 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 11.72 (s, 1H), 10.27 (s, 1H), 8.66 (s, 1H), 8.51 (d, J=3.0 Hz, 1H) 8.14 (s, 1H), 7.93 (s, 1H), 7.87 (s, 1H), 7.81 (d, J=9.6 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.47 (d, J=7.8 Hz, 1H), 7.44-7.39 (m, 2H), 7.24-7.21 (m, 2H), 7.07 (dd, J=7.2, 7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C22H19N4O3 (M+H)+387.1457, found 387.1451.
  • Figure US20180194731A1-20180712-C00036
    • N-(3-((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)benzol[d]thiazole-2-carboxamide (A-16)
  • Pale solid (10 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 11.18 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.28 (d, J=8.4 Hz, 1H), 8.23 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 8.09 (s, 1H), 7.87 (s, 2H), 7.67 (dd, J=7.8, 7.8 Hz, 1H), 7.64-7.58 (m, 2H), 7.43 (dd, J=7.8, 7.8 Hz, 1H), 7.28 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C21H17N4O3S (M+H)+405.1016, found 405.1016.
  • Figure US20180194731A1-20180712-C00037
    • 5-((3-(Benzo[b]thiophene-3-carboxamido)benzyl)oxy)nicotinamide (A-17)
  • Yellowish solid (19 mg, 23%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.66 (s, 1H), 8.57 (s, 1H), 8.51 (s, 1H), 8.42 (d, J=8.4 Hz, 1H), 8.14, (s, 1H), 8.08 (d, J=7.8 Hz, 1H), 7.93 (s, 1H), 7.87 (s, 1H), 7.76 (d, J=9.0 Hz, 1H), 7.61 (s, 1H), 7.50-7.43 (m, 2H), 7.41 (dd, J=7.5, 7.5 Hz, 1H), 7.22 (d, J=7.2 Hz, 1H) 5.27 (s, 2H). HRMS (ESI+) calcd for C22H15N3O3S (M+H)+404.1069, found 404.1065.
  • Figure US20180194731A1-20180712-C00038
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-1H-indole-3-carboxamide (A-18)
  • Bronish solid (4 mg, 5%) 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.48 (s, 1H), 8.18 (d, J=7.8 Hz, 1H), 8.10 (s, 1H), 7.94 (s, 1H), 7.88-7.85 (m, 2H), 7.74 (d, J=8.4 Hz, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.54 (dd, J=7.8, 7.8 Hz, 1H), 7.49-7.43 (m, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.23-7.15 (m, 3H), 5.26 (s, 2H). HRMS (ESI+) calcd for C22H19N4O3 (M+H)+ 387.1452, found 387.1459.
  • Figure US20180194731A1-20180712-C00039
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-1H-indole-6-carboxamide (A-19)
  • White solid (60 mg, 65%). 1H NMR (DMSO-d6, 600 MHz) δ 11.45 (s, 1H), 10.22 (s, 1H), 8.65 (s, 1H), 8.51 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.78 (d, J=8.2 Hz, 1H), 7.64 (s, 2H), 7.60 (s, 1H), 7.54 (dd, J=2.6, 2.6 Hz, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.19 (d, J=7.5 Hz, 1H), 6.51 (s, 1H), 5.24 (s, 2H). HRMS (ESI+) calcd for C22H19N4O3 (M+H)+387.1452, found 387.1457.
  • Figure US20180194731A1-20180712-C00040
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-1H-indazole-6-carboxamide (A-20)
  • White solid (20 mg, 21%). 1H NMR (DMSO-d6, 600 MHz) δ 13.44 (s, 1H), 10.42 (s, 1H), 8.84 (s, 1H), 8.63 (d, J=2.2 Hz, 1H), 8.17 (d, J=6.0 Hz, 2H), 8.14 (s, 1H), 7.96 (s, 1H), 7.90-7.86 (m, 2H), 7.77 (d, J=7.8 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C21H18N5O3 (M+H)+ 388.1404, found 388.1401.
  • Figure US20180194731A1-20180712-C00041
    • 5-((3-(2-Methylbenzamido)benzyl)oxy)nicotinamide (A-21)
  • White solid (43 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.36 (s, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.49 (d, J=2.6 Hz, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.69 (d, J=7.0 Hz, 1H), 7.60 (s, 1H), 7.45 (d, J=7.3 Hz, 1H), 7.41-7.35 (m, 2H), 7.31-7.28 (m, 2H), 7.20 (d, J=7.5 Hz, 1H), 5.24 (s, 2H), 2.38 (s, 3H). HRMS (ESI+) calcd for C21H20N3O3 (M+H)+362.1499, found 362.1506.
  • Figure US20180194731A1-20180712-C00042
    • 5-((3-(3-Methylbenzamido)benzyl)oxy)nicotinamide (A-22)
  • White solid (69 mg, 93%). 1H NMR (DMSO-d6, 600 MHz) δ 10.27 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.5 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.78-7.72 (m, 3H), 7.61 (s, 1H), 7.43-7.37 (m, 3H), 7.21 (d, J=7.5 Hz, 1H), 5.25 (s, 2H), 2.40 (s, 3H). HRMS (ESI+) calcd for C21H20N3O3 (M+H)+362.1499, found 362.1504.
  • Figure US20180194731A1-20180712-C00043
    • 5-((3-(4-Methylbenzamido)benzyl)oxy)nicotinamide (A-23)
  • White solid (38 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.21 (s, 1H), 8.64 (s, 1H), 8.48 (d, J=2.2 Hz, 1H), 8.12 (s, 1H), 7.91 (s, 1H), 7.87-7.84 (m, 3H), 7.73 (d, J=8.1 Hz, 1H), 7.60 (s, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.32 (d, J=7.9 Hz, 2H), 7.18 (d, J=7.5 Hz, 1H), 5.23 (s, 2H), 2.37 (s, 3H). HRMS (ESI+) calcd for C21H20N3O3 (M+H)+362.1499, found 362.1506.
  • Figure US20180194731A1-20180712-C00044
    • 5-((3-(2-Methoxybenzamido)benzyl)oxy)nicotinamide (A-24)
  • White solid (53 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.18 (s, 1H), 8.65 (d, J=1.6 Hz, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.86 (dd, J=2.6, 1.8 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.62 (dd, J=7.6, 1.6 Hz, 1H), 7.61 (s, 1H), 7.52-7.48 (m, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.21-7.16 (m, 2H), 7.06 (dd, J=7.5, 7.5 Hz, 1H), 5.24 (s, 2H), 3.89 (s, 3H). HRMS (ESI+) calcd for C21H20N3O4 (M+H)+378.1448, found 378.1453.
  • Figure US20180194731A1-20180712-C00045
    • 5-((3-(3-Methoxybenzamido)benzyl)oxy)nicotinamide (A-25)
  • White solid (51 mg, 64%). 1H NMR (DMSO-d6, 600 MHz) δ 10.28 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.88-7.85 (m, 1H), 7.75 (d, J=7.9 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.49 (s, 1H), 7.44 (dd, J=7.9, 7.9 Hz, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.6 Hz, 1H), 7.15 (dd, J=8.2, 2.0 Hz, 1H), 5.25 (s, 2H), 3.84 (s, 3H). HRMS (ESI+) calcd for C21H20N3O4 (M+H)+ 378.1448, found 378.1450.
  • Figure US20180194731A1-20180712-C00046
    • 5-((3-(4-Methoxybenzamido)benzyl)oxy)nicotinamide (A-26)
  • White solid (40 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.15 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.6 Hz, 1H), 8.14 (s, 1H), 7.97 (d, J=8.8 Hz, 2H), 7.91 (s, 1H), 7.85 (s, 1H), 7.75 (d, J=8.2 Hz, 1H), 7.62 (s, 1H), 7.37 (dd, J=7.9, 7.9 Hz, 1H), 7.19 (d, J=7.6 Hz, 1H), 7.06 (d, J=8.7 Hz, 2H), 5.24 (s, 2H), 3.84 (s, 3H). HRMS (ESI+) calcd for C21H20N3O4 (M+H)+378.1448, found 378.1455.
  • Figure US20180194731A1-20180712-C00047
    • 5-((3-(2-Chlorobenzamido)benzyl)oxy)nicotinamide (A-27)
  • White solid (35 mg, 43%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.5 Hz, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.86 (s, 1H), 7.66 (d, J=7.9 Hz, 1H), 7.64-7.55 (m, 3H), 7.50 (dd, J=7.6, 7.6 Hz, 1H), 7.45 (dd, J=7.5, 7.5 Hz, 1H), 7.38 (dd, J=7.9, 7.9 Hz, 1H), 7.22 (d, J=7.5 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H17ClN3O3 (M+H)+ 382.0953, found 382.0962.
  • Figure US20180194731A1-20180712-C00048
    • 5-((3-(3-Chlorobenzamido)benzyl)oxy)nicotinamide (A-28)
  • White solid (45 mg, 56%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.66 (d, J=1.5 Hz, 1H), 8.50 (d, J=2.8 Hz, 1H), 8.15 (s, 1H), 8.01 (s, 1H), 7.94-7.90 (m, 2H), 7.87 (dd, J=2.2, 2.2 Hz, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.66 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.57 (dd, J=7.8, 7.8 Hz, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.6 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C20H17ClN3O3 (M+H)+382.0953, found 382.0960.
  • Figure US20180194731A1-20180712-C00049
    • 5-((3-(4-Chlorobenzamido)benzyl)oxy)nicotinamide (A-29)
  • White solid (53 mg, 66%). 1H NMR (DMSO-d6, 600 MHz) δ 10.43 (s, 1H), 8.66 (d, J=1.5 Hz, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.17 (s, 1H), 8.00 (d, J=8.5 Hz, 2H), 7.93 (s, 1H), 7.88 (dd, J=1.9, 1.9 Hz, 1H), 7.76 (d, J=8.2 Hz, 1H), 7.63-7.58 (m, 3H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.5 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H17ClN3O3 (M+H)+382.0953, found 382.0962.
  • Figure US20180194731A1-20180712-C00050
    • 5-((3-(2-Nitrobenzamido)benzyl)oxy)nicotinamide (A-30)
  • White solid (42 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.74 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.15 (d, J=8.2 Hz, 1H), 8.13 (s, 1H), 7.89-7.86 (m, 2H), 7.82 (s, 1H), 7.79-7.75 (m, 2H), 7.63 (d, J=8.2 Hz, 1H), 7.61 (s, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.6 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C20H17N4O5 (M+H)+393.1193 found 393.1199.
  • Figure US20180194731A1-20180712-C00051
    • 5-((3-(3-Nitrobenzamido)benzyl)oxy)nicotinamide (A-31)
  • White solid (67 mg, 82%). 1H NMR (DMSO-d6, 600 MHz) δ 10.65 (s, 1H), 8.80 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.2 Hz, 1H), 8.44 (d, J=8.4 Hz, 1H), 8.41 (d, J=7.8 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.88-7.83 (m, 2H), 7.78 (d, J=8.2 Hz, 1H), 7.61 (s, 1H), 7.42 (dd, J=7.9, 7.9 Hz, 1H), 7.26 (d, J=7.6 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C20H17N4O5 (M+H)+393.1193, found 393.1196.
  • Figure US20180194731A1-20180712-C00052
    • 5-((3-(4-Nitrobenzamido)benzyl)oxy)nicotinamide (A-32)
  • White solid (41 mg, 50%). 1H NMR (DMSO-d6, 600 MHz) δ 10.64 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.6 Hz, 1H), 8.37 (d, J=8.8 Hz, 2H), 8.19 (d, J=8.7 Hz, 2H), 8.15 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.77 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.42 (dd, J=7.9, 7.9 Hz, 1H), 7.25 (d, J=7.6 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C20H17N4O5 (M+H)+393.1193 found 393.1200.
  • Figure US20180194731A1-20180712-C00053
    • 683_5-((3-(2-Cyanobenzamido)benzyl)oxy)nicotinamide (A-33)
  • Pale solid (10 mg, 13%). 1H NMR (DMSO-d6, 600 MHz) δ 10.29 (s, 1H), 8.66 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.27 (d, J=7.2 Hz, 1H), 8.14 (s, 1H), 7.92-7.85 (m, 3H), 7.82-7.78 (m, 1H), 7.64-7.52 (m, 4H), 7.45 (d, J=7.8 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C21H17N4O3 (M+H)+373.1301, found 373.1302.
  • Figure US20180194731A1-20180712-C00054
    • 5-((3-(3-Cyanobenzamido)benzyl)oxy)nicotinamide (A-34)
  • White solid (30 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 10.38 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.41 (s, 1H), 8.25 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 8.07 (d, J=7.8 Hz, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.78-7.73 (m, 2H), 7.62 (s, 1H), 7.42 (dd, J=8.1, 8.1 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C21H17N4O3 (M+H)+373.1301, found 373.1300.
  • Figure US20180194731A1-20180712-C00055
    • 5-((3-(4-Cyanobenzamido)benzyl)oxy)nicotinamide (A-35)
  • Pale solid (28 mg, 37%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 8.11 (d, J=9.0 Hz, 2H), 8.03 (d, J=7.8 Hz, 2H), 7.92 (s, 1H), 7.88-7.84 (m, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.41 (dd, J=8.1, 8.1 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C21H17N4O3 (M+H)+373.1301, found 373.1303.
  • Figure US20180194731A1-20180712-C00056
    • 5-((3-(2-Fluorobenzamido)benzyl)oxy)nicotinamide (A-36)
  • White solid (80 mg, 91%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.0 Hz, 1H), 8.13 (s, 1H), 7.87 (d, J=14.5 Hz, 2H), 7.68-7.65 (m, 2H), 7.61-7.55 (m, 2H), 7.40-7.31 (m, 3H), 7.22 (d, J=7.5 Hz, 1H), 5.24 (s, 2H). HRMS (ESI+) calcd for C20H17FN3O3 (M+H)+ 366.1248, found 366.1253.
  • Figure US20180194731A1-20180712-C00057
    • 5-((3-(3-Fluorobenzamido)benzyl)oxy)nicotinamide (A-37)
  • White solid (50 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.37 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.76 (dd, J=15.0, 11.7 Hz, 2H), 7.61-7.57 (m, 2H), 7.48-7.38 (m, 2H), 7.23 (d, J=7.3 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H17FN3O3 (M+H)+366.1248, found 366.1250.
  • Figure US20180194731A1-20180712-C00058
    • 5-((3-(4-Fluorobenzamido)benzyl)oxy)nicotinamide (A-38)
  • White solid (40 mg, 46%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=2.6 Hz, 1H), 8.15 (s, 1H), 8.04 (dd, J=8.4, 5.6 Hz, 2H), 7.91 (s, 1H), 7.87 (s, 1H), 7.74 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.42-7.35 (m, 2H), 7.25 (dd, J=8.4, 8.4 Hz, 1H), 7.22 (d, J=7.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H17FN3O3 (M+H)+366.1248, found 366.1250.
  • Figure US20180194731A1-20180712-C00059
    • 5-((3-(2,4-Difluorobenzamido)benzyl)oxy)nicotinamide (A-39)
  • White solid (60 mg, 65%). 1H NMR (DMSO-d6, 600 MHz) δ 10.47 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.5 Hz, 1H), 8.13 (s, 1H), 7.84 (s, 2H), 7.75 (dd, J=15.3, 8.2 Hz, 1H), 7.67 (d, J=7.9 Hz, 1H), 7.61 (s, 1H), 7.44-7.37 (m, 2H), 7.24-7.20 (m, 2H), 5.24 (s, 2H). HRMS (ESI+) calcd for C20H16F2N3O3 (M+H)+384.1154, found 384.1151.
  • Figure US20180194731A1-20180712-C00060
    • 5-((3-(3,4-Difluorobenzamido)benzyl)oxy)nicotinamide (A-40)
  • White solid (30 mg, 33%). 1H NMR (DMSO-d6, 600 MHz) δ 10.37 (s, 1H), 8.66 (d, J=1.6 Hz, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 8.05-8.02 (m, 1H), 7.89 (s, 1H), 7.88-7.84 (m, 2H), 7.74 (d, J=8.1 Hz, 1H), 7.63-7.56 (m, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H16F2N3O3 (M+H)+384.1154, found 384.1161.
  • Figure US20180194731A1-20180712-C00061
    • 5-((3-(2-Fluoro-4-methylbenzamido)benzyl)oxy)nicotinamide (A-41)
  • White solid (18 mg, 20%). 1H NMR (DMSO-d6, 600 MHz) δ 10.36 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.86 (d, J=8.4 Hz, 2H), 7.67 (d, J=7.6 Hz, 1H), 7.61 (s, 1H), 7.56 (dd, J=7.9, 7.9 Hz, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.9 Hz, 1H), 7.18 (d, J=11.4 Hz, 1H), 7.14 (d, J=7.6 Hz, 1H), 5.24 (s, 2H), 2.38 (s, 3H). HRMS (ESI+) calcd for C21H19FN3O03 (M+H)+380.1405, found 380.1411.
  • Figure US20180194731A1-20180712-C00062
    • 5-((3-(3-Fluoro-4-methylbenzamido)benzyl)oxy)nicotinamide (A-42)
  • White solid (56 mg, 62%). 1H NMR (DMSO-d6, 600 MHz) δ 10.28 (s, 1H), 8.65 (d, J=1.6 Hz, 1H), 8.49 (d, J=2.9 Hz, 1H), 8.13 (s, 1H), 7.91 (s, 1H), 7.86-7.84 (m, 1H), 7.76-7.72 (m, 3H), 7.60 (s, 1H), 7.45 (dd, J=7.8, 7.8 Hz, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.6 Hz, 1H), 5.24 (s, 2H), 2.31 (s, 3H). HRMS (ESI+) calcd for C21H19FN3O3 (M+H)+ 380.1405, found 380.1406.
  • Figure US20180194731A1-20180712-C00063
    • 5-((3-(2-Fluoro-4-methoxybenzamido)benzyl)oxy)nicotinamide (A-43)
  • White solid (33 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 10.23 (s, 1H), 8.64 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.12 (s, 1H), 7.86-7.83 (m, 2H), 7.68-7.58 (m, 3H), 7.36 (dd, J=7.9, 7.9 Hz, 1H), 7.20 (d, J=7.3 Hz, 1H), 6.94 (d, J=12.5 Hz, 1H), 6.88 (dd, J=8.5, 2.0 Hz, 1H), 5.23 (s, 2H), 3.83 (s, 3H). HRMS (ESI+) calcd for C21H19FN3O4 (M+H)+396.1354, found 396.1366.
  • Figure US20180194731A1-20180712-C00064
    • 5-((3-(3-Fluoro-4-methoxybenzamido)benzyl)oxy)nicotinamide (A-44)
  • White solid. 1H NMR (DMSO-d6, 600 MHz) δ 10.19 (s, 1H), 8.64 (s, 1H), 8.49 (d, J=2.5 Hz, 1H), 8.12 (s, 1H), 7.89 (s, 1H), 7.86-7.82 (m, 3H), 7.74 (d, J=7.8 Hz, 1H), 7.60 (s, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.30 (dd, J=8.5, 8.5 Hz, 1H), 7.21 (d, J=7.5 Hz, 1H), 5.24 (s, 2H), 3.91 (s, 3H). HRMS (ESI+) calcd for C21H19FN3O4 (M+H)+396.1354, found 396.1354.
  • Figure US20180194731A1-20180712-C00065
    • 5-((3-(4-Chloro-2-fluorobenzamido)benzyl)oxy)nicotinamide (A-45)
  • White solid (70 mg, 73%). 1H NMR (DMSO-d6, 600 MHz) δ 10.54 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 7.86 (s, 2H), 7.72 (dd, J=8.1, 8.1 Hz, 1H), 7.66 (d, J=8.1 Hz, 1H), 7.62 (d, J=10.1 Hz, 2H), 7.43 (d, J=8.4 Hz, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H16ClFN3O3 (M+H)+400.0859, found 400.0856.
  • Figure US20180194731A1-20180712-C00066
    • 5-((3-(4-Chloro-3-fluorobenzamido)benzyl)oxy)nicotinamide (A-46)
  • White solid (30 mg, 31%). 1H NMR (DMSO-d6, 600 MHz) δ 10.43 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.14 (s, 1H), 7.99 (dd, J=10.1, 1.8 Hz, 1H), 7.91 (s, 1H), 7.86-7.85 (m, 2H), 7.79 (dd, J=7.8, 7.8 Hz, 1H), 7.74 (dd, J=8.1, 8.1 Hz, 1H), 7.62 (s, 1H), 7.41 (t, J=7.9 Hz, 1H), 7.24 (d, J=7.6 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C20H16ClFN3O3 (M+H)+400.0859, found 400.0860.
  • Figure US20180194731A1-20180712-C00067
    • 5-((3-(4-Ethylbenzamido)benzyl)oxy)nicotinamide (A-47)
  • White solid (55 mg, 61%). 1H NMR (DMSO-d6, 600 MHz) δ 10.23 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=2.2 Hz, 1H), 8.15 (s, 1H), 7.94 (s, 1H), 7.90 (d, J=8.1 Hz, 2H), 7.87 (s, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.62 (s, 1H), 7.42-7.35 (m, 3H), 7.20 (d, J=7.6 Hz, 1H), 5.25 (s, 2H), 2.68 (q, J=7.8 Hz, 2H), 1.21 (t, J=7.5 Hz, 3H). HRMS (ESI+) calcd for C22H22N3O3 (M+H)+376.1656, found 376.1658.
  • Figure US20180194731A1-20180712-C00068
    • 5-((3-(4-Isopropylbenzamido)benzyl)oxy)nicotinamide (A-48)
  • Pale solid (30 mg, 32%). 1H NMR (DMSO-d6, 600 MHz) δ 10.23 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.6 Hz, 1H), 8.14 (s, 1H), 7.93 (s, 1H), 7.89 (d, J=8.1 Hz, 2H), 7.86 (s, 1H), 7.75 (d, J=7.9 Hz, 1H), 7.61 (s, 1H), 7.41-7.36 (m, 3H), 7.20 (d, J=7.5 Hz, 1H), 5.24 (s, 2H), 3.00-2.94 (m, 1H), 1.24 (d, J=6.9 Hz, 6H). HRMS (ESI+) calcd for C23H24N3O3 (M+H)+390.1812, found 390.1817.
  • Figure US20180194731A1-20180712-C00069
    • 5-((3-(4-(tert-Butyl)benzamido)benzyl)oxy)nicotinamide (A-49)
  • White solid (55 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.24 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=1.8 Hz, 1H), 8.14 (s, 1H), 7.93 (s, 1H), 7.89 (d, J=8.2 Hz, 2H), 7.86 (s, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J=8.1 Hz, 2H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (d, J=7.3 Hz, 1H), 5.25 (s, 2H), 1.32 (s, 9H). HRMS (ESI+) calcd for C24H26N3O3 (M+H)+404.1969, found 404.1976.
  • Figure US20180194731A1-20180712-C00070
    • 5-((3-(4-Cyclohexylbenzamido)benzyl)oxy)nicotinamide (A-50)
  • White solid (45 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.22 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.93 (s, 1H), 7.90-7.84 (m, 3H), 7.74 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.40-7.35 (m, 3H), 7.20 (d, J=7.2 Hz, 1H), 5.24 (s, 2H), 2.59 (t, J=12.0 Hz, 1H), 1.84-1.77 (m, 4H), 1.76-1.68 (m, 1H), 1.49-1.34 (m, 4H), 1.30-1.22 (m, 1H). HRMS (ESI+) calcd for C26H28N3O3 (M+H)+430.2131, found 430.2124.
  • Figure US20180194731A1-20180712-C00071
    • 5-((3-(4-Phenylbenzamido)benzyl)oxy)nicotinamide (A-51)
  • White solid (70 mg, 69%). 1H NMR (DMSO-d6, 600 MHz) δ 10.36 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 7.07 (d, J=8.4 Hz, 2H), 7.96 (s, 1H), 7.87 (s, 1H), 7.83 (d, J=8.4 Hz, 2H), 7.80-7.74 (m, 3H), 7.62 (s, 1H), 7.50 (dd, J=7.5, 7.5 Hz, 2H), 7.53-7.38 (m, 2H), 7.22 (d, J=7.5 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C26H22N3O3 (M+H)+ 424.1661, found 424.1666.
  • Figure US20180194731A1-20180712-C00072
    • 5-((3-(4-(Thiophen-2-yl)benzamido)benzyl)oxy)nicotinamide (A-52)
  • White solid (9.0 mg, 10%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.65 (s, 1H), 8.50 (s, 1H), 8.14 (s, 1H), 8.02 (d, J=7.8 Hz, 2H), 7.94 (s, 1H), 7.87 (s, 1H), 7.82 (d, J=7.8 Hz, 2H), 7.77 (d, J=8.4 Hz, 1H), 7.69 (s, 1H), 7.75 (d, J=5.4 Hz, 1H), 7.61 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.24-7.17 (m, 2H), 5.26 (s, 2H). HRMS (ESI+) calcd for C24H20N3O3S (M+H)+430.1225, found 430.1227.
  • Figure US20180194731A1-20180712-C00073
    • 5-((3-(4-(Thiazol-2-yl)benzamido)benzyl)oxy)nicotinamide (A-53)
  • Pale solid (31 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 10.44 (s, 1H), 8.66 (s, 1H), 8.51 (s, 1H), 8.17-8.06 (m, 5H), 8.01 (d, J=3.0 Hz, 1H), 7.95 (s, 1H), 7.89 (d, J=3.0 Hz, 1H), 7.87 (s, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C23H19N4O3S (M+H)+431.1178, found 431.1183.
  • Figure US20180194731A1-20180712-C00074
    • 5-((3-(4-(1H-Pyrrol-1-yl)benzamido)benzyl)oxy)nicotinamide (A-54)
  • Pale solid (9.0 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=1.2 Hz, 1H), 8.14 (s, 1H), 8.07 (d, J=7.8 Hz, 2H), 7.94 (s, 1H), 7.87 (s, 1H), 7.80-7.74 (m, 3H), 7.62 (s, 1H), 7.52 (s, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 6.32 (s, 2H), 5.26 (s, 2H). HRMS (ESI+) calcd for C24H21N4O3 (M+H)+413.1614, found 413.1612.
  • Figure US20180194731A1-20180712-C00075
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(1H-pyrazol-1-yl)nicotinamide (A-55)
  • Pale solid (16 mg, 19%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.68-8.62 (m, 2H), 8.50 (d, J=2.4 Hz, 1H), 8.17-8.08 (m, 3H), 8.02 (d, J=9.0 Hz, 2H), 7.94 (s, 1H), 7.87 (s, 1H), 7.82 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 6.61 (s, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C23H20N5O3 (M+H)+414.1566, found 414.1567.
  • Figure US20180194731A1-20180712-C00076
    • 5-((3-(4-(1H-Imidazol-1-yl)benzamido)benzyl)oxy)nicotinamide (A-56)
  • Brownish solid (10 mg, 8.1%). 1H NMR (DMSO-d6, 600 MHz) δ 10.38 (s, 1H), 8.66 (s, 1H), 8.50 (s, 1H), 8.42 (s, 1H), 8.17-8.08 (m, 3H), 7.94 (s, 1H), 7.89 (s, 1H), 7.88-7.83 (m, 3H), 7.77 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.41 (dd, J=8.1, 8.1 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 7.16 (s, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C23H20N5O3 (M+H)+ 414.1566, found 414.1564.
  • Figure US20180194731A1-20180712-C00077
    • 5-((3-(4-(4H-1,2,4-Triazol-4-yl)benzamido)benzyl)oxy)nicotinamide (A-57)
  • Pale solid (10 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 9.26 (s, 2H), 8.66 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.18-8.11 (m, 3H), 7.92 (dd, J=8.7, 8.7 Hz, 3H), 7.86 (s, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C22H19N6O3 (M+H)+415.1519, found 415.1518.
  • Figure US20180194731A1-20180712-C00078
    • 5-((3-(4-(Pyridin-2-yl)benzamido)benzyl)oxy)nicotinamide (A-58)
  • White solid (37 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 10.40 (s, 1H), 8.72 (d, J=1.8 Hz, 1H), 8.66 (s, 1H), 8.52 (s, 1H), 8.28-8.22 (m, 2H), 8.15 (s, 1H), 8.12-8.05 (m, 3H), 7.98-7.92 (m, 2H), 7.87 (s, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.45-7.38 (m, 2H), 7.23 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H21N4O3 (M+H)+425.1614, found 425.1615.
  • Figure US20180194731A1-20180712-C00079
    • 5-((3-(4-(Pyridin-3-yl)benzamido)benzyl)oxy)nicotinamide (A-59)
  • Pale solid (48 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.40 (s, 1H), 8.99 (s, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.51 (s, 1H), 8.18 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 8.10 (d, J=7.8 Hz, 2H), 7.96 (s, 1H), 7.92 (d, J=8.4 Hz, 2H), 7.87 (s, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.54 (dd, J=6.0, 6.0 Hz, 1H), 7.41 (dd, J=8.1, 8.1 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H21N4O3 (M+H)+425.1614, found 425.1617.
  • Figure US20180194731A1-20180712-C00080
    • 5-((3-(4-(Pyridin-4-yl)benzamido)benzyl)oxy)nicotinamide (A-60)
  • Pale solid (70 mg, 66%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.69 (d, J=6.0 Hz, 2H), 8.66 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 8.12 (d, J=7.8 Hz, 2H), 7.98 (d, J=7.8 Hz, 2H), 7.96 (s, 1H), 7.87 (s, 1H), 7.82-7.76 (m, 3H), 7.61 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H21N4O3 (M+H)+425.1614, found 425.1614.
  • Figure US20180194731A1-20180712-C00081
    • 5-((3-(4-Ethynylbenzamido)benzyl)oxy)nicotinamide(A-61)
  • Yellowish solid (13 mg, 17%). 1H NMR (DMSO-d6, 600 MHz) δ 10.39 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 7.97 (d, J=7.8 Hz, 2H), 7.92 (s, 1H), 7.86 (s, 1H), 7.75 (d, J=7.2 Hz, 1H), 7.66-7.58 (m, 3H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 5.25 (s, 2H), 4.41 (s, 1H). HRMS (ESI+) calcd for C22H18N3O3 (M+H)+372.1348, found 372.1346.
  • Figure US20180194731A1-20180712-C00082
    • Methyl 4-((3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamoyl)benzoate (A-62)
  • Pale solid (250 mg, 75%). 1H NMR (DMSO-d6, 600 MHz) δ 10.56 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.19 (s, 1H), 8.12-8.06 (m, 4H), 7.94 (s, 1H), 7.89 (s, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.26 (s, 2H), 3.90 (s, 3H). HRMS (ESI+) calcd for C22H20N3O5 (M+H)+406.1403, found 406.1402.
  • Figure US20180194731A1-20180712-C00083
    • 4-((3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamoyl)benzoic acid (A-63)
  • White solid (13 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.72-8.63 (m, 1H), 8.59 (bs, 1H), 8.50 (bs, 1H), 8.14 (s, 1H), 8.06 (dd, J=7.8, 12.0 Hz, 4H), 7.95-7.90 (m, 1H), 7.88-7.82 (m, 1H), 7.79-7.74 (m, 1H), 7.62 (s, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.31-5.25 (m, 2H). HRMS (ESI+) calcd for C21H18N3O5 (M+H)+392.1246, found 392.1247.
  • Figure US20180194731A1-20180712-C00084
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)terephthalamide (A-64)
  • White solid (20 mg, 69%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.13 (d, J=11.4 Hz, 2H), 8.04-7.97 (m, 4H), 7.94 (s, 1H), 7.86 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.53 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C21H19N4O4 (M+H)+391.1406, found 391.1401.
  • Figure US20180194731A1-20180712-C00085
    • N1-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-N4-methylterephthalamide (A-65)
  • White solid (22 mg, 74%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.65 (s, 1H), 8.62-8.57 (m, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 8.03 (d, J=7.8 Hz, 2H), 7.96 (d, J=8.4 Hz, 2H), 7.93 (s, 1H), 7.86 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.40 (dd, J=7.5, 7.5 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.26 (s, 2H), 2.81 (d, J=4.2 Hz, 3H). HRMS (ESI+) calcd for C22H21N4O4 (M+H)+405.1563, found 405.1566.
  • Figure US20180194731A1-20180712-C00086
    • N1-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-N4,N4-dimethylterephthalamide (A-66)
  • White solid (0.8 mg, 4%). 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.47 (s, 1H), 8.02 (d, J=7.8 Hz, 2H), 7.93 (s, 1H), 7.89 (s, 1H), 7.69 (d, J=7.2 Hz, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.29 (d, J=7.2 Hz, 1H), 5.27 (s, 2H), 3.13 (s, 3H), 3.01 (s, 3H). HRMS (ESI+) calcd for C23H23N4O4 (M+H)+419.1719, found 419.1710.
  • Figure US20180194731A1-20180712-C00087
    • 5-((3-(4-Acetamidobenzamido)benzyl)oxy)nicotinamide (A-67)
  • Pale solid (7.0 mg, 8%). 1H NMR (DMSO-d6, 600 MHz) δ 10.21 (s, 1H), 10.17 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.94-7.89 (m, 3H), 7.86 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.61 (s, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.19 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 2.08 (s, 3H). HRMS (ESI+) calcd for C22H21N4O4 (M+H)+ 405.1563, found 405.1560.
  • Figure US20180194731A1-20180712-C00088
    • 5-((3-(4-Acetylbenzamido)benzyl)oxy)nicotinamide (A-68)
  • Pale solid (30 mg, 37%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (s, 1H), 8.46 (d, J=3.0 Hz, 1H), 8.19 (d, J=7.2 Hz, 1H), 8.17 (d, J=7.8 Hz, 1H), 7.94-7.92 (m, 1H), 7.89 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.66 (dd, J=8.4, 8.4 Hz, 1H), 7.42 (dd, J=7.5, 7.5 Hz, 1H), 7.28 (d, J=7.2 Hz, 1H), 5.27 (s, 2H), 2.68 (s, 3H). HRMS (ESI+) calcd for C22H20N3O4 (M+H)+390.1454, found 390.1459.
  • Figure US20180194731A1-20180712-C00089
    • 5-((3-(4-Phenoxybenzamido)benzyl)oxy)nicotinamide (A-69)
  • White solid (32 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 10.26 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.14 (s, 1H), 8.00 (d, J=8.4 Hz, 2H), 7.92 (s, 1H), 7.86 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.46 (dd, J=7.8, 7.8 Hz, 2H), 7.39 (dd, J=7.5, 7.5 Hz, 1H), 7.25-7.19 (m, 2H), 7.14-7.07 (m, 4H), 5.25 (s, 2H). HRMS (ESI+) calcd for C26H22N3O4 (M+H)+440.1610, found 440.1608.
  • Figure US20180194731A1-20180712-C00090
    • 5-((3-(4-(Benzyloxy)benzamido)benzyl)oxy)nicotinamide (A-70)
  • White solid (18 mg, 16%). 1H NMR (DMSO-d6, 600 MHz) δ 10.14 (s, 1H), 8.65 (d, J=1.6 Hz, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.13 (s, 1H), 7.96-7.94 (m, 2H), 7.91 (s, 1H), 7.86 (dd, J=2.6, 1.8 Hz, 1H), 7.74 (d, J=8.1 Hz, 1H), 7.60 (s, 1H), 7.48 (d, J=7.3 Hz, 2H), 7.42-7.33 (m, 4H), 7.19 (d, J=7.6 Hz, 1H), 7.14 (d, J=8.8 Hz, 2H), 5.24 (s, 2H), 5.20 (s, 2H). HRMS (ESI+) calcd for C27H24N3O4 (M+H)+454.1761, found 454.1774.
  • Figure US20180194731A1-20180712-C00091
    • 5-((3-(4-(Methylamino)benzamido)benzyl)oxy)nicotinamide (A-71)
  • Pale solid (1.0 mg, 1%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (s, 1H), 7.93 (s, 1H), 7.83 (s, 1H), 7.78 (d, J=7.8 Hz, 2H), 7.63 (d, J=8.4 Hz, 1H), 7.37 (dd, J=7.5, 7.5 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 6.63 (d, J=7.8 Hz, 2H), 5.25 (s, 2H), 2.83 (s, 3H). HRMS (ESI+) calcd for C21H21N4O3 (M+H)+377.1614, found 377.1608.
  • Figure US20180194731A1-20180712-C00092
    • 5-((3-(4-(Ethylamino)benzamido)benzyl)oxy)nicotinamide (A-72)
  • Pale solid (2.0 mg, 2.5%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.46 (d, J=3.0 Hz, 1H), 7.92 (dd, J=2.1, 2.1 Hz, 1H), 7.83 (s, 1H), 7.78-7.75 (m, 2H), 7.63 (d, J=8.4 Hz, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 6.64 (d, J=8.4 Hz, 2H), 5.25 (s, 2H), 3.19 (q, J=7.2 Hz, 2H), 1.26 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C22H23N4O3 (M+H)+391.1770, found 391.1771.
  • Figure US20180194731A1-20180712-C00093
    • 5-((3-(4-(Dimethylamino)benzamido)benzyl)oxy)nicotinamide (A-73)
  • Pale solid (5.0 mg, 6%). 1H NMR (CD3OD, 600 MHz) δ 8.61 (s, 1H), 8.46 (s, 1H), 7.92 (s, 1H), 7.86-7.77 (m, 3H), 7.62 (d, J=7.8 Hz, 1H), 7.38 (dd, J=7.5, 7.5 Hz, 1H), 7.23 (d, J=6.6, 1H), 6.78 (d, J=7.2 Hz, 2H), 5.24 (s, 2H), 3.04 (s, 6H). HRMS (ESI+) calcd for C22H23N4O3 (M+H)+391.1770, found 391.1762.
  • Figure US20180194731A1-20180712-C00094
    • 5-((3-(4-(Diethylamino)benzamido)benzyl)oxy)nicotinamide (A-74)
  • Pale solid (4.0 mg, 5%). 1H NMR (CD3OD, 600 MHz) δ 8.61 (s, 1H), 8.46 (s, 1H), 7.92 (s, 1H), 7.84-7.79 (m, 3H), 7.62 (d, J=7.8 Hz, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=6.6, 1H), 6.73 (d, J=9.0 Hz, 2H), 5.25 (s, 2H), 3.46 (q, J=6.9 Hz, 4H), 1.19 (t, J=7.2 Hz, 6H). HRMS (ESI+) calcd for C24H27N4O3 (M+H)+419.2083, found 419.2077.
  • Figure US20180194731A1-20180712-C00095
    • 5-((3-(4-(Pyrrolidin-1-yl)benzamido)benzyl)oxy)nicotinamide (A-75)
  • White solid (12 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 9.89 (s, 1H), 8.64 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.88-7.84 (m, 3H), 7.73 (d, J=8.1 Hz, 1H), 7.60 (s, 1H), 7.34 (dd, J=7.6, 7.6 Hz, 1H), 7.14 (d, J=7.6 Hz, 1H), 6.58 (d, J=8.5 Hz, 2H), 5.22 (s, 2H), 3.34-3.28 (m, 4H), 2.00-1.94 (m, 4H). HRMS (ESI+) calcd for C24H25N4O3 (M+H)+417.1921, found 417.1921.
  • Figure US20180194731A1-20180712-C00096
    • 5-((3-(4-(Piperidin-1-yl)benzamido)benzyl)oxy)nicotinamide (A-76)
  • White solid (26 mg, 25%). 1H NMR (DMSO-d6, 600 MHz) 9.96 (s, 1H), 8.63 (s, 1H), 8.48 (s, 1H), 8.12 (s, 1H), 7.90 (s, 1H), 7.86-7.82 (m, 3H), 7.72 (d, J=7.9 Hz, 1H), 7.60 (s, 1H), 7.34 (dd, J=7.8, 7.8 Hz, 1H), 7.14 (d, J=7.4 Hz, 1H), 6.96 (d, J=8.5 Hz, 2H), 5.21 (s, 2H), 3.40-3.30 (m, 4H), 1.61-1.57 (m, 6H). HRMS (ESI+) calcd for C25H27N4O3 (M+H)+431.2078, found 431.208.
  • Figure US20180194731A1-20180712-C00097
    • 5-((3-(4-Morpholinobenzamido)benzyl)oxy)nicotinamide (A-77)
  • White solid (72 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 10.02 (s, 1H), 8.64 (s, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 7.93-7.87 (m, 3H), 7.86 (s, 1H), 7.74 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.35 (dd, J=7.8, 7.8 Hz, 1H), 7.16 (d, J=7.6 Hz, 1H), 7.02 (d, J=8.7 Hz, 2H), 5.23 (s, 2H), 3.78-3.72 (m, 4H), 3.28-3.22 (m, 4H). HRMS (ESI+) calcd for C24H25N4O4 (M+H)+433.1870, found 433.1878.
  • Figure US20180194731A1-20180712-C00098
    • 5-((3-(4-(4-Methylpiperazin-1-yl)benzamido)benzyl)oxy)nicotinamide (A-78)
  • White solid (32 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 10.00 (s, 1H), 8.64 (s, 1H), 8.48 (s, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.88-7.85 (m, 3H), 7.73 (d, J=8.1 Hz, 1H), 7.60 (s, 1H), 7.35 (dd, J=7.6, 7.6 Hz, 1H), 7.16 (d, J=7.3 Hz, 1H), 7.01 (d, J=8.2 Hz, 2H), 5.23 (s, 2H), 3.40-3.30 (m, 4H), 2.50-2.45 (m, 4H), 2.24 (s, 3H). HRMS (ESI+) calcd for C25H28N5O3 (M+H)+ 446.2114, found 446.2194.
  • Figure US20180194731A1-20180712-C00099
    • 5-((3-(4-((Dimethylamino)methyl)benzamido)benzyl)oxy)nicotinamide (A-79)
  • Pale solid (15 mg, 71%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.96-7.91 (m, 3H), 7.88 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.51 (d, J=7.8 Hz, 2H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 5.25 (s, 2H), 3.71 (s, 2H), 2.38 (s, 6H). HRMS (ESI+) calcd for C23H25N4O3 (M+H)+405.1927, found 405.1924.
  • Figure US20180194731A1-20180712-C00100
    • 5-((3-(4-(Methoxymethyl)benzamido)benzyl)oxy)nicotinamide (A-80)
  • Pale solid (10 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 10.30 (s, 1H), 8.65 (s, 1H), 8.50 (s, 1H), 8.14 (s, 1H), 7.93-7.91 (m, 3H), 7.86 (s, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.46 (d, J=7.8 Hz, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.2 Hz, 1H), 5.25 (s, 2H), 4.50, (s, 2H), 3.33 (s, 3H). HRMS (ESI+) calcd for C22H22N3O4 (M+H)+392.1610, found 392.1601.
  • Figure US20180194731A1-20180712-C00101
    • 5-((3-(4-((Diethylamino)methyl)benzamido)benzyl)oxy)nicotinamide (A-81)
  • White solid (17 mg, 75%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.45 (d, J=3.0 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 3.72 (s, 2H), 2.61 (q, J=7.2 Hz, 4H), 1.10 (t, J=7.2 Hz, 6H). HRMS (ESI+) calcd for C25H29N4O3 (M+H)+433.2240, found 433.2236.
  • Figure US20180194731A1-20180712-C00102
    • 5-((3-(4-(Pyrrolidin-1-ylmethyl)benzamido)benzyl)oxy)nicotinamide (A-82)
  • Pale solid (18 mg, 82%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.96-7.91 (m, 3H), 7.88 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.54 (d, J=7.8 Hz, 2H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 5.26 (s, 2H), 3.89 (s, 2H), 2.79-2.72 (m, 4H), 1.92-1.86 (m, 4H). HRMS (ESI+) calcd for C25H27N4O3 (M+H)+431.2083, found 431.2080.
  • Figure US20180194731A1-20180712-C00103
    • 5-((3-(4-(Piperidin-1-ylmethyl)benzamido)benzyl)oxy)nicotinamide (A-83)
  • Pale solid (19 mg, 84%). 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.46 (d, J=3.0 Hz, 1H), 7.97 (d, J=7.8 Hz, 2H), 7.93 (s, 1H), 7.88 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.57 (d, J=7.8 Hz, 2H), 7.41 (dd, J=7.5, 7.5 Hz, 1H), 7.28 (d, J=7.2 Hz, 1H), 5.27 (s, 2H), 3.94 (s, 2H), 2.88-2.72 (m, 4H), 1.78-1.66 (m, 4H), 1.62-1.52 (m, 2H). HRMS (ESI+) calcd for C26H29N4O3 (M+H)+445.2240, found 445.2243.
  • Figure US20180194731A1-20180712-C00104
    • 5-((3-(4-(Azetidin-1-ylmethyl)benzamido)benzyl)oxy)nicotinamide (A-84)
  • Pale solid (20 mg, 94%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (d, J=3.0 Hz, 1H), 7.96 (d, J=7.8 Hz, 2H), 7.94-7.91 (m, 1H), 7.88 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 4.09 (s, 2H), 3.76 (t, J=7.5 Hz, 4H), 2.33 (quin, J=7.8 Hz, 2H). HRMS (ESI+) calcd for C24H25N4O3 (M+H)+ 417.1927, found 417.1925.
  • Figure US20180194731A1-20180712-C00105
    • 5-((3-(4-(Morpholinomethyl)benzamido)benzyl)oxy)nicotinamide (A-85)
  • Yellowish solid (11 mg, 12%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.49 (d, J=7.8 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 3.69 (t, J=4.5, 4.5 Hz, 4H), 3.59 (s, 2H), 2.50-2.44 (m, 4H). HRMS (ESI+) calcd for C25H27N4O4 (M+H)+447.2032, found 447.2029.
  • Figure US20180194731A1-20180712-C00106
    • 5-((3-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzyl)oxy)nicotinamide (A-86)
  • Yellowish solid (3.0 mg, 3.3%). 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.46 (d, J=3.0 Hz, 1H), 7.96-7.91 (m, 3H), 7.88 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.51 (d, J=7.8 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 5.26 (s, 2H), 3.68 (s, 2H), 3.02-2.86 (m, 4H), 2.74-2.62 (m, 4H), 2.61 (s, 3H). HRMS (ESI+) calcd for C26H30N5O3 (M+H)+460.2349, found 460.2349.
  • Figure US20180194731A1-20180712-C00107
    • 5-((3-(4-((4,4-Difluoropiperidin-1-yl)methyl)benzamido)benzyl)oxy)nicotinamide (A-87)
  • Pale solid (8.7 mg, 48%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 3.65 (s, 2H), 2.62-2.54 (m, 4H), 2.03-1.94 (m, 4H). HRMS (ESI+) calcd for C26H27F2N4O3 (M+H)+481.2051, found 481.2050.
  • Figure US20180194731A1-20180712-C00108
    • 5-((3-(4-((3,3-Difluoropiperidin-1-yl)methyl)benzamido)benzyl)oxy)nicotinamide (A-88)
  • Pale solid (9.2 mg, 50%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 3.67 (s, 2H), 2.62 (t, J=11.4 Hz, 2H), 2.52-2.46 (m, 2H), 1.93-1.84 (m, 2H), 1.80-1.74 (m, 2H). HRMS (ESI+) calcd for C26H27F2N4O3 (M+H)+ 481.2051, found 481.2050.
  • Figure US20180194731A1-20180712-C00109
    • 5-((3-(4-((3,3-Difluoropyrrolidin-1-yl)methyl)benzamido)benzyl)oxy)nicotinamide (A-89)
  • Pale solid (12 mg, 68%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (s, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.49 (d, J=7.8 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.2 Hz, 1H), 5.25 (s, 2H), 3.73 (s, 2H), 2.89 (t, J=13.2 Hz, 2H), 2.78 (t, J=6.9 Hz, 2H), 2.33-2.24 (m, 2H). HRMS (ESI+) calcd for C25H25F2N4O3 (M+H)+ 467.1895, found 467.1892.
  • Figure US20180194731A1-20180712-C00110
    • 5-((3-(4-((3,3-Difluoroazetidin-1-yl)methyl)benzamido)benzyl)oxy)nicotinamide (A-90)
  • Pale solid (5.1 mg, 30%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.48 (d, J=8.4 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 5.26 (s, 2H), 3.85 (s, 2H), 3.66 (t, J=12.0 Hz, 4H). HRMS (ESI+) calcd for C24H23F2N4O3 (M+H)+453.1738, found 453.1740.
  • Figure US20180194731A1-20180712-C00111
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)picolinamide (A-91)
  • White solid (61 mg, 73%). 1H NMR (DMSO-d6, 600 MHz) δ 10.69 (s, 1H), 8.74 (d, J=4.1 Hz, 1H), 8.65 (s, 1H), 8.50 (s, 1H), 8.17-8.12 (m, 2H), 8.10-8.05 (m, 2H), 7.88-7.84 (m, 2H), 7.68 (dd, J=5.3, 5.3 Hz, 1H), 7.61 (s, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.5 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C19H17N4O3 (M+H)+349.1295, found 349.1305.
  • Figure US20180194731A1-20180712-C00112
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)nicotinamide (A-92)
  • White solid (60 mg, 72%). 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 9.11 (s, 1H), 8.76 (d, J=4.0 Hz, 1H), 8.65 (s, 1H), 8.50 (s, 1H), 8.29 (d, J=7.9 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.62 (s, 1H), 7.57 (dd, J=6.9, 6.9 Hz, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.5 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C19H17N4O3 (M+H)+349.1295, found 349.1300.
  • Figure US20180194731A1-20180712-C00113
    • 5-((3-(Isonicotinamido)benzyl)oxy)nicotinamide (A-93)
  • White solid (30 mg, 36%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 8.79 (d, J=5.7 Hz, 2H), 8.65 (s, 1H), 8.50 (d, J=2.5 Hz, 1H), 8.15 (s, 1H), 7.91 (s, 1H), 7.87-7.84 (m, 3H), 7.76 (d, J=8.1 Hz, 1H), 7.63 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.25 (d, J=7.5 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C19H17N4O3 (M+H)+349.1295, found 349.1300.
  • Figure US20180194731A1-20180712-C00114
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)pyrimidine-4-carboxamide (A-94)
  • White solid (40 mg, 48%). 1H NMR (DMSO-d6, 600 MHz) δ 10.87 (s, 1H), 9.41 (s, 1H), 9.12 (d, J=5.1 Hz, 1H), 8.64 (s, 1H), 8.49 (d, J=2.6 Hz, 1H), 8.12 (d, J=4.7 Hz, 2H), 8.06 (s, 1H), 7.87-7.84 (m, 2H), 7.60 (s, 1H), 7.41 (dd, J=7.6, 7.6 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1247.
  • Figure US20180194731A1-20180712-C00115
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)pyridazine-4-carboxamide (A-95)
  • White solid (40 mg, 48%). 1H NMR (DMSO-d6, 600 MHz) δ 10.76 (s, 1H), 9.63 (s, 1H), 9.48 (d, J=5.4 Hz, 1H), 8.64 (s, 1H), 8.48 (d, J=2.6 Hz, 1H), 8.12 (s, 1H), 8.11-8.09 (m, 1H), 7.89 (s, 1H), 7.86 (s, 1H), 7.74 (d, J=8.7 Hz, 1H), 7.60 (s, 1H), 7.43 (dd, J=7.9, 7.9 Hz, 1H), 7.27 (d, J=7.2 Hz, 1H) 5.26 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1251.
  • Figure US20180194731A1-20180712-C00116
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)pyrazine-2-carboxamide (A-96)
  • White solid (35 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 10.78 (s, 1H), 9.29 (s, 1H), 8.92 (s, 1H), 8.80 (s, 1H), 8.64 (s, 1H), 8.50 (s, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 7.87 (s, 1H), 7.84 (d, J=8.1 Hz, 1H), 7.61 (s, 1H), 7.41 (dd, J=7.6, 7.6 Hz, 1H), 7.25 (d, J=7.3 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1250.
  • Figure US20180194731A1-20180712-C00117
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)pyridazine-3-carboxamide (A-97)
  • White solid (25 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 11.12 (s, 1H), 9.46 (dd, J=5.0, 1.8 Hz, 1H), 8.71 (s, 1H), 8.62 (s, 1H), 8.31 (dd, J=8.5, 1.8 Hz, 1H), 8.22 (s, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 7.97 (dd, J=8.4, 5.0 Hz, 1H), 7.88 (d, J=7.8 Hz, 1H), 7.73 (s, 1H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.5 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1257.
  • Figure US20180194731A1-20180712-C00118
    • (E)-5-((3-(3-(Pyridin-2-yl)acrylamido)benzyl)oxy)nicotinamide (A-98)
  • Pale solid (41 mg, 53%). 1H NMR (DMSO-d6, 600 MHz) δ 10.43 (s, 1H), 8.67-8.62 (m, 2H), 8.49 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.88-7.83 (m, 3H), 7.68 (d, J=8.4 Hz, 1H), 7.65-7.58 (m, 3H), 7.42-7.35 (m, 2H), 7.32 (d, J=15.6 Hz, 1H), 7.19 (d, J=7.8 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1457, found 375.1456.
  • Figure US20180194731A1-20180712-C00119
    • (E)-5-((3-(3-(Pyridin-3-yl)acrylamido)benzyl)oxy)nicotinamide (A-99)
  • White solid (41 mg, 53%). 1H NMR (DMSO-d6, 600 MHz) δ 10.35 (s, 1H), 8.82 (d, J=1.8 Hz, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.58 (d, J=4.2 Hz, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 8.04 (d, J=7.8 Hz, 1H), 7.85 (d, J=2.4 Hz, 1H), 7.83 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.65-7.58 (m, 2H), 7.48 (dd, J=7.8, 4.8 Hz, 1H), 7.38 (dd, J=7.5, 7.5 Hz, 1H), 7.19 (d, J=7.2 Hz, 1H), 6.93 (d, J=15.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1457, found 375.1457.
  • Figure US20180194731A1-20180712-C00120
    • (E)-5-((3-(3-(Pyridin-4-yl)acrylamido)benzyl)oxy)nicotinamide (A-100)
  • White solid (35 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.44 (s, 1H), 8.67-8.61 (m, 3H), 8.49 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 7.86 (s, 1H), 7.83 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.59-7.53 (m, 3H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (d, J=7.2 Hz, 1H), 7.04 (d, J=15.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1457, found 375.1459.
  • Figure US20180194731A1-20180712-C00121
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-phenylnicotinamide (A-101)
  • White solid (37 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 10.53 (s, 1H), 9.20 (d, J=2.4 Hz, 1H), 8.66 (d, J=1.2 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.40 (dd, J=8.4, 1.8 Hz, 1H), 8.19 (d, J=7.2 Hz, 2H), 8.15 (d, J=8.4 Hz, 2H), 7.95 (s, 1H), 7.89-7.85 (m, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.55 (dd, J=7.5, 7.5 Hz, 1H), 7.50 (dd, J=7.2, 7.2 Hz, 2H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.25 (d, J=7.2 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C25H21N4O3 (M+H)+425.1614, found 425.1613.
  • Figure US20180194731A1-20180712-C00122
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(thiophen-2-yl)nicotinamide (A-102)
  • Pale solid (32 mg, 36%). 1H NMR (DMSO-d6, 600 MHz) δ 10.50 (s, 1H), 9.05 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.34 (d, J=7.8 Hz, 1H), 8.14 (s, 1H), 8.08 (d, J=8.4 Hz, 1H), 7.95 (d, J=4.2 Hz, 1H), 7.93 (s, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.78-7.73 (m, 2H), 7.62 (s, 1H), 7.42 (dd, J=8.1, 8.1 Hz, 1H), 7.27-7.21 (m, 2H), 5.27 (s, 2H). HRMS (ESI+) calcd for C23H19N4O3S (M+H)+431.1178, found 431.1171.
  • Figure US20180194731A1-20180712-C00123
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(furan-2-yl)nicotinamide (A-103)
  • Pale solid (24 mg, 28%). 1H NMR (DMSO-d6, 600 MHz) δ 10.50 (s, 1H), 9.11 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 7.93 (d, J=6.0 Hz, 2H), 7.87 (d, J=8.4 Hz, 2H), 7.76 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.42 (dd, J=8.1, 8.1 Hz, 1H), 7.28 (d, J=3.0 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 6.74-6.69 (m, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C23H19N4O4 (M+H)+415.1406, found 415.1401.
  • Figure US20180194731A1-20180712-C00124
    • N-((((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(1H-pyrrol-1-yl)nicotinamide (A-104)
  • Brownish solid (20 mg, 24%). 1H NMR (DMSO-d6, 600 MHz) δ 10.45 (s, 1H), 8.99 (s, 1H), 8.66 (s, 1H), 8.50 (s, 1H), 8.42 (d, J=6.6 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.87 (d, J=9.0 Hz, 2H), 7.80-7.73 (m, 3H), 7.62 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 6.36 (s, 2H), 5.27 (s, 2H). HRMS (ESI+) calcd for C23H20N5O3 (M+H)+414.1566, found 414.1572.
  • Figure US20180194731A1-20180712-C00125
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(1H-pyrazol-1-yl)nicotinamide (A-105)
  • Pale solid (35 mg, 41%). 1H NMR (DMSO-d6, 600 MHz) δ 10.53 (s, 1H), 9.02 (d, J=1.8 Hz, 1H), 8.71 (d, J=2.4 Hz, 1H), 8.67 (s, 1H), 8.53-8.48 (m, 2H), 8.15 (s, 1H), 8.06 (d, J=9.0 Hz, 1H), 7.91 (d, J=9.6 Hz, 2H), 7.87 (s, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.42 (dd, J=7.5, 7.5 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 6.64 (s, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C22H19N6O3 (M+H)+ 415.1519, found 415.1521.
  • Figure US20180194731A1-20180712-C00126
    • 5-((3-(2-Fluoro-[1,1′-biphenyl]-4-ylcarboxamido)benzyl)oxy)nicotinamide (A-106)
  • Pale solid (25 mg, 23%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=1.2 Hz, 1H), 8.14 (s, 1H), 7.95 (s, 1H), 7.92 (d, J=9.0 Hz, 2H), 7.87 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.72 (dd, J=7.8, 7.8 Hz, 1H), 7.66-7.57 (m, 3H), 7.53 (dd, J=7.2, 7.2 Hz, 2H), 7.47 (dd, J=6.9, 6.9 Hz, 1H), 7.42 (dd, J=8.1, 8.1 Hz, 1H), 7.24 (d, J=6.6 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C26H21FN3O3 (M+H)+442.1567, found 442.1574.
  • Figure US20180194731A1-20180712-C00127
    • 5-((3-(3-Fluoro-4-(pyridin-3-yl)benzamido)benzyl)oxy)nicotinamide (A-107)
  • Pale solid (20 mg, 18%). 1H NMR (DMSO-d6, 600 MHz) δ 10.47 (s, 1H), 8.72 (d, J=5.4 Hz, 2H), 8.66 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.98-7.92 (m, 3H), 7.87 (s, 1H), 7.83 (dd, J=8.1, 8.1 Hz, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.66 (d, J=4.8 Hz, 2H), 7.62 (s, 1H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.25 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H20FN4O3 (M+H)+443.1519, found 443.1520.
  • Figure US20180194731A1-20180712-C00128
    • 5-((3-(3-Fluoro-4-(pyridin-4-yl)benzamido)benzyl)oxy)nicotinamide (A-108)
  • Pale solid (35 mg, 32%). 1H NMR (DMSO-d6, 600 MHz) δ 10.45 (s, 1H), 8.84 (s, 1H), 8.66 (s, 2H), 8.51 (s, 1H), 8.14 (s, 1H), 8.06 (d, J=7.8 Hz, 1H), 7.98-7.92 (m, 3H), 7.87 (s, 1H), 7.83-7.75 (m, 2H), 7.62 (s, 1H), 7.57 (dd, J=6.0, 6.0 Hz, 1H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H20FN4O3 (M+H)+443.1519, found 443.1522.
  • Figure US20180194731A1-20180712-C00129
    • 5-((3-(4-Bromobenzamido)benzyl)oxy)nicotinamide (A-109)
  • White solid (850 mg, 61%). 1H NMR (DMSO-d6, 600 MHz) δ 10.38 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 7.93-7.89 (m, 3H), 7.86 (s, 1H), 7.77-7.72 (m, 3H), 7.61 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.21 (d, J=7.2 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H17BrN3O3 (M+H)+426.0448, found 426.0452.
  • Figure US20180194731A1-20180712-C00130
    • 5-((3-(4-Bromo-3-fluorobenzamido)benzyl)oxy)nicotinamide (A-110)
  • White solid (240 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 7.94 (d, J=9.5 Hz, 1H), 7.91-7.89 (m, 2H), 7.85 (s, 1H), 7.75 (dd, J1=17.3 Hz, J2=8.2 Hz, 2H), 7.61 (s, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.23 (d, J=7.5 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C20H16BrFN3O3 (M+H)+444.0354, found 444.0359.
  • Figure US20180194731A1-20180712-C00131
    • 5-((3-(4-(Trifluoromethyl)benzamido)benzyl)oxy)nicotinamide (A-11)
  • White solid (40 mg, 40%). 1H NMR (DMSO-d6, 600 MHz) δ 10.54 (s, 1H), 8.65 (s, 1H), 8.50 (d, J=2.6 Hz, 1H), 8.15 (d, J=7.8 Hz, 3H), 7.92 (d, J=7.9 Hz, 3H), 7.85 (s, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.63 (s, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.24 (d, J=7.6 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C21H17F3N3O3 (M+H)+416.1217, found 416.1225.
  • Figure US20180194731A1-20180712-C00132
    • 5-((3-(3-Fluoro-4-(trifluoromethyl)benzamido)benzyl)oxy)nicotinamide (A-112)
  • White solid (50 mg, 56%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 8.06 (d, J=12.0 Hz, 1H), 8.01-7.96 (m, 2H), 7.91 (s, 1H), 7.86 (s, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C21H16F4N3O3 (M+H)+434.1122, found 434.1132.
  • Figure US20180194731A1-20180712-C00133
    • 5-((3-(3-Fluoro-4-(trifluoromethoxy)benzamido)benzyl)oxy)nicotinamide (A-113)
  • White solid (47 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.46 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 8.08 (d, J=10.8 Hz, 1H), 7.94-7.88 (m, 2H), 7.86 (s, 1H), 7.79-7.72 (m, 2H), 7.62 (s, 1H), 7.41 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=6.6 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C21H16F4N3O4 (M+H)+450.1071, found 450.1072.
  • Figure US20180194731A1-20180712-C00134
    • 5-((3-(3-Fluoro-4-morpholinobenzamido)benzyl)oxy)nicotinamide (A-114)
  • White solid (7 mg, 11%). 1H NMR (DMSO-d6, 600 MHz) δ 10.17 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.82-7.77 (m, 2H), 7.74 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (d, J=6.6 Hz, 1H), 7.14 (dd, J=9.0, 9.0 Hz, 1H), 5.24 (s, 2H), 3.78-3.73 (m, 4H), 3.15-3.11 (m, 4H). HRMS (ESI+) calcd for C24H24FN4O4 (M+H)+451.1776, found 451.1787.
  • Figure US20180194731A1-20180712-C00135
    • 5-((3-(3-Fluoro-4-(piperidin-1-ylmethyl)benzamido)benzyl)oxy)nicotinamide (A-115)
  • Brownish solid (22 mg, 38%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (s, 1H), 7.91 (s, 1H), 7.87 (s, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.70-7.64 (m, 2H), 7.57 (dd, J=7.2, 7.2 Hz, 1H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 5.24 (s, 2H), 3.67 (s, 2H), 2.58-2.46 (m, 4H), 1.66-1.58 (m, 4H), 1.50-1.42 (m, 2H). HRMS (ESI+) calcd for C26H28FN4O3 (M+H)+463.2140, found 463.2154.
  • Figure US20180194731A1-20180712-C00136
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-fluoronicotinamide (A-116)
  • Pale solid (100 mg, 67%). 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 8.82 (d, J=1.8 Hz, 1H), 8.65 (s, 1H), 8.52-8.46 (m, 2H), 8.13 (s, 1H), 7.89 (s, 1H), 7.86 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 8.37 (dd, J=2.4, 8.4 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H), 5.26 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1203.
  • Figure US20180194731A1-20180712-C00137
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-5-fluoronicotinamide (A-117)
  • White solid (40 mg, 53%). 1H NMR (DMSO-d6, 600 MHz) δ 10.56 (s, 1H), 8.99 (s, 1H), 8.80 (d, J=2.4 Hz, 1H), 8.65 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.22 (d, J=9.6 Hz, 1H), 8.14 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.42 (dd, J=7.5, 7.5 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+ 367.1201, found 367.1215.
  • Figure US20180194731A1-20180712-C00138
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-methylnicotinamide (A-118)
  • White solid (27 mg, 36%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 9.00 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.22-8.17 (m, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.44-7.36 (m, 2H), 7.23 (d, J=7.2 Hz, 1H), 5.26 (s, 2H), 2.56 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+ 363.1452, found 363.1457.
  • Figure US20180194731A1-20180712-C00139
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-(trimethyl)nicotinamide (A-119)
  • White solid (44 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 10.70 (s, 1H), 9.25 (s, 1H), 8.65 (s, 1H), 8.57 (d, J=7.8 Hz, 1H), 8.50 (d, J=1.8 Hz, 1H), 8.14 (s, 1H), 8.11 (d, J=8.4 Hz, 1H), 7.91 (s, 1H), 7.86 (s, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.62 (s, 1H), 7.43 (dd, J=7.5, 7.5 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C20H16F3N4O3 (M+H)+417.1169, found 417.1175.
  • Figure US20180194731A1-20180712-C00140
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-methoxynicotinamide (A-120)
  • White solid (42 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.31 (s, 1H), 8.79 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.26-8.20 (m, 1H), 8.14 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.73 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.22 (d, J=7.2 Hz, 1H), 6.95 (d, J=9.0 Hz, 1H), 5.25 (s, 2H), 3.94 (s, 3H). HRMS (ESI+) calcd for C20H19N4O4 (M+H)+379.1401, found 379.1400.
  • Figure US20180194731A1-20180712-C00141
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-ethoxynicotinamide (A-121)
  • White solid (37 mg, 46%). 1H NMR (DMSO-d6, 600 MHz) δ 10.29 (s, 1H), 8.77 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.24-8.20 (m, 1H), 8.14 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.2 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 5.25 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C21H21N4O4 (M+H)+393.1557, found 393.1566.
  • Figure US20180194731A1-20180712-C00142
    • 6-(Benzyloxy)-N-(3-(((5-carbamoylpyridin-3-yl)oxy)methyl)phenyl)nicotinamide (A-122)
  • White solid (40 mg, 43%). 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.79 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.25 (d, J=7.8 Hz, 1H), 8.14 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.47 (d, J=8.4 Hz, 2H), 7.39 (dd, J=7.5, 7.5 Hz, 3H), 7.34 (dd, J=6.9, 6.9 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 5.45 (s, 2H), 5.25 (s, 2H). HRMS (ESI+) calcd for C26H23N4O4 (M+H)+455.1714, found 455.1719.
  • Figure US20180194731A1-20180712-C00143
    • 5-((3-(2-Fluoroisonicotinamido)benzyl)oxy)nicotinamide (A-123)
  • Pale solid (12 mg, 14%). 1H NMR (DMSO-d6, 600 MHz) δ 10.63 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.45 (d, J=4.9 Hz, 1H), 8.14 (br s, 1H), 7.90 (s, 1H), 7.85 (s, 1H), 7.83 (d, J=4.9 Hz, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.66 (s, 1H), 7.61 (br s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.27 (d, J=7.6 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1205.
  • Figure US20180194731A1-20180712-C00144
    • 5-((3-(2,6-Difluoroisonicotinamido)benzyl)oxy)nicotinamide (A-124)
  • White solid (13 mg, 17%). 1H NMR (DMSO-d6, 600 MHz) δ 10.67 (s, 1H), 8.65 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.85 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.66 (s, 2H), 7.62 (s, 1H), 7.44 (dd, J=7.2, 7.2 Hz, 1H), 7.28 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C19H15F2N4O3 (M+H)+385.1107, found 385.1114.
  • Figure US20180194731A1-20180712-C00145
    • 5-((3-(2-Aminoisonicotinamido)benzyl)oxy)nicotinamide (A-125)
  • White solid (13 mg, 10%). 1H NMR (DMSO-d6, 600 MHz) δ 10.35 (s, 1H), 8.69 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.05 (d, J=5.4 Hz, 1H), 7.90 (s, 1H), 7.85 (s, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.39 (dd, J=7.5, 7.5 Hz, 1H), 7.22 (d, J=7.8, 1H), 6.92 (d, J=4.8 Hz, 1H), 6.86 (s, 1H), 6.20 (s, 2H), 5.25 (s, 2H). HRMS (ESI+) calcd for C19H18NSO3 (M+H)+364.1404, found 364.1414.
  • Figure US20180194731A1-20180712-C00146
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-5-phenylpicolinamide (A-126)
  • White solid (15 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 10.74 (s, 1H), 9.04 (d, J=1.2 Hz, 1H), 8.66 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.37 (d, J=9.0 Hz, 1H), 8.23 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 8.12 (s, 1H), 7.90-7.86 (m, 2H), 7.84 (d, J=7.8 Hz, 2H), 7.61 (s, 1H), 7.59-7.48 (m, 3H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C25H21N4O3 (M+H)+425.1608, found 425.1616.
  • Figure US20180194731A1-20180712-C00147
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-5-(prop-1-yn-1-yl)picolinamide (A-127)
  • White solid (30 mg, 77%). 1H NMR (DMSO-d6, 600 MHz) δ 10.70 (s, 1H), 8.72 (d, J=1.2 Hz, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 8.11 (d, J=7.8 Hz, 1H), 8.08 (s, 1H), 8.05 (dd, J=2.4, 8.4 Hz, 1H), 7.88-7.83 (m, 2H), 7.61 (s, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.25 (s, 2H), 2.14 (s, 3H). HRMS (ESI+) calcd for C22H19N4O3 (M+H)+387.1452, found 387.1462.
  • Figure US20180194731A1-20180712-C00148
    • 5-((3-(4-(2-Oxopiperidin-1-yl)benzamido)benzyl)oxy)nicotinamide (A-128)
  • White solid (15.0 mg, 16%). 1H NMR (DMSO-d6, 600 MHz) δ 10.30 (s, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.98-7.92 (m, 3H), 7.86 (s, 1H), 7.75 (d, J=7.2 Hz, 1H), 7.61 (s, 1H), 7.45 (d, J=8.4 Hz, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.2 Hz, 1H), 5.25 (s, 2H), 3.67 (t, J=5.7 Hz, 2H), 2.43 (t, J=6.6 Hz, 2H), 1.93-1.82 (m, 4H). HRMS (ESI+) calcd for C25H25N4O4 (M+H)+445.1870, found 445.1874.
  • Figure US20180194731A1-20180712-C00149
    • 5-((3-(4-(3-Oxomorpholino)benzamido)benzyl)oxy)nicotinamide (A-129)
  • White solid (7.5 mg, 8.2%). 1H NMR (DMSO-d6, 600 MHz) δ 10.33 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.00 (d, J=8.4 Hz, 2H), 7.93 (s, 1H), 7.86 (s, 1H), 7.76 (d, J=6.0 Hz, 1H), 7.63-7.57 (m, 3H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 5.25 (s, 2H), 4.24 (s, 2H), 4.01 (t, J=4.8 Hz, 2H), 3.82 (t, J=5.1 Hz, 2H). HRMS (ESI+) calcd for C24H23N4O5 (M+H)+447.1663, found 447.1672.
  • Figure US20180194731A1-20180712-C00150
    • 5-((3-(4-(2-Oxopyrrolidin-1-yl)benzamido)benzyl)oxy)nicotinamide (A-130)
  • White solid (14 mg, 26%). 1H NMR (DMSO-d6, 600 MHz) δ 10.24 (s, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.99 (d, J=9.0 Hz, 2H), 7.92 (s, 1H), 7.86 (dd, J=3.0, 1.8 Hz, 1H), 7.82 (d, J=9.0 Hz, 2H), 7.76 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (d, J=7.2 Hz, 1H), 5.25 (s, 2H), 3.90 (t, J=7.5 Hz, 2H), 2.53 (t, J=8.4 Hz, 2H), 2.12-2.06 (m, 2H). HRMS (ESI+) calcd for C24H23N4O4 (M+H)+ 431.1714, found 431.1711.
  • Figure US20180194731A1-20180712-C00151
    • 5-((3-(4-(N-Methylacetamido)benzamido)benzyl)oxy)nicotinamide (A-131)
  • White solid (20 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 10.36 (s, 1H), 8.65 (s, 1H), 8.50 (s, 1H), 8.14 (s, 1H), 8.01 (d, J=7.8 Hz, 2H), 7.93 (s, 1H), 7.86 (d, J=1.2 Hz, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J=7.8 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (d, J=7.2 Hz, 1H), 5.26 (s, 2H), 3.32 (s, 3H), 3.22 (s, 3H). HRMS (ESI+) calcd for C23H23N4O4 (M+H)+ 419.1714, found 419.1717.
  • Figure US20180194731A1-20180712-C00152
    • 5-((3-(4-(1,1-Dioxido-3-oxothiomorpholino)benzamido)benzyl)oxy)nicotinamide (A-132)
  • White solid (8.0 mg, 37%). 1H NMR (CD3OD, 600 MHz) δ 8.60 (s, 1H), 8.43 (d, J=3.0 Hz, 1H), 8.05 (d, J=9.0 Hz, 3H), 7.90 (dd, J=1.8, 1.8 Hz, 1H), 7.77 (s, 1H), 7.64-7.58 (m, 2H), 7.55-7.49 (m, 2H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 6.84 (d, J=9.0 Hz, 2H), 5.23 (s, 2H), 3.86 (t, J=6.9 Hz, 2H), 3.70 (t, J=6.9 Hz, 2H). HRMS (ESI+) calcd for C24H23N4O6S (M+H)+495.1333, found 495.1342.
  • Figure US20180194731A1-20180712-C00153
    • 5-((3-(4-(N-Ethylacetamido)benzamido)benzyl)oxy)nicotinamide (A-133)
  • White solid (5.0 mg, 17%). 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.04 (d, J=8.4 Hz, 2H), 7.93 (dd, J=1.8, 1.8 Hz, 1H), 7.89 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.45-7.39 (m, 3H), 7.28 (d, J=7.2 Hz, 1H), 5.27 (s, 2H), 3.79 (q, J=7.2, Hz, 2H), 3.31 (s, 3H), 1.14 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C24H25N4O4 (M+H)+433.1870, found 433.1871.
  • Figure US20180194731A1-20180712-C00154
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)-6-chloronicotinamide (A-134)
  • White solid (47 mg, 60%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 8.95 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.35 (d, J=8.4 Hz, 1H), 8.13 (s, 1H), 7.89 (s, 1H), 7.86 (s, 1H), 7.76-7.68 (m, 2H), 7.61 (s, 1H), 7.42 (dd, J=7.5, 7.5 Hz, 1H), 7.25 (d, J=6.6 Hz, 1H), 5.27 (s, 2H). HRMS (ESI+) calcd for C19H16ClN4O3 (M+H)+383.0905, found 383.0915.
  • Figure US20180194731A1-20180712-C00155
    • 5-((3-(4-(Chloromethyl)benzamido)benzyl)oxy)nicotinamide (A-135)
  • White solid (130 mg, 53%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.13 (s, 1H), 7.96 (d, J=8.4 Hz, 2H), 7.92 (s, 1H), 7.86 (dd, J=2.4, 2.4 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.61 (s, 1H), 7.59 (d, J=8.4, 2H), 7.39 (dd, J=7.5, 7.5 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 5.25 (s, 2H), 4.85 (s, 2H). HRMS (ESI+) calcd for C21H19ClN3O3 (M+H)+396.1109, found 396.1110.
    • Example 2
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00156
    • 5-((3-(Phenylsulfonamido)benzyl)oxy)nicotinamide (B1-1)
  • To a solution of intermediate IA4 (60 mg, 0.24 mmol) and DIPEA (87 μL, 0.50 mmol)) in DMF (1 mL) was added benzenesulfonyl chloride (49 μL, 0.38 mmol) and the mixture was allowed to stir at rt overnight. The organic solvent was removed and the resulting residue was purified by flash column chromatography (0-10% MeOH/CH2Cl2) to give compound B1-1 as a white solid (25 mg, 27%). 1H NMR (DMSO-d6, 600 MHz) δ 10.36 (br s, 1H), 8.65 (s, 1H), 8.42 (d, J=2.7 Hz, 1H), 8.13 (br s, 1H), 7.79 (s, 1H), 7.73 (d, J=7.8 Hz, 2H), 7.61 (br s, 1H), 7.58 (t, J=7.5 Hz, 1H), 7.50 (t, J=7.5 Hz, 2H), 7.25 (t, J=7.7 Hz, 1H), 7.22 (s, 1H), 7.12 (d, J=7.5 Hz, 1H), 7.04 (d, J=8.0 Hz, 1H), 5.16 (s, 2H). HRMS (ESI+) calcd for C19H18N3O4S (M+H)+384.1013, found 384.1010.
  • Compounds B1-2 to B1-13 were prepared in a manner similar to that described for compound B1-1.
  • Figure US20180194731A1-20180712-C00157
    • 5-((3-(2-Methylphenylsulfonamido)benzyl)oxy)nicotinamide (B1-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.65 (s, 1H), 8.41 (s, 1H), 8.13 (s, 1H), 7.84 (d, J=7.2 Hz, 1H), 7.78 (s, 1H), 7.62 (s, 1H), 7.46 (dd, J=7.2, 7.2 Hz, 1H), 7.35-7.27 (m, 2H), 7.23 (dd, J=8.1, 8.1 Hz, 1H), 7.17 (s, 1H), 7.07 (d, J=7.2 Hz, 1H), 7.02 (d, J=7.8 Hz, 1H), 5.14 (s, 2H), 2.56 (s, 3H). HRMS (ESI+) calcd for C20H20N3O4S (M+H)+398.1169, found 398.1172.
  • Figure US20180194731A1-20180712-C00158
    • 5-((3-(3-Methylphenylsulfonamido)benzyl)oxy)nicotinamide (B1-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.64 (s, 1H), 8.42 (s, 1H), 8.13 (s, 1H), 7.79 (s, 1H), 7.61 (s, 1H), 7.57 (s, 1H), 7.51 (d, J=6.6 Hz, 1H), 7.41-7.34 (m, 2H), 7.25 (dd, J=7.5, 7.5 Hz, 1H), 7.20 (s, 1H), 7.11 (d, J=6.6 Hz, 1H), 7.04 (d, J=8.4 Hz, 1H), 5.16 (s, 2H), 2.31 (s, 3H). HRMS (ESI+) calcd for C20H20N3O4S (M+H)+398.1169, found 398.1179.
  • Figure US20180194731A1-20180712-C00159
    • 5-((3-(4-Methylphenylsulfonamido)benzyl)oxy)nicotinamide (B1-4)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.29 (s, 1H), 8.65 (s, 1H), 8.42 (d, J=1.2 Hz, 1H), 8.13 (s, 1H), 7.79 (s, 1H), 7.64-7.57 (m, 3H), 7.29 (d, J=7.2 Hz, 2H), 7.24 (dd, J=7.5, 7.5 Hz, 1H), 7.21 (s, 1H), 7.10 (d, J=7.8 Hz, 1H), 7.02 (d, J=7.8 Hz, 1H), 5.16 (s, 2H), 2.31 (s, 3H). HRMS (ESI+) calcd for C20H20N3O4S (M+H)+398.1169, found 398.1173.
  • Figure US20180194731A1-20180712-C00160
    • 5-((3-(3-Methoxyphenylsulfonamido)benzyl)oxy)nicotinamide (B1-5)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.35 (s, 1H), 8.64 (s, 1H), 8.42 (s, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.61 (s, 1H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.30-7.23 (m, 3H), 7.21 (s, 1H), 7.16-7.09 (m, 2H), 7.05 (d, J=8.4 Hz, 1H), 5.15 (s, 2H), 3.74 (s, 3H). HRMS (ESI+) calcd for C20H20N3O5S (M+H)+414.1119, found 414.1126.
  • Figure US20180194731A1-20180712-C00161
    • 5-((3-(4-Methoxyphenylsulfonamido)benzyl)oxy)nicotinamide (B1-6)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.23 (s, 1H), 8.65 (s, 1H), 8.42 (d, J=1.8 Hz, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.65 (d, J=9.0 Hz, 2H), 7.62 (s, 1H), 7.27-7.20 (m, 2H), 7.10 (d, J=7.2 Hz, 1H), 7.04-6.98 (m, 3H), 5.16 (s, 2H), 3.78 (s, 3H). HRMS (ESI+) calcd for C20H20N3O5S (M+H)+414.1118, found 414.1127.
  • Figure US20180194731A1-20180712-C00162
    • 5-((3-(2-Chlorophenylsulfonamido)benzyl)oxy)nicotinamide (B1-7)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.68 (s, 1H), 8.65 (s, 1H), 8.41 (s, 1H), 8.13 (s, 1H), 8.00 (d, J=7.8 Hz, 1H), 7.77 (s, 1H), 7.62 (s, 1H), 7.59 (d, J=4.2 Hz, 2H), 7.49-7.42 (m, 1H), 7.24 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 7.05 (d, J=7.8 Hz, 1H), 5.14 (s, 2H). HRMS (ESI+) calcd for C19H17ClN3O4S (M+H)+418.0628, found 418.0631.
  • Figure US20180194731A1-20180712-C00163
    • 5-((3-(3-Chlorophenylsulfonamido)benzyl)oxy)nicotinamide (B1-8)
  • 1H NMR (DMSO-d6, 600 MHz) δ 8.65 (s, 1H), 8.42 (s, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.70-7.63 (m, 2H), 7.61 (s, 1H), 7.54 (dd, J=8.1, 8.1 Hz, 1H), 7.29 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (s, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.05 (d, J=8.4 Hz, 1H), 5.17 (s, 2H). HRMS (ESI+) calcd for C19H17ClN3O4S (M+H)+418.0623, found 418.0632.
  • Figure US20180194731A1-20180712-C00164
    • 5-((3-(4-Chlorophenylsulfonamido)benzyl)oxy)nicotinamide (B1-9)
  • 1H NMR (DMSO-d6, 600 MHz) δ 8.65 (s, 1H), 8.43 (s, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.71 (d, J=7.8 Hz, 2H), 7.65-7.56 (m, 3H), 7.27 (dd, J=8.1, 8.1 Hz, 1H), 7.21 (s, 1H), 7.15 (d, J=7.8 Hz, 1H), 7.03 (d, J=8.4 Hz, 1H), 5.17 (s, 2H). HRMS (ESI+) calcd for C19H17ClN3O4S (M+H)+418.0623, found 418.0631.
  • Figure US20180194731A1-20180712-C00165
    • 5-((3-(3-Nitrophenylsulfonamido)benzyl)oxy)nicotinamide (B1-10)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.64 (s, 1H), 8.63 (s, 1H), 8.48 (s, 1H), 8.44-8.37 (m, 2H), 8.12 (s, 1H), 8.08 (d, J=7.8 Hz, 1H), 7.80 (dd, J=8.1, 8.1 Hz, 1H), 7.77 (s, 1H), 7.61 (s, 1H), 7.28 (dd, J=8.1, 8.1 Hz, 1H), 7.19 (s, 1H), 7.15 (d, J=7.2 Hz, 1H), 7.06 (d, J=7.2 Hz, 1H), 5.15 (s, 2H). HRMS (ESI+) calcd for C19H7N4O6S (M+H)+429.0863, found 429.0870.
  • Figure US20180194731A1-20180712-C00166
    • 5-((3-(Naphthalene-1-sulfonamido)benzyl)oxy)nicotinamide (B1 1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.76 (s, 1H), 8.71 (d, J=7.8 Hz, 1H), 8.64 (s, 1H), 8.38 (s, 1H), 8.18 (d, J=7.2 Hz, 2H), 8.12 (s, 1H), 8.05 (d, J=8.4 Hz, 1H), 7.75 (s, 1H), 7.72 (dd, J=7.8, 7.8 Hz, 1H), 7.65 (dd, J=7.2, 7.2 Hz, 1H), 7.61 (s, 1H), 7.57 (dd, J=7.5, 7.5 Hz, 1H), 7.20-7.12 (m, 2H), 7.02 (d, J=6.6 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 5.09 (s, 2H). HRMS (ESI+) calcd for C23H20N3O4S (M+H)+ 434.1175, found 434.1170.
  • Figure US20180194731A1-20180712-C00167
    • 5-((3-(Naphthalene-2-sulfonamido)benzyl)oxy)nicotinamide (B1-12)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.47 (s, 1H), 8.64 (s, 1H), 8.43 (s, 1H), 8.38 (s, 1H), 8.16-8.08 (m, 2H), 8.05 (d, J=9.0 Hz, 1H), 7.99 (d, J=8.4 Hz, 1H), 7.79 (s, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.69 (dd, J=7.5, 7.5 Hz, 1H), 7.65-7.58 (m, 2H), 7.27 (s, 1H), 7.22 (dd, J=8.1, 8.1 Hz, 1H), 7.11-7.05 (m, 2H), 5.13 (s, 2H). HRMS (ESI+) calcd for C23H20N3O4S (M+H)+434.1175, found 434.1175.
  • Figure US20180194731A1-20180712-C00168
    • 5-((3-(5-(Dimethylamino)naphthalene-1-sulfonamido)benzyl)oxy)nicotinamide (B1-13)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.75 (s, 1H), 8.64 (s, 1H), 8.41 (d, J=9.0 Hz, 1H), 8.39-8.33 (m, 2H), 8.17 (d, J=7.2 Hz, 1H), 8.12 (s, 1H), 7.76 (s, 1H), 7.65-7.56 (m, 2H), 7.54 (dd, J=8.1, 8.1 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 7.20-7.12 (m, 2H), 7.01 (d, J=7.2 Hz, 1H), 6.97 (d, J=7.8 Hz, 1H), 5.09 (s, 2H), 2.79 (s, 6H). HRMS (ESI+) calcd for C25H25N4O4S (M+H)+477.1597, found 477.1604.
  • Figure US20180194731A1-20180712-C00169
    • 5-((3-(Benzylamino)benzyl)oxy)nicotinamide (B2-1)
  • To a mixture of intermediate IA4 (60 mg, 0.24 mmol), benzaldehyde (25 μL, 0.24 mmol), and NaBH(OAc)3 (127 mg, 0.60 mmol) in CH2Cl2 (3 mL) was added AcOH (13 μl, 0.23 mmol) and the mixture was allowed to stir at rt for 4 h. After the organic solvent was removed, the resulting residue was purified by flash column chromatography to give compound B2-1 as a white solid (30 mg, 37%). 1H NMR (DMSO-d6, 600 MHz) δ 8.63 (s, 1H), 8.42 (d, J=2.7 Hz, 1H), 8.12 (br s, 1H), 7.80 (s, 1H), 7.60 (br s, 1H), 7.34 (d, J=7.5 Hz, 2H), 7.30 (t, J=7.5 Hz, 2H), 7.21 (t, J=7.2 Hz, 1H), 7.05 (t, J=7.8 Hz, 1H), 6.69 (s, 1H), 6.60 (d, J=7.5 Hz, 1H), 6.52 (dd, J=8.2 Hz J2=1.6 Hz, 1H), 6.33 (t, J=6.0 Hz, 1H), 5.07 (s, 2H), 4.26 (d, J=6.1 Hz, 2H). HRMS (ESI+) calcd for C20H20N3O2 (M+H)+ 334.1550, found 334.1554.
  • Figure US20180194731A1-20180712-C00170
    • 5-((3-(3-Phenylureido)benzyl)oxy)nicotinamide (B3-1)
  • A solution of intermediate IA4 (60 mg, 0.24 mmol) and phenyl isocyanate (32 μL, 0.29 mmol)) in DMF (1 mL) was allowed to stir at rt for 4 h. The organic solvent was removed and the resulting residue was purified by flash column chromatography (0-10% MeOH/CH2Cl2) to give compound B3-1 as a white solid (40 mg, 46%). 1H NMR (DMSO-d6, 600 MHz) δ 8.74 (s, 1H), 8.65 (s, 2H), 8.49 (d, J=2.7 Hz, 1H), 8.13 (br s, 1H), 7.85 (t, J=2.1 Hz, 1H), 7.61 (br s, 1H), 7.59 (s, 1H), 7.45 (d, J=8.0 Hz, 2H), 7.40 (d, J=8.0 Hz, 1H), 7.31 (t, J=7.8 Hz, 1H), 7.28 (t, J=7.8 Hz, 2H), 7.07 (d, J=7.4 Hz, 1H), 6.97 (t, J=7.4 Hz, 1H), 5.22 (s, 2H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1461.
  • Compounds B3-2 was prepared in a manner similar to that described for compound B3-1.
  • Figure US20180194731A1-20180712-C00171
    • 5-((3-(3-Benzylureido)benzyl)oxy)nicotinamide (B3-2)
  • White solid (35 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 8.65-8.63 (m, 2H), 8.47 (d, J=2.8 Hz, 1H), 8.13 (br s, 1H), 7.84-7.82 (m, 1H), 7.61 (br s, 1H), 7.55 (s, 1H), 7.37-7.28 (m, 5H), 7.27-7.22 (m, 2H), 7.00 (d, J=7.5 Hz, 1H), 6.62 (t, J=5.9 Hz, 1H), 5.18 (s, 2H), 4.30 (d, J=6.0 Hz, 2H). HRMS (ESI+) calcd for C21H21N4O3 (M+H)+ 377.1608, found 377.1612.
  • Figure US20180194731A1-20180712-C00172
    • tert-Butyl (3-(((5-carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamate (B4-1)
  • A solution of intermediate IA4 (60 mg, 0.24 mmol), di-tert-butyl dicarbonate (83 mg, 0.38 mmol) and DIPEA (87 μL, 0.50 mmol) in CH2Cl2 (1 mL) was allowed to stir at rt overnight. After the organic solvent was removed, the resulting residue was purified by flash column chromatography (0-10% MeOH/CH2Cl2) to give compound B4-1 as a white solid (25 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 9.41 (br s, 1H), 8.64 (s, 1H), 8.47 (d, J=2.9 Hz, 1H), 8.13 (br s, 1H), 7.83 (s, 1H), 7.63-7.59 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 7.27 (t, J=7.8 Hz, 1H), 7.06 (d, J=7.4 Hz, 1H), 5.18 (s, 2H), 1.47 (s, 9H). HRMS (ESI+) calcd for C18H22N3O4 (M+H)+ 344.1605, found 344.1606.
  • Compounds B4-2 was prepared in a manner similar to that described for compound B4-1.
  • Figure US20180194731A1-20180712-C00173
    • Benzyl (3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamate (B4-2)
  • White solid (45 mg, 50%). 1H NMR (DMSO-d6, 600 MHz) δ 9.84 (br s, 1H), 8.65 (s, 1H), 8.47 (d, J=2.5 Hz, 1H), 8.13 (br s, 1H), 7.84 (s, 1H), 7.61 (s, 2H), 7.43 (s, 1H), 7.42 (s, 2H), 7.39 (t, J=7.5 Hz, 2H), 7.35 (d, J=7.2 Hz, 1H), 7.31 (t, J=7.9 Hz, 1H), 7.10 (d, J=7.5 Hz, 1H), 5.20 (s, 2H), 5.15 (s, 2H). HRMS (ESI+) calcd for C21H20N3O4 (M+H)+378.1448, found 378.1459.
    • Example 3
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00174
    Figure US20180194731A1-20180712-C00175
    Figure US20180194731A1-20180712-C00176
    • 4-Nitro-2,3-dihydro-1H-inden-1-one (IC1a) and 6-Nitro-2,3-dihydro-1H-inden-1-one (IC1b)
  • To a solution of 1-Indanone (20 g, 151 mmol) in concentrated H2SO4 (210 mL) at 0° C. was added KNO3 (15.3 g, 151 mmol) in several portions. The reaction mixture was allowed to stir for 1 h and poured over ice (1 L). The mixture was extracted with EtOAc and the organic phase was washed with brine and dried over Na2SO4. After filtration and removal of the solvent, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford IC1a as a yellow solid (3.00 g, 23%) 1H NMR (CDCl3, 600 MHz) δ 8.48 (d, J=8.4 Hz, 1H), 8.09 (d, J=7.2 Hz, 1H), 7.62 (dd, J=7.8, 7.8 Hz, 1H), 3.66 (t, J=6.0 Hz, 2H), 2.83-2.79 (m, 2H); and IC1b as a yellow solid (4.00 g, 30%) 1H NMR (CDCl3, 600 MHz) δ 8.57 (s, 1H), 8.45 (d, J=7.8 Hz, 1H), 7.67 (d, J=8.4 Hz, 1H), 3.28 (t, J=6.0 Hz, 2H), 2.86-2.82 (m, 2H).
    • 4-Nitro-2,3-dihydro-1H-inden-1-ol (IC2a)
  • To a solution of IC1a (1.50 g, 8.47 mmol) in MeOH was added NaBH4 (641 mg, 16.9 mmol) in several portions. The reaction mixture was allowed to stir at rt for 2 h. After the reaction was quenched with 1N HCl, the aqueous solution was extracted with EtOAc and the organic phase washed with brine and dried over Na2SO4. After filtration and removal of the solvent, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford IC2a as a light yellow solid (1.40 g, 92%). 1H NMR (CDCl3, 600 MHz) δ 8.13 (d, J=8.4 Hz, 1H), 7.73 (d, J=7.2 Hz, 1H), 7.44 (dd, J=7.5, 7.5 Hz, 1H), 5.33 (dd, J=6.6 Hz, 1H), 3.60-3.54 (m, 1H), 3.32-3.26 (m, 1H), 2.63-2.56 (m, 1H), 2.06-2.00 (m, 1H).
    • 6-Nitro-2,3-dihydro-1H-inden-1-ol (IC2d)
  • In a manner similar to that described for the preparation of compound IC2a. IC1b (2.50 g, 14.1 mmol) was reduced with NaBH4 (1.07 g, 28.2 mmol) in MeOH to give IC2d as a light yellow solid (2.40 g, 95%). 1H NMR (CDCl3, 600 MHz) δ 8.26-8.22 (m, 1H), 8.14-8.10 (m, 1H), 7.39-7.35 (m, 1H), 5.34-5.28 (m, 1H), 3.16-3.09 (m, 1H), 2.94-2.86 (m, 1H), 2.63-2.56 (m, 1H), 2.09-2.01 (m, 1H).
    • Methyl 5-((4-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3a)
  • To a solution of IC2a (1.28 g, 7.16 mmol), methyl 5-hydroxynicotinate (1.32 g, 8.59 mmol), and Ph3P (2.82 g, 10.7 mmol) in anhydrous THF (45 mL) at rt was added DIAD (2.17 g, 10.7 mmol) dropwise. After the mixture was stirred for 12 h and the solvent removed, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford IC3a as a yellow solid (1.70 g, 76%). 1H NMR (600 MHz, DMSO) δ 8.74 (s, 1H), 8.61 (d, J=3.0 Hz, 1H), 8.20 (d, J=7.8 Hz, 1H), 7.93 (s, 1H), 7.88 (d, J=6.6 Hz, 1H), 7.59 (dd, J=7.8, 7.8 Hz, 1H), 6.17 (dd, J=4.2, 6.6 Hz, 1H), 3.91 (s, 3H), 3.52-3.45 (m, 1H), 3.40-3.34 (m, 1H), 2.71-2.64 (m, 1H), 2.17-2.10 (m, 1H). HRMS (ESI+) calcd for C16H15N2O5 (M+H)+315.0975, found 315.0983.
    • Methyl 5-((6-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3d)
  • In a manner similar to that described for the preparation of compound IC3a, IC3d was prepared from IC2d (1.14 g, 6.34 mmol) as a yellow solid (1.30 g, 65%). 1H NMR (600 MHz, CDCl3) δ 8.89 (s, 1H), 8.54 (d, J=3.0 Hz, 1H), 8.28 (s, 1H), 8.23 (dd, J=1.8, 7.8 Hz, 1H), 7.91 (s, 1H), 7.48 (s, 1H), 5.91-5.88 (m, 1H), 3.98 (s, 3H), 3.29-3.23 (m, 1H), 3.11-3.05 (m, 1H), 2.79-2.73 (m, 1H), 2.34-2.28 (m, 1H). HRMS (ESI+) calcd for C16H15N2O5 (M+H)+315.0975, found 315.0988.
    • Methyl 5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4a)
  • To a solution of compound IC3a (500 mg, 1.60 mmol) and NiCl2.6H2O (760 mg, 4.48 mmol) in MeOH (800 mL) was slowly added NaBH4 (250 mg, 6.40 mmol) and the mixture was stirred at rt for 2 h. The reaction was quenched with saturated NH4Cl (50 mL) and extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford compound IC4a as a white solid (290 mg, 64%). 1H NMR (DMSO-d6, 600 MHz) δ 8.70 (s, 1H), 8.56 (d, J=3.0 Hz, 1H), 7.88-7.86 (m, 1H), 6.93 (dd, J=7.8, 7.8 Hz, 1H), 6.58 (d, J=7.2 Hz, 1H), 6.56 (d, J=8.4, 1H), 5.95 (dd, J=3.3, 6.6 Hz, 1H), 5.02 (s, 2H), 3.90 (s, 3H), 2.82-2.77 (m, 1H), 2.69-2.64 (m, 1H), 2.57-2.2.51 (m, 1H), 2.05-2.00 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1241.
    • Methyl 5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4d)
  • In a manner similar to that described for the preparation of compound IC4a, IC3d (500 mg, 1.60 mmol) was reduced to afford IC4d as a light yellow solid (270 mg, 59%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (d, J=1.8 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 7.89 (dd, J=3.0, 1.8 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 6.69 (dd, J=8.4, 2.4 Hz, 1H), 5.76 (dd, J=6.6, 4.2 Hz, 1H), 3.97 (s, 3H), 3.65 (bs, 2H), 3.08-3.02 (m, 1H), 2.88-2.82 (m, 1H), 2.63-2.56 (m, 1H), 2.02-1.95 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1243.
    • 5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5a)
  • A solution of methyl ester IC4a (280 mg, 0.98 mmol) in NH3/MeOH (ca. 7N, 10 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (150 mL) and the organic layer was washed with H2O (150 mL) and then with brine (100 mL). After the organic layer was dried over Na2SO4 and filtered, the filtrate was concentrated and the residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to afford compound IC5a as a light yellow solid (260 mg, 98%). 1H NMR (DMSO-d6, 600 MHz) δ 8.64 (s, 1H), 8.43 (d, J=1.8 Hz, 1H), 8.14 (s, 1H), 7.86 (s, 1H), 7.61 (s, 1H), 6.93 (dd, J=7.5, 7.5 Hz, 1H), 6.58 (d, J=7.8, 1H), 6.50 (d, J=7.2 Hz, 1H), 5.90 (dd, J=3.6, 6.6 Hz, 1H), 5.02 (s, 2H), 2.82-2.77 (m, 1H), 2.68-2.63 (m, 1H), 2.58-2.52 (m, 1H), 2.04-2.00 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+ 270.1237, found 270.1247.
    • 5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5d)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of IC4d (250 mg, 0.88 mmol) afforded IC5d as a light yellow solid (230 mg, 97%). 1H NMR (DMSO-d6, 600 MHz) δ 8.65 (s, 1H), 8.45 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.87 (s, 1H), 7.61 (s, 1H), 6.97 (d, J=7.8 Hz, 1H), 6.59 (s, 1H), 6.56 (d, J=7.2, 1H), 5.86 (dd, J=5.1, 5.1 Hz, 1H), 4.96 (s, 2H), 2.90-2.85 (m, 1H), 2.75-2.69 (m, 1H), 2.57-2.50 (m, 1H), 2.00-1.95 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+270.1237, found 270.1237.
  • Figure US20180194731A1-20180712-C00177
    • 5-((4-(4-Methyl-3-nitrobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-1)
  • To a solution of IC5a (57 mg, 0.21 mmol) and Et3N (33 mg, 0.32 mmol) in anhydrous DMF (2 mL) at rt was added 4-methyl-3-nitrobenzoyl chloride (84 mg, 0.42 mmol) dropwise. After the mixture was allowed to stir at rt for 12 h, the reaction was quenched with saturated NH4Cl (10 mL). The resulting mixture was extracted with EtOAc and the organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (MeOH/CH2Cl2) to afford compound C1-1 as a light yellow solid (37 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.67 (s, 1H), 8.57 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.16 (s, 1H), 7.92 (s, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.47-7.43 (m, 1H), 7.34-7.29 (m, 2H), 6.06 (dd, J=3.9, 5.7 Hz, 1H), 3.07-3.01 (m, 1H), 2.92-2.85 (m, 1H), 2.64-2.57 (m, 4H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C23H21N4O5 (M+H)+433.1506, found 433.1509.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for the preparation of compound C1-1.
  • Figure US20180194731A1-20180712-C00178
    • 5-((4-(4-Methylbenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.95 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.89 (d, J=7.8 Hz, 2H), 7.63 (s, 1H), 7.47 (dd, J=4.2, 4.2 Hz, 1H), 7.34 (d, J=7.8 Hz, 2H), 7.30-7.26 (m, 2H), 6.05 (dd, J=3.6, 6.0 Hz, 1H), 3.07-3.01 (m, 1H), 2.92-2.85 (m, 1H), 2.62-2.56 (m, 1H), 2.39 (s, 3H), 2.09-2.03 (m, 1H). HRMS (ESI) calcd for C23H22N3O3 (M+H)+388.1656, found 388.1654.
  • Figure US20180194731A1-20180712-C00179
    • 5-((4-(4-Methoxybenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.88 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 7.97 (d, J=8.4 Hz, 2H), 7.91 (s, 1H), 7.63 (s, 1H), 7.47-7.44 (m, 1H), 7.30-7.23 (m, 2H), 7.06 (d, J=8.4 Hz, 2H), 6.05 (dd, J=3.6, 6.0 Hz, 1H), 3.84 (s, 3H), 3.06-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.62-2.56 (m, 1H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C23H22N3O4 (M+H)+404.1605, found 404.1613.
  • Figure US20180194731A1-20180712-C00180
    • 5-((4-(4-Chlorobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-4)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.13 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 8.00 (d, J=9.0 Hz, 2H), 7.91 (s, 1H), 7.65-7.60 (m, 3H), 7.48-7.45 (m, 1H), 7.32-7.28 (m, 2H), 6.07-6.04 (m, 1H), 3.06-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.63-2.56 (m, 1H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C22H19ClN3O3 (M+H)+408.1109, found 408.1116.
  • Figure US20180194731A1-20180712-C00181
    • 5-((4-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-5)
  • 1H NMR (DMF-d7, 600 MHz) δ 9.77 (s, 1H), 8.85 (s, 1H), 8.57 (s, 1H), 8.36 (s, 1H), 8.09 (s, 1H), 8.07-8.02 (m, 2H), 7.68 (d, J=7.8 Hz, 1H), 7.64 (s, 1H), 7.38-7.32 (m, 2H), 7.12 (d, J=9.0 Hz, 2H), 6.15-6.11 (m, 1H), 3.87-3.80 (m, 4H), 3.36-3.30 (m, 4H), 3.25-3.18 (m, 1H), 3.08-3.01 (m, 1H), 2.76-2.68 (m, 1H), 2.22-2.14 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2036.
  • Figure US20180194731A1-20180712-C00182
    • 5-((4-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C1-6)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.80 (d, J=5.4 Hz, 2H), 8.67 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.88 (d, J=4.8 Hz, 2H), 7.62 (s, 1H), 7.50-7.47 (m, 1H), 7.34-7.30 (m, 2H), 6.08-6.04 (m, 1H), 3.08-3.02 (m, 1H), 2.92-2.86 (m, 1H), 2.64-2.57 (m, 1H), 2.10-2.03 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1452, found 375.1463.
  • Figure US20180194731A1-20180712-C00183
    • 5-((6-(4-Methyl-3-nitrobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.67 (s, 1H), 8.56 (d, J=1.2 Hz, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.20 (d, J=6.6 Hz, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.85 (s, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.35 (d, J=9.0 Hz, 1H), 6.05 (dd, J=3.6, 3.6 Hz, 1H), 3.07-3.01 (m, 1H), 2.92-2.86 (m, 1H), 2.69-2.63 (m, 1H), 2.59 (s, 3H), 2.09-2.04 (m, 1H). HRMS (ESI+) calcd for C23H21N4O5 (M+H)+433.1506, found 433.1509.
  • Figure US20180194731A1-20180712-C00184
    • 5-((6-(4-Methylbenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.17 (s, 1H), 8.67 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.88-7.86 (m, 2H), 7.85 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.34-7.30 (m, 3H), 6.02 (dd, J=5.4, 5.4 Hz, 1H), 3.06-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.68-2.61 (m, 1H), 2.38 (s, 3H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C23H22N3O3 (M+H)+388.1656, found 388.1655.
  • Figure US20180194731A1-20180712-C00185
    • 5-((6-(4-Methoxybenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.10 (s, 1H), 8.67 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 7.95 (d, J=9.0 Hz, 2H), 7.90 (s, 1H), 7.86 (s, 1H), 7.72 (d, J=7.2 Hz, 1H), 7.63 (s, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.05 (d, J=9.0 Hz, 2H), 6.02 (dd, J=5.4, 5.4 Hz, 1H), 3.83 (s, 3H), 3.06-3.00 (m, 1H), 2.91-2.85 (m, 1H), 2.68-2.61 (m, 1H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C23H22N3O4 (M+H)+404.1605, found 404.1609.
  • Figure US20180194731A1-20180712-C00186
    • 5-((6-(4-Chlorobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-4)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.33 (s, 1H), 8.67 (s, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 7.97 (d, J=8.4 Hz, 2H), 7.90 (s, 1H), 7.86 (s, 1H), 7.72 (dd, J=1.2, 8.4 Hz, 2H), 7.63 (s, 1H), 7.60 (d, J=9.6 Hz, 1H), 7.33 (d, J=8.4 Hz, 1H), 6.03 (dd, J=4.5, 6.3 Hz, 1H), 3.06-3.00 (m, 1H), 2.92-2.85 (m, 1H), 2.68-2.60 (m, 1H), 2.09-2.03 (m, 1H). HRMS (ESI+) calcd for C22H19ClN3O3 (M+H)+408.1109, found 408.1113.
  • Figure US20180194731A1-20180712-C00187
    • 5-((6-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-5)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.98 (s, 1H), 8.67 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.93-7.83 (m, 4H), 7.72 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.29 (d, J=7.8 Hz, 1H), 7.01 (d, J=8.4 Hz, 2H), 6.03-5.98 (m, 1H), 3.78-3.70 (m, 4H), 3.28-3.21 (m, 4H), 3.06-2.98 (m, 1H), 2.92-2.83 (m, 1H), 2.68-2.60 (m, 1H), 2.10-2.02 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2036.
  • Figure US20180194731A1-20180712-C00188
    • 5-((6-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C4-6)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 8.77 (d, J=6.0 Hz, 2H), 8.67 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 7.90 (s, 1H), 7.88-7.83 (m, 3H), 7.73 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.35 (d, J=7.8 Hz, 1H), 6.06-6.02 (m, 1H), 3.08-3.02 (m, 1H), 2.94-2.86 (m, 1H), 2.68-2.62 (m, 1H), 2.10-2.03 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+ 375.1452, found 375.1458.
    • (S)-4-Nitro-2,3-dihydro-1H-inden-1-ol (IC2b)
  • To a solution of compound IC1a (1.00 g, 5.65 mmol) and (R)—CBS (78 mg, 0.28 mmol) in DCM (20 mL) at −20° C. was slowly added BH3.SMe2 (0.57 mL, 5.65 mmol) and the mixture was stirred at this temperature for 1 h. After the reaction was quenched with saturated NH4Cl (20 mL) and stirred at rt for 3 h, the mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford compound IC2b as a light yellow solid (900 mg, 89%). 1H NMR (CDCl3, 600 MHz) δ 8.13 (d, J=8.4 Hz, 1H), 7.73 (d, J=7.2 Hz, 1H), 7.44 (dd, J=7.5, 7.5 Hz, 1H), 5.33 (dd, J=6.6, 6.6 Hz, 1H), 3.60-3.52 (m, 1H), 3.32-3.24 (m, 1H), 2.63-2.56 (m, 1H), 2.06-2.00 (m, 1H).
    • (R)-4-Nitro-2,3-dihydro-1H-inden-1-ol (IC2c)
  • In a manner similar to that described for the preparation of compound IC2b, IC1a (1.77 g, 10.0 mmol) was reduced with BH3.SMe2 (1.00 mL, 10.0 mmol) in the presence of (S)—CBS (139 mg, 0.50 mmol) to give IC2c as a white solid (1.61 g, 90%). 1H NMR (CDCl3, 600 MHz) δ 8.12 (d, J=8.4 Hz, 1H), 7.72 (d, J=7.2 Hz, 1H), 7.43 (dd, J=7.5, 7.5 Hz, 1H), 5.32 (dd, J=6.6, 6.6 Hz, 1H), 3.60-3.52 (m, 1H), 3.32-3.24 (m, 1H), 2.63-2.56 (m, 1H), 2.06-2.00 (m, 1H).
    • (R)-6-Nitro-2,3-dihydro-1H-inden-1-ol (IC2e)
  • In a manner similar to that described for the preparation of compound IC2b, IC1b (1.00 g, 5.65 mmol) was reduced with BH3.SMe2 (0.57 mL, 5.65 mmol) in the presence of (S)—CBS (78 mg, 0.28 mmol) in DCM to give IC2e (850 mg, 84%) as a light yellow solid. 1H NMR (CDCl3, 600 MHz) δ 8.26-8.22 (m, 1H), 8.14 (dd, J=2.4, 8.4 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 5.32 (dd, J=6.6, 6.6 Hz, 1H), 3.16-3.09 (m, 1H), 2.94-2.86 (m, 1H), 2.64-2.58 (m, 1H), 2.09-2.01 (m, 1H).
    • (S)-6-Nitro-2,3-dihydro-1H-inden-1-ol (IC2f)
  • In a manner similar to that described for the preparation of compound IC2b. IC1b (1.00 g, 5.65 mmol) was reduced with BH3.SMe2 (0.57 mL, 5.65 mmol) in the presence of (R)—CBS (78 mg, 0.28 mmol) to give IC2f as a light yellow solid (900 mg, 89%). 1H NMR (CDCl3, 600 MHz) δ 8.26-8.22 (m, 1H), 8.14 (dd, J=2.4, 8.4 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 5.32 (dd, J=6.6, 6.6 Hz, 1H), 3.16-3.09 (m, 1H), 2.94-2.86 (m, 1H), 2.64-2.58 (m, 1H), 2.09-2.01 (m, 1H).
    • (S)-Methyl 5-((4-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3b)
  • In a manner similar to that described for the preparation of compound IC3a, IC2c (500 mg, 2.79 mmol) and methyl 5-hydroxynicotinate (513 g, 3.35 mmol) were treated with DIAD and Ph3P to afford IC3b as a yellow solid (580 g, 66%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 7.90 (s, 1H), 7.11 (dd, J=7.8, 7.8 Hz, 1H), 6.85 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.2 Hz, 1H), 5.82 (dd, J=3.6, 6.6 Hz, 1H), 3.96 (s, 3H), 3.00-2.92 (m, 1H), 2.80-2.73 (m, 1H), 2.66-2.60 (m, 1H), 2.28-2.22 (m, 1H). HRMS (ESI+) calcd for C16H15N2O (M+H)+315.0975, found 315.0984.
    • (R)-Methyl 5-((4-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3c)
  • In a manner similar to that described for the preparation of compound IC3a, IC2b (500 mg, 2.79 mmol) and methyl 5-hydroxynicotinate (513 g, 3.35 mmol) were treated with DIAD and Ph3P to afford IC3c as a yellow solid (560 g, 64%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (s, 1H), 7.90 (s, 1H), 7.11 (dd, J=7.8, 7.8 Hz, 1H), 6.85 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.2 Hz, 1H), 5.82 (dd, J=3.6, 6.6 Hz, 1H), 3.96 (s, 3H), 3.00-2.92 (m, 1H), 2.80-2.73 (m, 1H), 2.66-2.60 (m, 1H), 2.28-2.22 (m, 1H). HRMS (ESI+) calcd for C16H15N2O (M+H)+315.0975, found 315.0985.
    • (R)-Methyl 5-((6-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3e)
  • In a manner similar to that described for the preparation of compound IC3a, IC2f (550 mg, 3.07 mmol) and methyl 5-hydroxynicotinate (554 g, 3.68 mmol) were treated with DIAD and Ph3P to afford IC3e as a yellow solid (629 g, 64%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=3.0 Hz, 1H), 7.89 (dd, J=2.4, 2.4 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (s, 1H), 6.69 (dd, J=1.8, 8.1 Hz, 1H), 5.76 (dd, J=4.2, 6.0 Hz, 1H), 3.97 (s, 3H), 3.08-3.02 (m, 1H), 2.88-2.82 (m, 1H), 2.63-2.56 (m, 1H), 2.22-2.14 (m, 1H). HRMS (ESI+) calcd for C16H15N2O (M+H)+315.0975, found 315.0981.
    • (S)-Methyl 5-((6-Nitro-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC3f)
  • In a manner similar to that described for the preparation of compound IC3a, IC2e (700 mg, 3.91 mmol) and methyl 5-hydroxynicotinate (718 g, 4.69 mmol) were treated with DIAD and Ph3P to afford IC3f as a yellow solid (800 g, 65%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 7.89 (s, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (s, 1H), 6.69 (d, J=8.4 Hz, 1H), 5.88-5.74 (m, 1H), 3.97 (s, 3H), 3.08-3.02 (m, 1H), 2.88-2.82 (m, 1H), 2.63-2.56 (m, 1H), 2.22-2.14 (m, 1H). HRMS (ESI+) calcd for C16H15N2O (M+H)+315.0975, found 315.0986.
    • (S)-Methyl 5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4b)
  • In a manner similar to that described for the preparation of compound IC4a, IC3d (250 mg, 0.80 mmol) was reduced to afford IC4b as a light yellow solid (180 mg, 80%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 7.90 (dd, J=1.8, 1.8 Hz, 1H), 7.11 (dd, J=7.8, 7.8 Hz, 1H), 6.85 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.8 Hz, 1H), 5.83 (dd, J=6.0, 3.6 Hz, 1H), 3.96 (s, 3H), 3.00-2.92 (m, 1H), 2.80-2.73 (m, 1H), 2.67-2.60 (m, 1H), 2.28-2.22 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1237.
    • (R)-Methyl 5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4c)
  • In a manner similar to that described for the preparation of compound IC4a, IC3c (250 mg, 0.80 mmol) was reduced to afford IC4c as a light yellow solid (160 mg, 70%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (s, 1H), 7.90 (s, 1H), 7.11 (dd, J=7.8, 7.8 Hz, 1H), 6.85 (d, J=7.2 Hz, 1H), 6.67 (d, J=7.8 Hz, 1H), 5.84-5.80 (m, 1H), 3.96 (s, 3H), 3.00-2.92 (m, 1H), 2.80-2.73 (m, 1H), 2.67-2.59 (m, 1H), 2.29-2.22 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1241.
    • (R)-Methyl 5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4e)
  • In a manner similar to that described for the preparation of compound IC4a, IC3e (314 mg, 1.00 mmol) was reduced to afford IC4e as a yellow solid (200 mg, 70%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 7.89 (s, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (s, 1H), 6.69 (d, J=8.4 Hz, 1H), 5.77-5.74 (m, 1H), 3.96 (s, 3H), 3.08-3.01 (m, 1H), 2.88-2.81 (m, 1H), 2.64-2.56 (m, 1H), 2.22-2.14 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1239.
    • (S)-Methyl 5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinate (IC4f)
  • In a manner similar to that described for the preparation of compound IC4a, IC3f (314 mg, 1.00 mmol) was reduced to afford IC4f as a yellow solid (220 mg, 77%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (d, J=1.2 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 7.89 (dd, J=2.4, 2.4 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (d, J=1.8 Hz, 1H), 6.69 (dd, J=7.8, 1.8 Hz, 1H), 5.76 (dd, J=6.0, 3.6 Hz, 1H), 3.97 (s, 3H), 3.07-3.02 (m, 1H), 2.88-2.82 (m, 1H), 2.63-2.56 (m, 1H), 2.21-2.14 (m, 1H). HRMS (ESI+) calcd for C16H17N2O3 (M+H)+285.1234, found 285.1239.
    • (S)-5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5b)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of IC4b (180 mg, 0.63 mmol) afforded IC5b as a white solid (160 mg, 94%). 1H NMR (CDCl3, 600 MHz) δ 8.57 (d, J=1.8 Hz, 1H), 8.50 (d, J=3.0 Hz, 1H), 7.81 (dd, J=2.4, 2.4 Hz, 1H), 7.11 (dd, J=7.8 Hz, 1H), 6.86 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.2 Hz, 1H), 5.84 (dd, J=6.6, 3.6 Hz, 1H), 2.99-2.92 (m, 1H), 2.80-2.73 (m, 1H), 2.68-2.61 (m, 1H), 2.28-2.22 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+270.1237, found 270.1249.
    • (R)-5-((4-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5c)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of IC4c (160 mg, 0.56 mmol) afforded IC5c as a white solid (140 mg, 93%). 1H NMR (CDCl3, 600 MHz) δ 8.59 (d, J=1.8 Hz, 1H), 8.48 (d, J=3.0 Hz, 1H), 7.81 (dd, J=2.4, 2.4 Hz, 1H), 7.11 (dd, J=7.8 Hz, 1H), 6.85 (d, J=7.8 Hz, 1H), 6.67 (d, J=7.8 Hz, 1H), 5.83 (dd, J=7.2, 3.6 Hz, 1H), 2.98-2.91 (m, 1H), 2.78-2.72 (m, 1H), 2.66-2.60 (m, 1H), 2.27-2.21 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+270.1237, found 270.1235.
    • (R)-5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5e)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of IC4e (220 mg, 0.77 mmol) afforded IC5e as a light yellow solid (180 mg, 86%). 1H NMR (CDCl3, 600 MHz) δ 8.57 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 7.81 (s, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (s, 1H), 6.69 (d, J=8.4 Hz, 1H), 5.77 (dd, J=4.8, 4.8 Hz, 1H), 3.08-3.01 (m, 1H), 2.88-2.82 (m, 1H), 2.63-2.56 (m, 1H), 2.20-2.14 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+270.1237, found 270.1240.
    • (S)-5-((6-Amino-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (IC5f)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of IC4f (200 mg, 0.70 mmol) afforded IC5f as a light yellow solid (150 mg, 79%). 1H NMR (CDCl3, 600 MHz) δ 8.58 (d, J=1.2 Hz, 1H), 8.49 (d, J=3.0 Hz, 1H), 7.80 (dd, J=2.4, 2.4 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 6.74 (s, 1H), 6.69 (dd, J=8.4, 2.4 Hz, 1H), 5.77 (dd, J=6.0, 4.2 Hz, 1H), 3.07-3.00 (m, 1H), 2.87-2.81 (m, 1H), 2.62-2.55 (m, 1H), 2.20-2.13 (m, 1H). HRMS (ESI+) calcd for C15H16N3O2 (M+H)+270.1237, found 270.1249.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for the preparation of compound C1-1.
  • Figure US20180194731A1-20180712-C00189
    • (S)-5-((4-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C2-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.80 (d, J=5.4 Hz, 2H), 8.67 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.88 (d, J=4.8 Hz, 2H), 7.63 (s, 1H), 7.51-7.47 (m, 1H), 7.35-7.30 (m, 2H), 6.06 (dd, J=3.6, 6.0 Hz, 1H), 3.08-3.01 (m, 1H), 2.93-2.85 (m, 1H), 2.65-2.56 (m, 1H), 2.11-2.03 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1452, found 375.1460.
  • Figure US20180194731A1-20180712-C00190
    • (S)-5-((4-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C2-2)
  • 1H NMR (CD3OD, 600 MHz) δ 8.65 (s, 1H), 8.45 (s, 1H), 7.97 (s, 1H), 7.89 (d, J=8.4 Hz, 2H), 7.44 (d, J=7.2 Hz, 1H), 7.34-7.26 (m, 2H), 7.03 (d, J=8.4 Hz, 2H), 6.04-5.99 (m, 1H), 3.88-3.78 (m, 4H), 3.35-3.25 (m, 4H), 3.16-3.08 (m, 1H), 3.00-2.92 (m, 1H), 2.72-2.62 (m, 1H), 2.24-2.16 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2031.
  • Figure US20180194731A1-20180712-C00191
    • (S)-5-((4-([1,1′-Biphenyl]-4-ylcarboxamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C2-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.10 (s, 1H), 8.67 (s, 1H), 8.50 (d, J=1.8 Hz, 1H), 8.17 (s, 1H), 8.08 (d, J=8.4 Hz, 2H), 7.92 (s, 1H), 7.84 (d, J=7.8 Hz, 2H), 7.76 (d, J=7.8 Hz, 2H), 7.63 (s, 1H), 7.55-7.47 (m, 3H), 7.43 (dd, J=7.2, 7.2 Hz, 1H), 7.34-7.28 (m, 2H), 6.08-6.04 (m, 1H), 3.10-3.02 (m, 1H), 2.95-2.88 (m, 1H), 2.65-2.56 (m, 1H), 2.11-2.03 (m, 1H). HRMS (ESI+) calcd for C25H24N3O3 (M+H)+450.1812, found 450.1812.
  • Figure US20180194731A1-20180712-C00192
    • (R)-5-((4-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C3-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.33 (s, 1H), 8.80 (d, J=4.2 Hz, 2H), 8.67 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.88 (d, J=4.2 Hz, 2H), 7.63 (s, 1H), 7.49 (d, J=4.8 Hz, 1H), 7.35-7.30 (m, 2H), 6.08-6.04 (m, 1H), 3.08-3.01 (m, 1H), 2.93-2.85 (m, 1H), 2.65-2.56 (m, 1H), 2.11-2.03 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1452, found 375.1465.
  • Figure US20180194731A1-20180712-C00193
    • (R)-5-((4-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C3-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.75 (s, 1H), 8.67 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.93-7.85 (m, 3H), 7.63 (s, 1H), 7.46 (d, J=7.2 Hz, 1H), 7.29-7.23 (m, 2H), 7.03 (d, J=9.0 Hz, 2H), 6.06-6.02 (m, 1H), 3.79-3.72 (m, 4H), 3.28-3.22 (m, 4H), 3.08-3.00 (m, 1H), 2.91-2.84 (m, 1H), 2.63-2.55 (m, 1H), 2.09-2.02 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2039.1.
  • Figure US20180194731A1-20180712-C00194
    • (R)-5-((4-([1,1′-Biphenyl]-4-carboxamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C3-3)
  • White solid (4.0 mg, 5%). 1H NMR (CD3OD, 600 MHz) δ 8.65 (s, 1H), 8.46 (s, 1H), 8.06 (d, J=7.8 Hz, 2H), 7.99 (s, 1H), 7.79 (d, J=8.4 Hz, 2H), 7.70 (d, J=8.4 Hz, 2H), 7.52-7.46 (m, 3H), 7.42-7.39 (m, 1H), 7.38-7.32 (m, 2H), 6.06-6.02 (m, 1H), 3.20-3.13 (m, 1H), 3.03-2.96 (m, 1H), 2.74-2.66 (m, 1H), 2.26-2.19 (m, 1H). HRMS (ESI+) calcd for C2H24N3O3 (M+H)+450.1812, found 450.1819.
  • Figure US20180194731A1-20180712-C00195
    • (R)-5-((6-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C5-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 8.77 (d, J=6.0 Hz, 2H), 8.67 (s, 1H), 8.50 (s, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.88-7.82 (m, 3H), 7.73 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.35 (d, J=8.4 Hz, 1H), 6.06-6.01 (m, 1H), 3.08-3.01 (m, 1H), 2.94-2.86 (m, 1H), 2.68-2.62 (m, 1H), 2.10-2.03 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1452, found 375.1461.
  • Figure US20180194731A1-20180712-C00196
    • (R)-5-((6-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C5-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.98 (s, 1H), 8.67 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.93-7.83 (m, 4H), 7.72 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.29 (d, J=7.8 Hz, 1H), 7.01 (d, J=7.8 Hz, 2H), 6.03-5.98 (m, 1H), 3.78-3.71 (m, 4H), 3.27-3.20 (m, 4H), 3.06-2.98 (m, 1H), 2.92-2.83 (m, 1H), 2.68-2.60 (m, 1H), 2.10-2.02 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2034.
  • Figure US20180194731A1-20180712-C00197
    • (R)-5-((6-([1,1′-Biphenyl]-4-ylcarboxamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C5-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.68 (s, 1H), 8.51 (s, 1H), 8.16 (s, 1H), 8.05 (d, J=7.8 Hz, 2H), 7.91 (s, 2H), 7.83 (d, J=8.4 Hz, 2H), 7.78-7.73 (m, 3H), 7.63 (s, 1H), 7.51 (dd, J=7.2, 7.2 Hz, 2H), 7.45-7.40 (m, 1H), 7.34 (d, J=7.8 Hz, 1H), 6.06-6.02 (m, 1H), 3.08-3.01 (m, 1H), 2.93-2.85 (m, 1H), 2.70-2.62 (m, 1H), 2.11-2.03 (m, 1H). HRMS (ESI+) calcd for C25H24N3O3 (M+H)+450.1812, found 450.1820.
  • Figure US20180194731A1-20180712-C00198
    • (S)-5-((6-(Isonicotinamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C6-1)
  • 1H NMR (CD3OD, 600 MHz) δ 8.72 (d, J=5.4 Hz, 2H), 8.65 (s, 1H), 8.45 (s, 1H), 7.99-7.96 (m, 1H), 7.87 (d, J=5.4 Hz, 2H), 7.83 (s, 1H), 7.68-7.64 (m, 1H), 7.35 (d, J=8.4 Hz, 1H), 6.01-5.97 (m, 1H), 3.17-3.10 (m, 1H), 3.00-2.93 (m, 1H), 2.74-2.67 (m, 1H), 2.26-2.19 (m, 1H). HRMS (ESI+) calcd for C21H19N4O3 (M+H)+375.1452, found 375.1465.
  • Figure US20180194731A1-20180712-C00199
    • (S)-5-((6-(4-Morpholinobenzamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C6-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.98 (s, 1H), 8.67 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 7.93-7.83 (m, 4H), 7.72 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.29 (d, J=7.8 Hz, 1H), 7.01 (d, J=8.4 Hz, 2H), 6.03-5.98 (m, 1H), 3.78-3.70 (m, 4H), 3.28-3.21 (m, 4H), 3.06-2.98 (m, 1H), 2.92-2.83 (m, 1H), 2.68-2.60 (m, 1H), 2.10-2.02 (m, 1H). HRMS (ESI+) calcd for C26H27N4O4 (M+H)+459.2027, found 459.2037.
  • Figure US20180194731A1-20180712-C00200
    • (S)-5-((6-([1,1′-Biphenyl]-4-ylcarboxamido)-2,3-dihydro-1H-inden-1-yl)oxy)nicotinamide (C6-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.32 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.17 (s, 1H), 8.05 (d, J=8.4 Hz, 2H), 7.91 (s, 2H), 7.83 (d, J=8.4 Hz, 2H), 7.78-7.73 (m, 3H), 7.63 (s, 1H), 7.51 (dd, J=7.5, 7.5 Hz, 2H), 7.45-7.41 (m, 1H), 7.34 (d, J=7.2 Hz, 1H), 6.06-6.02 (m, 1H), 3.08-3.01 (m, 1H), 2.93-2.85 (m, 1H), 2.70-2.62 (m, 1H), 2.11-2.03 (m, 1H). HRMS (ESI+) calcd for C2H24N3O3 (M+H)+450.1812, found 450.1820.
  • Figure US20180194731A1-20180712-C00201
    Figure US20180194731A1-20180712-C00202
    • 5-Nitro-3,4-dihydronaphthalen-1(2H)-one (IC6a) and 7-Nitro-3,4-dihydronaphthalen-1(2H)-one (IC6b)
  • In a manner similar to that described for the preparation of compounds IC1a and IC1b, tetralone (5.53 g, 37.8 mmol) was subjected to a nitration reaction to afford IC6a as a yellow solid (1.48 g, 20%) 1H NMR (DMSO-d6, 600 MHz) δ 8.22 (d, J=7.8 Hz, 1H), 8.19 (d, J=8.4 Hz, 1H), 7.61 (dd, J=7.5, 7.5 Hz, 1H), 3.09 (t, J=6.3 Hz, 2H), 2.68 (t, J=6.9 Hz, 2H), 2.06 (p, J=6.3 Hz, 2H). HRMS (ESI−) calcd for C10H8NO3 (M−H)− 190.0510, found 190.0505; and IC6b as a yellow solid (4.00 g, 55%) 1H NMR (DMSO-d6, 600 MHz) δ 8.54 (s, 1H), 8.36 (d, J=8.4 Hz, 1H), 7.67 (d, J=8.4 Hz, 1H), 3.08 (t, J=5.7 Hz, 2H), 2.70 (t, J=6.6 Hz, 2H), 2.09 (p, J=6.3 Hz, 2H). HRMS (ESI−) calcd for C10H8NO3 (M−H)− 190.0510, found 190.0511.
    • 5-Nitro-1,2,3,4-tetrahydronaphthalen-1-ol (IC7a)
  • In a manner similar to that described for the preparation of compound IC2a, IC6a (1.35 g, 7.06 mmol) was reduced with NaBH4 to afford IC7a as a light yellow solid (1.25 g, 92%). 1H NMR (DMSO-d6, 600 MHz) δ 8.26 (s, 1H), 7.99 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 5.55 (d, J=6.0 Hz, 1H), 4.66-4.61 (m, 1H), 2.88-2.75 (m, 2H), 2.01-1.94 (m, 1H), 1.93-1.85 (m, 1H), 1.76-1.62 (m, 2H). HRMS (ESI+) calcd for C10H10NO3 (M−H)− 192.0666, found 192.0659.
    • 7-Nitro-1,2,3,4-tetrahydronaphthalen-1-ol (IC7b)
  • In a manner similar to that described for the preparation of compound IC2a, IC6b (1.50 g, 7.85 mmol) was reduced with NaBH4 to give IC7b as a white solid (1.40 g, 92%). 1H NMR (DMSO-d6, 600 MHz) δ 7.76 (d, J=7.8 Hz, 2H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 5.43 (d, J=5.4 Hz, 1H), 4.65-4.60 (m, 1H), 2.89-2.82 (m, 1H), 2.80-2.73 (m, 1H), 1.96-1.84 (m, 2H), 1.74-1.64 (m, 2H). HRMS (ESI+) calcd for C10H10NO3 (M−H)− 192.0666, found 192.0669.
    • Methyl 5-((5-Nitro-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinate (IC8a)
  • In a manner similar to that described for the preparation of compound IC3a, IC7a (468 mg, 2.42 mmol) and methyl 5-hydroxynicotinate (371 mg, 2.42 mmol) were treated with DIAD and Ph3P to afford IC8a as a yellow solid (600 mg, 75%). 1H NMR (CDCl3, 600 MHz) δ 8.88 (s, 1H), 8.53 (d, J=3.0 Hz, 1H), 7.91 (s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (dd, J=8.1, 8.1 Hz, 1H), 5.50 (dd, J=4.8, 4.8 Hz, 1H), 3.98 (s, 3H), 3.17-3.11 (m, 1H), 3.04-2.96 (m, 1H), 2.22-2.15 (m, 1H), 2.12-1.98 (m, 2H), 1.93-1.86 (m, 1H). HRMS (ESI+) calcd for C17H17N2O5 (M+H)+329.1132, found 329.1139.
    • Methyl 5-((7-Nitro-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinate (IC8b)
  • In a manner similar to that described for the preparation of compound IC3a, IC7b (505 mg, 3.30 mmol) and methyl 5-hydroxynicotinate (638 mg, 3.30 mmol) were treated with DIAD and Ph3P to afford IC8b as a yellow solid (810 mg, 75%). 1H NMR (CDCl3, 600 MHz) δ 8.89 (s, 1H), 8.55 (d, J 2.4 Hz, 1H), 8.24 (s, 1H), 8.12 (d, J=9.0 Hz, 1H), 7.92 (s, 1H), 7.35 (d, J=8.4, 1H), 5.51 (dd, J=4.8, 4.8 Hz, 1H), 3.98 (s, 3H), 3.05-2.99 (m, 1H), 2.91-2.85 (m, 1H), 2.17-2.10 (m, 2H), 2.08-2.02 (m, 1H), 1.93-1.87 (m, 1H). HRMS (ESI+) calcd for C17H17N2O5 (M+H)+329.1132, found 329.1134.
    • Methyl 5-((5-Amino-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinate (IC9a)
  • In a manner similar to that described for the preparation of compound IC4a, IC8a (737 mg, 2.24 mmol) was reduced to afford IC9a as a light yellow solid (620 mg, 94%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.53 (s, 1H), 7.91 (s, 1H), 7.06 (dd, J=7.8, 7.8 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.68 (d, J=8.4 Hz, 1H), 5.45-5.40 (m, 1H), 3.96 (s, 3H), 3.68 (bs, 2H), 2.64-2.57 (m, 1H), 2.49-2.41 (m, 1H), 2.19-2.06 (m, 2H), 2.03-1.95 (m, 1H), 1.94-1.86 (m, 1H). HRMS (ESI+) calcd for C17H19N2O3 (M+H)+299.1390, found 299.1400.
    • Methyl 5-((7-Amino-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinate (IC9b)
  • In a manner similar to that described for the preparation of compound IC4a, IC8b (682 mg, 2.08 mmol) was reduced to afford IC9b as a white solid (580 mg, 94%). 1H NMR (CDCl3, 600 MHz) δ 8.83 (s, 1H), 8.53 (s, 1H), 7.90 (s, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.66-6.61 (m, 2H), 5.38-5.34 (m, 1H), 3.96 (s, 3H), 3.60 (bs, 2H), 2.81-2.75 (m, 1H), 2.71-2.63 (m, 1H), 2.12-2.05 (m, 1H), 2.04-1.92 (m, 2H), 1.81-1.74 (m, 1H). HRMS (ESI+) calcd for C17H19N2O3 (M+H)+299.1390, found 299.1390.
    • 5-((5-Amino-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (IC10a)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of methyl ester IC9a (400 mg, 1.34 mmol) in the presence of CaCl2 (149 mg, 1.34 mmol) afforded IC10a as a white solid (320 mg, 84%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.40 (s, 1H), 7.95 (s, 1H), 6.95 (dd, J=7.5, 7.5 Hz, 1H), 6.71 (d, J=7.8 Hz, 1H), 6.68 (d, J=7.2 Hz, 1H), 5.54-5.48 (m, 1H), 2.67-2.60 (m, 1H), 2.50-2.42 (m, 1H), 2.16-2.01 (m, 2H), 2.00-1.95 (m, 1H), 1.92-1.80 (m, 1H). HRMS (ESI+) calcd for C16H15N3O2 (M+H)+284.1394, found 284.1397.
    • 5-((7-Amino-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (IC10b)
  • In a manner similar to that described for the preparation of compound IC5a, aminolysis of methyl ester IC9b (500 mg, 1.73 mmol) in the presence of CaCl2 (192 mg, 1.73 mmol) afforded IC10b as a white solid (410 mg, 85%). 1H NMR (DMSO-d6, 600 MHz) δ 8.64 (d, J=1.8 Hz, 1H), 8.45 (d, J=3.0 Hz, 1H), 8.14 (s, 1H), 7.89 (dd, J=1.8, 1.8 Hz, 1H), 7.61 (s, 1H), 6.82 (d, J=8.4 Hz, 1H), 6.52-6.47 (m, 2H), 5.49 (t, J=4.8 Hz, 1H), 4.86 (s, 2H), 2.68-2.62 (m, 1H), 2.60-2.53 (m, 1H), 1.96-1.91 (m, 2H), 1.86-1.79 (m, 1H), 1.73-1.66 (m, 1H). HRMS (ESI+) calcd for C16H15N3O2 (M+H)+284.1394, found 284.1399.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for the preparation of compound C1-1.
  • Figure US20180194731A1-20180712-C00203
    • 5-((5-(4-Methyl-3-nitrobenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C7-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.14 (s, 1H), 8.66 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 8.22 (d, J=7.8 Hz, 1H), 8.16 (s, 1H), 7.95 (s, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.36-7.30 (m, 2H), 7.29-7.25 (m, 1H), 5.73-5.69 (m, 1H), 2.84-2.76 (m, 1H), 2.67-2.59 (m, 4H), 2.06-1.93 (m, 2H), 1.90-1.81 (m, 1H), 1.80-1.73 (m, 1H). HRMS (ESI+) calcd for C24H23N4O (M+H)+447.1663, found 447.1667.
  • Figure US20180194731A1-20180712-C00204
    • 5-((5-(4-Methylbenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C7-2)
  • 1H NMR (CD3OD, 600 MHz) δ 8.65 (s, 1H), 8.44 (s, 1H), 7.99 (s, 1H), 7.87 (d, J=7.2 Hz, 2H), 7.36-7.30 (m, 4H), 7.27 (dd, J=7.8, 7.8 Hz, 1H), 5.66 (dd, J=4.2, 4.2 Hz, 1H), 2.92-2.86 (m, 1H), 2.75-2.68 (m, 1H), 2.43 (s, 3H), 2.19-2.13 (m, 1H), 2.10-1.97 (m, 2H), 1.89-1.83 (m, 1H). HRMS (ESI+) calcd for C24H24N3O3 (M+H)+402.1812, found 402.1817.
  • Figure US20180194731A1-20180712-C00205
    • 5-((5-(4-Methoxybenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C7-3)
  • 1H NMR (CD3OD, 600 MHz) δ 8.65 (s, 1H), 8.44 (s, 1H), 7.99 (s, 1H), 7.96 (d, J=8.4 Hz, 2H), 7.34 (d, J=7.8 Hz, 1H), 7.31 (d, J=7.8 Hz, 1H), 7.27 (dd, J=7.5, 7.5 Hz, 1H), 7.05 (d, J=8.4 Hz, 2H), 5.67 (dd, J=4.2, 4.2 Hz, 1H), 3.88 (s, 3H), 2.94-2.85 (m, 1H), 2.75-2.68 (m, 1H), 2.20-2.14 (m, 1H), 2.11-1.97 (m, 2H), 1.90-1.83 (m, 1H). HRMS (ESI+) calcd for C24H24N3O4 (M+H)+ 418.1761, found 418.1773.
  • Figure US20180194731A1-20180712-C00206
    • 5-((5-(4-Chlorobenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C7-4)
  • 1H NMR (DMSO-d6, 600 MHz) δ 9.95 (s, 1H), 8.66 (s, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.16 (s, 1H), 8.01 (d, J=9.0 Hz, 2H), 7.95 (s, 1H), 7.65-7.59 (m, 3H), 7.34 (dd, J=6.0, 6.0 Hz, 1H), 7.30 (d, J=7.8 Hz, 1H), 7.26 (dd, J=7.8, 7.8 Hz, 1H), 5.72-5.69 (m, 1H), 2.85-2.77 (m, 1H), 2.67-2.59 (m, 1H), 2.06-1.93 (m, 2H), 1.91-1.82 (m, 1H), 1.81-1.74 (m, 1H). HRMS (ESI+) calcd for C23H21ClN3O3 (M+H)+422.1266, found 422.1275.
  • Figure US20180194731A1-20180712-C00207
    • 5-((7-(4-Methyl-3-nitrobenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C8-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.66 (s, 1H), 8.55 (s, 1H), 8.51 (s, 1H), 8.18 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.94 (s, 1H), 7.75-7.00 (m, 2H), 7.66 (d, J=7.2 Hz, 1H), 7.63 (s, 1H), 7.19 (d, J=8.4 Hz, 1H), 5.68-5.64 (m, 1H), 2.86-2.79 (m, 1H), 2.76-2.68 (m, 1H), 2.58 (s, 3H), 2.07-1.95 (m, 2H), 1.92-1.83 (m, 1H), 1.82-1.74 (m, 1H). HRMS (ESI+) calcd for C23H21ClN3O3 (M+H)+447.1663, found 447.1671.
  • Figure US20180194731A1-20180712-C00208
    • 5-((7-(4-Methylbenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C8-2)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.01 (s, 1H), 8.66 (s, 1H), 8.50 (s, 1H), 8.15 (s, 1H), 7.96-7.92 (m, 1H), 7.85 (d, J=7.2 Hz, 2H), 7.76 (s, 1H), 7.71 (d, J=7.2 Hz, 1H), 7.62 (s, 1H), 7.31 (d, J=6.6 Hz, 2H), 7.15 (d, J=7.8 Hz, 1H), 5.66-5.62 (m, 1H), 2.84-2.78 (m, 1H), 2.75-2.67 (m, 1H), 2.37 (s, 3H), 2.04-1.96 (m, 2H), 1.92-1.83 (m, 1H), 1.82-1.74 (m, 1H). HRMS (ESI+) calcd for C24H24N3O3 (M+H)+402.1812, found 402.1815.
  • Figure US20180194731A1-20180712-C00209
    • 5-((7-(4-Methoxybenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C8-3)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.03 (s, 1H), 8.66 (s, 1H), 8.50 (s, 1H), 8.15 (s, 1H), 7.96-7.90 (m, 3H), 7.75 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.62 (s, 1H), 7.15 (d, J=7.2 Hz, 1H), 7.03 (d, J=8.4 Hz, 2H), 5.66-5.62 (m, 1H), 3.82 (s, 3H), 2.84-2.78 (m, 1H), 2.75-2.67 (m, 1H), 2.04-1.96 (m, 2H), 1.92-1.83 (m, 1H), 1.82-1.74 (m, 1H). HRMS (ESI+) calcd for C24H24N3O4 (M+H)+418.1761, found 418.1759.
  • Figure US20180194731A1-20180712-C00210
    • 5-((7-(4-Chlorobenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)nicotinamide (C8-4)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.26 (s, 1H), 8.66 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.16 (s, 1H), 7.98-7.91 (m, 3H), 7.74 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.58 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 1H), 5.67-5.63 (m, 1H), 2.85-2.78 (m, 1H), 2.76-2.68 (m, 1H), 2.06-1.95 (m, 2H), 1.92-1.83 (m, 1H), 1.82-1.74 (m, 1H). HRMS (ESI+) calcd for C23H21ClN3O3 (M+H)+422.1266, found 422.1268.
  • Figure US20180194731A1-20180712-C00211
    • 5-((7-(4-Morpholinobenzamido)-1,2,3,4-tetrahydronaphthalen-1-yl-oxy)nicotinamide (C8-5)
  • 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.44 (d, J=2.4 Hz, 1H), 7.98 (s, 1H), 7.82 (d, J=9.0 Hz, 2H), 7.67 (s, 1H), 7.56 (d, J=7.8 Hz, 1H), 7.15 (d, J=9.0 Hz, 1H), 6.97 (d, J=9.0 Hz, 2H), 5.59-5.55 (m, 1H), 3.81 (t, J=4.8 Hz, 4H), 3.25 (t, J=4.8 Hz, 4H), 2.90-2.84 (m, 1H), 2.80-2.73 (m, 1H), 2.15-2.08 (m, 2H), 2.05-1.96 (m, 1H), 1.88-1.81 (m, 1H). HRMS (ESI+) calcd for C27H29N4O4 (M+H)+473.2183, found 473.2195.
    • Example 4
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00212
    • Methyl 3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)benzoate (ID3)
  • A mixture of methyl 3-(bromomethyl)benzoate (ID1, 1.14 g, 4.98 mmol), 5-hydroxynicotinamide (ID2, 760 mg, 5.50 mmol) and Cs2CO3 (3.27 g, 10.0 mmol) was allowed to stir at rt for 20 h and then poured into ice-water (300 mL). The resulting mixture was extracted with EtOAc (300 mL) and the organic layer was washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by the flash column chromatography (0-10% MeOH/CH2Cl2) to give compound ID3 as a pale solid (335 mg, 23%). 1H NMR (DMSO-d6, 600 MHz) δ 8.66 (d, J=1.8 Hz, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.13 (brs, 1H), 8.08 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.87 (dd, J=2.1, 2.1 Hz, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.61 (brs, 1H), 7.58 (dd, J=7.8, 7.8 Hz, 1H), 5.33 (s, 2H), 3.87 (s, 3H). HRMS (ESI+) calcd for C15H15N2O4 (M+H)+ 287.1026, found 287.1023.
    • 3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)benzoic acid (ID4)
  • A mixture of ID3 (300 mg, 1.05 mmol) in THF (6 mL), MeOH (3 mL) and 1N NaOH (6 mL) was allowed to stir at rt for 16 h. After the organic solvents were removed in vacuo, the mixture was acidified with 1N HCl to pH=5 and the precipitate was collected, washed with water and dried to give compound ID4 as a white solid (146 mg, 51%). 1H NMR (DMSO-d6, 600 MHz) δ 8.66 (d, J=1.8 Hz, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.14 (brs, 1H), 8.06 (s, 1H), 7.92 (d, J=7.8 Hz, 1H), 7.87 (dd, J=2.4, 2.4 Hz, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.62 (brs, 1H), 7.54 (dd, J=7.8, 7.8 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C14H13N2O4 (M+H)+273.0870, found 273.0871.
  • Figure US20180194731A1-20180712-C00213
    • 5-((3-((4-Methyl-3-nitrophenyl)carbamoyl)benzyl)oxy)nicotinamide (D1-1)
  • A mixture of ID4 (120 mg, 0.44 mmol), PyBOP (345 mg, 0.66 mmol), DIPEA (350 μL, 2.01 mmol) and 4-methyl-3-nitroaniline (101 mg, 0.66 mmol) in DMF (5 mL) was allowed to stir at rt for 20 h. After DMF was removed, the residue was dissolved in EtOAc (100 mL) and the solution was washed with water (40×2 mL) and brine (40 mL). The organic layer was dried over Na2SO4 and filtered and the filtrate was concentrated. The residue was purified by the flash column chromatography (0-10% MeOH/CH2Cl2) to give compound D1-1 as a pale solid (33 mg, 18%). 1H NMR (DMSO-d6, 600 MHz) δ 10.65 (s, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.55 (d, J=2.4 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.14 (brs, 1H), 8.09 (s, 1H), 8.00 (dd, J=8.7, 2.1 Hz, 1H), 7.97 (d, J=7.8 Hz, 1H), 7.89 (s, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.64-7.58 (m, 2H), 7.50 (d, J=8.4 Hz, 1H), 5.34 (s, 2H), 2.50 (s, 3H). HRMS (ESI+) calcd for C21H19N4O5 (M+H)+407.1350, found 407.1343.
  • Figure US20180194731A1-20180712-C00214
    • Methyl 3-((5-Carbamoylpyridin-3-yl)methoxy)benzoate (ID7)
  • A To a solution of methyl 3-hydroxybenzoate (ID5, 350 mg, 2.30 mmol), 5-(hydroxymethyl)nicotinamide (ID6, 290 mg, 1.91 mmol) and PPh3 (758 mg, 2.89 mmol) in THF (10 mL) at rt was slowly added DIAD (0.56 mL, 2.89 mmol) and the resulting mixture was allowed to stir for 24 h. After the organic solvent was removed, the residue was purified by the flash column chromatography (0-5% MeOH/CH2Cl2) to give compound ID7 as a white solid (193 mg, 35%). 1H NMR (DMSO-d6, 600 MHz) δ 9.01 (d, J=1.8 Hz, 1H), 8.81 (d, J=1.8 Hz, 1H), 8.31 (s, 1H), 8.21 (brs, 1H), 7.64 (brs, 1H), 7.60-7.55 (m, 2H), 7.48 (dd, J=7.8, 7.8 Hz, 1H), 7.37-7.33 (m, 1H), 5.29 (s, 2H), 3.85 (s, 3H). HRMS (ESI+) calcd for C15H15N2O4 (M+H)+287.1026, found 287.1031.
    • 3-((5-Carbamoylpyridin-3-yl)methoxy)benzoic acid (ID8)
  • Compound ID8 was prepared in a manner similar to that described for compound ID4. White solid (145 mg, 89%). 1H NMR (DMSO-d6, 600 MHz) δ 13.13 (brs, 1H), 9.04 (s, 0.3H), 9.00 (d, J=1.8 Hz, 0.7H), 8.89 (d, J=1.8 Hz, 0.3H), 8.81 (d, J=1.2 Hz, 0.7 Hz), 8.35 (s, 0.3H), 8.31 (s, 0.7H), 8.21 (brs, 1H), 7.63 (brs, 1H), 7.59-7.54 (m, 2H), 7.44 (dd, J=8.4, 8.4 Hz, 1H), 7.31 (dd, J=8.4, 1.8 Hz, 1H), 5.31 (s, 0.6H), 5.28 (s, 1.4H). HRMS (ESI+) calcd for C14H13N2O4 (M+H)+273.0870, found 273.0871.
  • Figure US20180194731A1-20180712-C00215
    • 5-((3-((4-Methyl-3-nitrophenyl)carbamoyl)phenoxy)methyl)nicotinamide (D2-1)
  • Compound D2-1 was prepared in a manner similar to that described for compound D1-1. Yellow solid (35 mg, 20%). 1H NMR (DMSO-d6, 600 MHz) δ 10.56 (s, 1H), 9.02 (d, J=1.8 Hz, 1H), 8.83 (d, J=1.8 Hz, 1H), 8.55 (d, J=1.8 Hz, 1H), 8.34 (s, 1H), 8.22 (brs, 1H), 8.00 (dd, J=8.4, 2.4 Hz, 1H), 7.67-7.63 (m, 2H), 7.61 (d, J=7.2 Hz, 1H), 7.53-7.47 (m, 2H), 7.32 (dd, J=8.4, 2.4 Hz, 1H), 5.31 (s, 2H), 2.50 (s, 3H). HRMS (ESI+) calcd for C21H19N4O (M+H)+407.1350, found 407.1348.
  • Figure US20180194731A1-20180712-C00216
    • Methyl 5-((3-Nitrophenoxy)methyl)nicotinate (ID11)
  • To a solution of 3-nitrophenol (ID9, 900 mg, 6.46 mmol), methyl 5-(hydroxymethyl) nicotinate (ID10, 900 mg, 5.38 mmol), and Ph3P (2.12 g, 8.07 mmol) in anhydrous CH2Cl2 (40 mL) at rt was added DIAD (1.63 g, 8.07 mmol) dropwise. The mixture was allowed to stir at rt for 12 h and concentrated. The residue was purified by flash column chromatography to afford ID11 as a light yellow solid (340 mg, 22%). 1H NMR (CDCl3, 600 MHz) δ 9.23 (d, J=2.4 Hz, 1H), 8.88 (d, J=2.4 Hz, 1H), 8.41 (dd, J=1.8, 1.8 Hz, 1H), 7.90 (dd, J=8.4, 1.2 Hz, 1H), 7.85 (dd, J=2.4, 2.4 Hz, 1H), 7.50 (dd, J=8.4, 8.4 Hz, 1H), 7.32 (dd, J=7.8, 1.8 Hz, 1H), 5.22 (s, 2H), 3.99 (s, 3H). HRMS (ESI+) calcd for C14H13N2O5 (M+H)+289.0819, found 289.0820.
    • Methyl 5-((3-Aminophenoxy)methyl)nicotinate (ID12)
  • To a solution of ID11 (312 mg, 1.09 mmol) in anhydrous EtOH (40 mL) at rt was added tin (II) chloride (1.50 g, 7.92 mmol) and the mixture was heated at 70° C. for 12 h. The reaction was quenched with saturated NaHCO3 (150 mL) and the mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (MeOH/CH2Cl2) to afford compound ID12 as a light yellow oil (200 mg, 71%). 1H NMR (CDCl3, 600 MHz) δ 9.17 (d, J=1.8 Hz, 1H), 8.82 (d, J=1.8 Hz, 1H), 8.37-8.35 (m, 1H), 7.06 (t, J=8.1 Hz, 1H), 6.37 (dd, J=8.1 Hz, J2=2.2 Hz, 1H), 6.34-6.30 (m, 2H), 5.06 (s, 2H), 3.96 (s, 3H), 3.73 (br s, 2H). HRMS (ESI+) calcd for C14H15N2O3 (M+H)+259.1077, found 259.1082.
    • 5-((3-Aminophenoxy)methyl)nicotinamide (ID13)
  • A solution of ID12 (200 mg, 0.77 mmol) in NH3/MeOH (ca. 7N, 5 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the solution was washed with H2O (150 mL) and brine (100 mL). The organic layer was dried over Na2SO4, concentrated, and the residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to afford ID13 as a light brownish solid (56 mg, 30%). 1H NMR (CD3OD, 600 MHz) δ 8.96 (d, J=1.8 Hz, 1H), 8.75 (d, J=1.8 Hz, 1H), 8.35 (t, J=1.8 Hz, 1H), 7.00 (t, J=8.1 Hz, 1H), 6.41-6.40 (m, 1H), 6.38-6.34 (m, 2H), 5.14 (s, 2H). HRMS (ESI+) calcd for C13H14N3O2 (M+H)+244.1081, found 244.1077.
  • Figure US20180194731A1-20180712-C00217
    • 5-((3-(4-Methyl-3-nitrobenzamido)phenoxy)methyl)nicotinamide (D3-1)
  • Compound D3-1 was prepared from ID13 in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 10.46 (s, 1H), 9.01 (s, 1H), 8.81 (s, 1H), 8.56 (s, 1H), 8.31 (s, 1H), 8.24-8.18 (m, 2H), 7.68 (d, J=8.4 Hz, 1H), 7.64 (s, 1H), 7.59 (s, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.30 (dd, J=7.8, 7.8 Hz, 1H), 6.84 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 2.60 (s, 3H). HRMS (ESI+) calcd for C21H9N4O (M+H)+ 407.1350, found 407.1358.
  • Figure US20180194731A1-20180712-C00218
    • Methyl 5-((3-Nitrobenzyl)thio)nicotinate (ID16)
  • To a mixture of (3-nitrobenzyl) mercaptan (ID14, 350 mg, 2.00 mmol), methyl 5-bromonicotinate (ID15, 432 mg, 2.00 mmol), Pd2(dba)3 (46 mg, 0.05 mmol), and Xantphos (58 mg, 0.10 mmol) in 1,4-dioxane (10 mL) was added DIPEA (517 mg, 4.0 mmol) dropwise under Ar protection. The reaction mixture was allowed to stir at 110° C. for 16 h and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID16 as a light yellow solid (490 mg, 81%). 1H NMR (CDCl3, 600 MHz) δ 8.09 (d, J=1.8 Hz, 1H), 8.63 (d, J=2.4 Hz, 1H), 8.18 (dd, J=2.4, 2.4 Hz, 1H), 8.15 (s, 1H), 8.13 (d, J=7.8 Hz, 1H), 7.60 (d, J=7.2 Hz, 1H), 7.48 (dd, J=7.8, 7.8 Hz, 1H), 4.22 (s, 2H), 3.95 (s, 3H). HRMS (ESI+) calcd for C14H13N2O5S (M+H)+305.0591, found 305.0595.
    • Methyl 5-((3-Aminobenzyl)thio)nicotinate (ID17)
  • To a solution of ID16 (490 mg, 1.60 mmol) and NiCl2.6H2O (761 mg, 3.20 mmol) in MeOH (100 mL) was slowly added NaBH4 (242 mg, 6.40 mmol) and the mixture was allowed to stir at rt for 3 h. The reaction was quenched with saturated NH4Cl (50 mL) and the mixture was extracted with EtOAc. The organic phase washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID17 as a white solid (120 mg, 27%). 1H NMR (CDCl3, 600 MHz) δ 8.98 (d, J=1.8 Hz, 1H), 8.62 (d, J=2.3 Hz, 1H), 8.19-8.18 (m, 1H), 7.07 (t, J=7.6 Hz, 1H), 6.66 (d, J=7.6 Hz, 1H), 6.63-6.62 (m, 1H), 6.58-6.55 (m, 1H), 4.06 (s, 2H), 3.94 (s, 3H), 3.67 (br s, 2H). HRMS (ESI+) calcd for C14H15N2O2S (M+H)+275.0849, found 275.0848.
    • 5-((3-Aminobenzyl)thio)nicotinamide (ID18)
  • In a manner similar to that described for the preparation of compound ID13, aminolysis of ID17 afforded compound ID18 as a light brownish solid (80 mg, 70%). 1H NMR (CD3OD, 600 MHz) δ 8.77 (s, 1H), 8.51 (s, 1H), 8.19 (s, 1H), 6.99 (m, 1H), 6.70 (s, 1H), 6.61 (d, J=7.2 Hz, 1H), 6.59 (d, J=7.7 Hz, 1H), 4.13 (s, 2H). HRMS (ESI+) calcd for C13H14N3OS (M+H)+260.0852, found 260.0849.
  • Figure US20180194731A1-20180712-C00219
    • 5-((3-(Isonicotinamido)benzyl)thio)nicotinamide (D4-1)
  • Compound D4-1 was prepared from ID18 through an amide formation reaction in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 8.82-8.75 (m, 2H), 8.62 (s, 1H), 8.17 (d, J=15.6 Hz, 2H), 7.89-7.82 (m, 3H), 7.64 (s, 2H), 7.30 (dd, J=7.5, 7.5 Hz, 1H), 7.12 (d, J=7.2 Hz, 1H), 4.38 (s, 2H). HRMS (ESI+) calcd for C19H17N4O2S (M+H)+365.1067, found 365.1074.
  • Figure US20180194731A1-20180712-C00220
    • 5-((3-(4-Morpholinobenzamido)benzyl)thio)nicotinamide (D4-2)
  • Compound D4-2 was prepared from ID18 through an amide formation reaction in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 9.97 (s, 1H), 8.80 (s, 1H), 8.62 (s, 1H), 8.20-8.12 (m, 2H), 7.90-7.84 (m, 3H), 7.67-7.60 (m, 2H), 7.25 (dd, J=7.8, 7.8 Hz, 1H), 7.07-6.99 (m, 3H), 4.35 (s, 2H), 3.75 (t, J=4.5 Hz, 4H), 3.25 (t, J=4.5 Hz, 4H). HRMS (ESI+) calcd for C24H25N4O3S (M+H)+449.1642, found 449.1646.
  • Figure US20180194731A1-20180712-C00221
    • 5-((3-(4-Methylbenzamido)benzyl)amino)nicotinamide (D5-1)
  • 1H NMR (DMSO-d6, 600 MHz) δ 10.16 (s, 1H), 8.22 (s, 1H), 8.09 (s, 1H), 7.94 (br s, 1H), 7.86 (d, J=7.8 Hz, 2H), 7.81 (s, 1H), 7.66 (d, J=8.1 Hz, 1H), 7.39 (s, 1H), 7.34-7.28 (m, 4H), 7.10 (d, J=7.5 Hz, 1H), 6.73 (t, J=5.8 Hz, 1H), 4.34 (d, J=5.8 Hz, 2H), 2.38 (s, 3H). HRMS (ESI+) calcd for C21H21N4O2 (M+H)+361.1659, found 361.1660.
  • Figure US20180194731A1-20180712-C00222
    • (E)-5-(3-Nitrostyryl)nicotinamide (ID21)
  • A mixture of 5-bromonicotinamide (ID20, 1.61 g, 8.01 mmol), Pd(OAc)2 (36 mg, 0.16 mmol), P(O-tolyl)3 (146 mg, 0.48 mmol) and NaOAc (1.32 g, 16.1 mmol) in anhydrous DMF (16 mL) was evacuated and back-filled with argon and 1-nitro-3-vinylbenzene (ID19, 1.35 mL, 9.68 mmol) was added. The resulting mixture was heated at 130° C. for 25 h, cooled to rt, and then poured to ice-water (250 mL). The solid formed was filtered, washed with water, and dried to give compound ID21 as a pale solid (1.71 g, 79%). 1H NMR (DMSO-d6, 600 MHz) δ 8.93 (s, 1H), 8.92 (s, 1H), 8.52 (s, 1H), 8.48 (s, 1H), 8.20 (s, 1H), 8.15 (d, J=7.2 Hz, 1H), 8.10 (d, J=7.2 Hz, 1H), 7.76-7.55 (m, 4H). HRMS (ESI+) calcd for C14H12N3O3 (M+H)+270.0873, found 270.0876.
    • (E)-5-(3-Aminostyryl)nicotinamide (ID22)
  • To a suspension of compound ID21 (1.56 g, 5.79 mmol) in EtOH (200 mL) was added SnCl2 (7.71 g, 40.7 mmol) and the resulting mixture was heated at 70° C. for 22 h and cooled to rt. After addition of water (150 mL), sat. NaHCO3 (150 mL) and subsequently EtOAc (100 mL), the solid formed was collected and washed with EtOAc. Another portion of compound ID22 was also obtained from the filtrate in a similar manner to give compound ID22 in total as a yellow solid (1.19 g, 86%). 1H NMR (DMSO-d6, 600 MHz) δ 8.87 (d, J=2.4 Hz, 1H), 8.85 (d, J=1.8 Hz, 1H), 8.44 (dd, J=1.8, 1.8 Hz, 1H), 8.18 (brs, 1H), 7.63 (brs, 1H), 7.31 (d, J=16.8 Hz, 1H), 7.14 (d, J=16.2 Hz, 1H), 7.05 (dd, J=7.5, 7.5 Hz, 1H), 6.82-6.78 (m, 2H), 6.54 (dd, J=9.0, 1.8 Hz, 1H), 5.12 (s, 2H). HRMS (ESI+) calcd for C14H14N3O (M+H)+240.1131, found 240.1128.
  • Figure US20180194731A1-20180712-C00223
    • (E)-5-(3-(4-Methyl-3-nitrobenzamido)styryl)nicotinamide (D6-1)
  • A solution of compound ID22 (600 mg, 2.51 mmol), 4-methyl-3-nitrobenzoyl chloride (0.55 mL, 3.78 mmol) and DIPEA (0.87 mL, 4.99 mmol) in CH2Cl2 (25 mL) and DMF (5 mL) was allowed to stir at rt for 16 h. After the organic solvents were removed, the residue was diluted with water (50 mL) and EtOAc (50 mL) and the resulting mixture was allowed to stir vigorously for 30 min. The solid formed was collected, washed with water, and triturated with hot MeOH (100 mL) to give compound D6-1 as a yellow solid (744 mg, 74%). 1H NMR (DMSO-d6, 600 MHz) δ 10.54 (s, 1H), 8.90 (s, 2H), 8.61 (s, 1H), 8.50 (d, J=1.2 Hz, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 8.09 (s, 1H), 7.74-7.60 (m, 3H), 7.52-7.38 (m, 3H), 7.30 (d, J=16.2 Hz, 1H), 2.61 (s, 3H). HRMS (ESI+) calcd for C22H19N4O4 (M+H)+403.1401, found 403.1396.
  • Figure US20180194731A1-20180712-C00224
    • 5-(3-(3-Amino-4-methylbenzamido)phenethyl)nicotinamide (D7-1)
  • A mixture of compound D6-1 (205 mg, 0.51 mmol) and 10% Pd/C (33 mg) in anhydrous DMF (10 mL) was hydrogenated (balloon) at rt for 6 h and filtered. The filtrate was concentrated and the residue was purified by the flash column chromatography (0-10% MeOH/CH2Cl2) to give compound D7-1 as a pale solid (85 mg, 44%). 1H NMR (DMSO-d6, 600 MHz) δ 9.94 (s, 1H), 8.85 (d, J 1.2 Hz, 1H), 8.55 (d, J=1.2 Hz, 1H), 8.12 (s, 2H), 7.69 (s, 1H), 7.60-7.54 (m, 2H), 7.22 (dd, J=7.8, 7.8 Hz, 1H), 7.16 (s, 1H), 7.07 (d, J=7.8 Hz, 1H), 7.04 (d, J=7.8 Hz, 1H), 6.93 (d, J=7.8 Hz, 1H), 5.06 (brs, 2H), 3.00-2.94 (m, 2H), 2.94-2.88 (m, 2H), 2.11 (s, 3H). HRMS (ESI+) calcd for C22H23N4O2 (M+H)+375.1816, found 375.1816.
    • 5-(3-Aminophenethyl)nicotinamide (ID23)
  • A mixture of compound ID22 (303 mg, 1.27 mmol) in MeOH (20 mL) was hydrogenated (balloon) in the presence of 10% Pd/C (35 mg) to give compound ID23 as a white solid (293 mg, 96%). 1H NMR (DMSO-d6, 600 MHz) δ 8.84 (d, J=2.4 Hz, 1H), 8.51 (d, J=1.8 Hz, 1H), 8.11 (brs, 1H), 8.08 (dd, J=2.1, 2.1 Hz, 1H), 7.55 (brs, 1H), 6.90 (dd, J=7.8, 7.8 Hz, 1H), 6.24 (s, 1H), 6.40-6.34 (m, 2H), 4.93 (s, 2H), 2.90 (dd, J=7.8, 7.8 Hz, 2H), 2.75 (dd, J=8.1, 8.1 Hz, 2H). HRMS (ESI+) calcd for C14H16N3O (M+H)+242.1288, found 242.1286.
  • Figure US20180194731A1-20180712-C00225
    • 5-(3-(4-Methyl-3-nitrobenzamido)phenethyl)nicotinamide (D8-1)
  • Compound D8-1 was prepared from compound ID23 in a manner similar to that described for compound D6-1. Pale solid (127 mg, 76%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.85 (d, J=1.8 Hz, 1H), 8.58 (d, J=1.2 Hz, 1H), 8.55 (d, J=1.8 Hz, 1H), 8.21 (dd, J=7.5, 1.5 Hz, 1H), 8.14-8.08 (m, 2H), 7.72-7.66 (m, 2H), 7.60 (d, J=7.8 Hz, 1H), 7.56 (brs, 1H), 7.28 (dd, J=7.8, 7.8 Hz, 1H), 7.00 (d, J=7.8 Hz, 1H), 3.01-2.96 (m, 2H), 2.96-2.91 (m, 2H), 2.60 (s, 3H). HRMS (ESI+) calcd for C22H21N4O4 (M+H)+405.1557, found 405.1563.
  • Figure US20180194731A1-20180712-C00226
    • Trimethyl((3-nitrophenyl)ethynyl)silane (ID25)
  • To a mixture of 1-iodo-3-nitrobenzene (ID24, 1.5 g, 6.00 mmol), ethynyltrimethylsilane (706 mg, 7.20 mmol), Pd(PPh3)2Cl2 (84 mg, 0.12 mmol), CuI (23 mg, 0.12 mmol), and PPh3 (63 mg, 0.24 mmol) in toluene (15 mL) was added DIPEA (2 mL) under Ar protection. The reaction mixture was allowed to stir at 80° C. for 16 h and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID25 as a light yellow oil (1.28 g, 93%). 1H NMR (CDCl3, 600 MHz) δ 8.31 (s, 1H), 8.17 (d, J=7.8 Hz, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.49 (dd, J=8.1, 8.1 Hz, 1H), 0.28 (s, 9H).
    • 1-Ethynyl-3-nitrobenzene (ID26)
  • A mixture of ID25 (1.20 g, 5.47 mmol) and K2CO3 (1.50 g, 10.9 mmol) in MeOH (30 mL) and THF (30 mL) was allowed to stir at rt for 3 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the solution was washed with H2O (150 mL) and brine (100 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to afford ID26 as a light yellow oil (790 mg, 98%). 1H NMR (CDCl3, 600 MHz) δ 8.32 (s, 1H), 8.21 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.54 (dd, J=8.1, 8.1 Hz, 1H), 3.26 (s, 1H); 13C NMR (CDCl3, 150 MHz) δ 148.17, 137.93, 129.56, 127.06, 124.03, 123.70, 81.22, 80.113.
    • 5-((3-Nitrophenyl)ethynyl)nicotinamide (ID27)
  • A Sonogashira coupling reaction of ID26 (518 mg, 3.52 mmol) and methyl 5-bromonicotinate (653 mg, 2.93 mmol) followed by aminolysis afforded ID27 as a light yellow solid (500 mg, 64% over two steps). 1H NMR (DMSO-d6, 600 MHz) δ 9.04 (s, 1H), 8.94 (s, 1H), 8.45 (s, 1H), 8.42 (s, 1H), 8.30 (d, J=7.2 Hz, 1H), 8.25 (s, 1H), 8.05 (d, J=7.8 Hz, 1H), 7.79-7.71 (m, 2H). HRMS (ESI+) calcd for C14H10N3O3 (M+H)+268.0717, found 268.0725.
    • 5-((3-Aminophenyl)ethynyl)nicotinamide (ID28)
  • In a manner similar to that described for the preparation of compound ID17, reduction of ID27 afforded compound ID28 as a white solid (150 mg, 33%). 1H NMR (CD3OD, 600 MHz) δ 8.95 (d, J=1.8 Hz, 1H), 8.79 (d, J=1.8 Hz, 1H), 8.35 (dd, J=1.8, 1.8 Hz, 1H), 7.12 (dd, J=7.8, 7.8 Hz, 1H), 6.90 (s, 1H), 6.87 (d, J=7.2 Hz, 1H), 6.76 (dd, J=7.8, 1.8 Hz, 1H). HRMS (ESI+) calcd for C14H12N3O (M+H)+238.0975, found 238.0982.
  • Figure US20180194731A1-20180712-C00227
    • 5-((3-(Isonicotinamido)phenyl)ethynyl)nicotinamide (D9-1)
  • Compound D9-1 was prepared from ID28 through an amide formation reaction in a manner similar to that described for compound A-1. Light yellow solid (10 mg, 12%). 1H NMR (DMSO-d6, 600 MHz) δ 10.69 (s, 1H), 9.01 (s, 1H), 8.90 (s, 1H), 8.80 (d, J=3.6 Hz, 2H), 8.41 (s, 1H), 8.25 (s, 1H), 8.13 (s, 1H), 7.89 (d, J=4.2 Hz, 2H), 7.82 (d, J=8.4 Hz, 1H), 7.71 (s, 1H), 7.48 (dd, J=8.1, 8.1 Hz, 1H), 7.39 (d, J=7.2 Hz, 1H). HRMS (ESI+) calcd for C20H15N4O2 (M+H)+343.1190, found 343.1195.
  • Figure US20180194731A1-20180712-C00228
    Figure US20180194731A1-20180712-C00229
    • 1-(3-Nitrophenyl)ethanol (ID30)
  • To a solution of 1-(3-nitrophenyl)ethanone (ID29, 2.32 g, 14.0 mmol) in MeOH (100 mL) at 0° C. was added NaBH4 (2.20 g, 58.2 mmol) and the resulting mixture was allowed to stir at 0° C. for 1 h. After concentration, the residue was diluted with EtOAc (150 mL) and water (50 mL) and the organic layer was washed with water (50 mL), brine (50 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was dried in vacuo to give compound ID30 as a yellowish oil (2.23 g, 95%). 1H NMR (CDCl3, 600 MHz) δ 8.25 (s, 1H), 8.12 (ddd, J=8.4, 1.2, 1.2 Hz, 1H), 7.72 (d, J=7.2 Hz, 1H), 7.52 (dd, J=8.1, 8.1 Hz, 1H), 5.02 (q, J=6.6 Hz, 1H), 2.07 (s, 1H), 1.54 (d, J=6.6 Hz, 3H).
    • Methyl 5-(1-(3-Nitrophenyl)ethoxy)nicotinate (ID31)
  • To a solution of compound ID30 (1.02 g, 6.10 mmol), 5-hydroxynicotinamide (ID2, 766 mg, 5.00 mmol) and PPh3 (1.97 g, 7.51 mmol) in anhydrous THF (40 mL) at 0° C. was slowly added DIAD (1.45 mL, 7.49 mmol). The resulting mixture was allowed to stir at 0° C. for 1 h and then at rt for 16 h. After concentration, the oily residue was triturated with Et2O and hexanes and the organic solvents were pooled and concentration. The residue was purified by the flash column chromatography (0-40% EtOAc/hexanes) to give compound ID31 as a pale solid (1.46 g, 96%). 1H NMR (CDCl3, 600 MHz) δ 8.80 (d, J=1.2 Hz, 1H), 8.46 (d, J=2.4 Hz, 1H), 8.27 (dd, J=2.1, 2.1 Hz, 1H), 8.16 (ddd, J=8.4, 2.4, 1.2 Hz, 1H), 7.74-7.70 (m, 2H), 7.56 (dd, J=8.1, 8.1 Hz, 1H), 5.52 (q, J=6.6 Hz, 1H), 3.92 (s, 3H), 1.72 (d, J=6.6 Hz, 3H). HRMS (ESI+) calcd for C15H15N2O5 (M+H)+303.0975, found 303.0969.
    • Methyl 5-(1-(3-Aminophenyl)ethoxy)nicotinate (ID32)
  • Compound ID32 was prepared from compound ID31 in a manner similar to that described for ID22. Clear syrup (231 mg, 18%). 1H NMR (CDCl3, 600 MHz) δ 8.60 (d, J=1.8 Hz, 1H), 8.37 (d, J=3.0 Hz, 1H), 7.79 (dd, J=3.0, 1.8 Hz, 1H), 7.07 (dd, J=7.8, 7.8 Hz, 1H), 6.76 (s, 1H), 6.71 (d, J=7.8 Hz, 1H), 6.61 (dd, J=8.1, 1.5 Hz, 1H), 5.40 (q, J=6.6 Hz, 1H), 3.89 (s, 3H), 1.63 (d, J=6.0 Hz, 3H). HRMS (ESI+) calcd for C15H17N2O3 (M+H)+273.1234, found 273.1237.
    • 5-(1-(3-Aminophenyl)ethoxy)nicotinamide (ID33)
  • Compound ID32 (221 mg, 0.81 mmol) was treated with 7N NH3/MeOH (20 mL) at 70° C. for 22 h to give compound ID33 as a white solid (177 mg, 85%). 1H NMR (CD3OD, 600 MHz) δ 8.51 (d, J=1.8 Hz, 1H), 8.30 (d, J=3.0 Hz, 1H), 7.74 (dd, J=3.0, 1.8 Hz, 1H), 7.07 (dd, J=7.8, 7.8 Hz, 1H), 6.76 (dd, J=2.1, 2.1 Hz, 1H), 6.72 (d, J=7.8 Hz, 1H), 6.63-6.60 (m, 1H), 5.40 (q, J=6.6 Hz, 1H), 1.63 (d, J=6.6 Hz, 3H). HRMS (ESI+) calcd for C14H16N3O2 (M+H)+258.1237, found 258.1236.
  • Figure US20180194731A1-20180712-C00230
    • 5-(1-(3-(4-Methyl-3-nitrobenzamido)phenyl)ethoxy)nicotinamide (D10-1)
  • Compound D10-1 was prepared from compound ID33 through an amide formation reaction in a manner similar to that described for compound A-1. White solid (45 mg, 25%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.57 (s, 1H), 8.56 (s, 1H), 8.40 (d, J=2.4 Hz, 1H), 8.19 (d, J=8.4 Hz, 1H), 8.09 (s, 1H), 7.86 (s, 1H), 7.74-7.69 (m, 2H), 7.67 (d, J=8.4 Hz, 1H), 7.57 (s, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 5.67 (q, J=6.6 Hz, 1H), 2.59 (s, 3H), 1.61 (d, J=6.0 Hz, 3H). HRMS (ESI+) calcd for C22H21N4O5 (M+H)+421.1506, found 421.1505.
  • Figure US20180194731A1-20180712-C00231
  • ID35.
  • To a mixture of 3-nitrobenzoic acid (1.33 g, 7.96 mmol) and N-methylmorpholine (886 mg, 8.75 mmol) in THF (20 mL) at 0° C. was added ethyl chloroformate (950 mg, 8.75 mmol). After being stirred for an additional 30 min at 0° C., the mixture was filtered and the insoluble salt was washed with THF (5 mL×3). To the filtrate were added D2O (10 mL) followed by NaBD4 (1.00 g, 23.9 mmol) and the mixture was allowed to stir at rt for 2 h. The reaction was quenched with saturated NH4Cl (50 mL) and the resulting mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford compound ID35 as a light yellow oil (1.10 g, 89%). 1H NMR (CDCl3, 600 MHz) δ 8.22 (s, 1H), 8.12 (d, J=8.4 Hz, 1H), 7.69 (d, J=7.2 Hz, 1H), 7.52 (dt, J=8.1, 2.1 Hz, 1H).
  • ID36.
  • To a mixture of ID35 (1.10 g, 7.09 mmol) and CBr4 (2.82 g, 8.51 mmol) in CH2C12 (100 mL) was added Ph3P (2.23 g, 8.51 mmol) and the reaction mixture was allowed to stir at rt for 12 h. After removal of the solvent, the residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID36 as a yellow oil (1.33 g, 86%). 1H NMR (CDCl3, 600 MHz) δ 8.65 (s, 1H), 8.55 (d, J=8.4 Hz, 1H), 8.11 (d, J=7.2 Hz, 1H), 7.52 (dd, J=7.8, 7.8 Hz, 1H).
  • ID37.
  • A mixture of methyl 5-hydroxynicotinate (1.03 g, 6.10 mmol), CsCO3 (3.97 g, 12.2 mmol) and ID36 (1.33 g, 6.10 mmol) in DMF (80 mL) was allowed to stir at rt for 12 h. After water (200 mL) was added, the precipitate was filtered, washed with hexanes, and dried in vacuo to afford ID37 as a white solid (1.40 g, 79%). 1H NMR (CDCl3, 600 MHz) δ 8.89 (d, J=1.8 Hz, 1H), 8.57 (d, J=3.0 Hz, 1H), 8.35 (dd, J=1.8, 1.8 Hz, 1H), 8.24 (dd, J=7.8, 1.8 Hz, 1H), 7.87 (dd, J=3.0, 1.8 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.62 (dd, J=8.1, 8.1 Hz, 1H), 3.97 (s, 3H). HRMS (ESI+) calcd for C14H11D2N2O (M+H)+291.0945, found 291.0955.
  • ID38.
  • To a solution of ID37 (800 mg, 2.76 mmol) and NiCl2.6H2O (1.31 g, 5.52 mmol) in MeOH (100 mL) was slowly added NaBH4 (420 mg, 11.04 mmol) and the mixture was allowed to stir at rt for 3 h. The reaction was quenched with saturated NH4Cl (50 mL) and the mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford ID38 as a light yellow solid (500 mg, 70%). 1H NMR (CDCl3, 600 MHz) δ 8.82 (d, J=1.8 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 7.83 (dd, J=3.0, 1.8 Hz, 1H), 7.18 (dd, J=7.8, 7.8 Hz, 1H), 6.80 (d, J=7.8 Hz, 1H), 6.75 (dd, J=1.8, 1.8 Hz, 1H), 6.66 (dd, J=6.6, 2.1 Hz, 1H), 3.95 (s, 3H). HRMS (ESI+) calcd for C14H13D2N2O3 (M+H)+261.1203, found 261.1211.
  • ID39.
  • A solution of ID38 (500 mg, 1.92 mmol) in NH3/MeOH (ca. 7N, 5 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the resulting solution was washed with H2O (150 mL) and brine (100 mL). The organic layer was dried over Na2SO4 and concentrated, and the residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to afford ID39 as a light brownish solid (430 mg, 91%). 1H NMR (DMSO-d6, 600 MHz) δ 8.63 (s, 1H), 8.44 (d, J=3.0 Hz, 1H), 8.12 (s, 1H), 7.82-7.78 (m, 1H), 7.60 (s, 1H), 7.02 (dd, J=7.5, 7.5 Hz, 1H), 6.63 (s, 1H), 6.57 (d, J=7.8 Hz, 1H), 6.52 (dd, J=7.8, 1.2 Hz, 1H), 5.13 (s, 2H). HRMS (ESI+) calcd for C13H12D2N3O2 (M+H)+246.1206, found 246.1210.
  • Figure US20180194731A1-20180712-C00232
  • D11-1.
  • Compound D11-1 was prepared from compound ID39 through an amide formation reaction in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 9.11 (s, 1H), 8.76 (d, J=3.6 Hz, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.29 (d, J=7.8 Hz, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.57 (dd, J=4.8, 6.6 Hz, 1H), 7.41 (dd, J=7.8, 7.8 Hz, 1H), 7.24 (d, J=7.2 Hz, 1H). HRMS (ESI+) calcd for C19H15D2N4O3 (M+H)+351.1421, found 351.1428.
  • Figure US20180194731A1-20180712-C00233
  • D11-2.
  • Compound D11-2 was prepared from compound ID39 through an amide formation reaction in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 10.56 (s, 1H), 8.83-8.65 (m, 2H), 8.65 (s, 1H), 8.50 (s, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.89-7.84 (m, 3H), 7.75 (d, J=7.2 Hz, 1H), 7.61 (s, 1H), 7.42 (dd, J=8.1, 8.1, Hz, 1H), 7.25 (d, J=7.2 Hz, 1H). HRMS (ESI+) calcd for C19H15D2N4O3 (M+H)+ 351.1421, found 351.1428.
  • Figure US20180194731A1-20180712-C00234
  • D11-3.
  • Compound D11-3 was prepared from compound ID39 through an amide formation reaction in a manner similar to that described for compound A-1. 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.96 (d, J=8.4 Hz, 2H), 7.92 (s, 1H), 7.86 (dd, J=1.8, 1.8 Hz, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.39 (dd, J=7.5, 7.5 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 4.85 (s, 2H). HRMS (ESI+) calcd for C21H17D2ClN3O3 (M+H)+398.1235, found 398.1236.
  • Figure US20180194731A1-20180712-C00235
  • D11-4.
  • A solution of D11-3 (18 mg, 0.045 mmol), piperidine (5 mg, 0.068 mmol), and DIPEA (9 mg, 0.065 mmol) in DMF (2 mL) was heated at 50° C. for 12 h. After the reaction was quenched with saturated NH4Cl (10 mL), the mixture was extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (MeOH/CH2Cl2) to afford compound D11-4 as a white solid (20 mg, 94%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (dd, J=8.3, 1.2 Hz, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.39 (dd, J=7.5, 7.5 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 3.62 (s, 2H), 2.56-2.44 (m, 4H), 1.62 (quin, J=6.0 Hz, 4H), 1.53-1.45 (m, 2H). HRMS (ESI+) calcd for C26H27D2N4O3 (M+H)+447.2360, found 447.2360.
  • The following compounds were prepared through a displacement reaction of D11-3 in a manner similar to that described for compound D11-4.
  • Figure US20180194731A1-20180712-C00236
  • D11-5.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.93-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.50 (d, J=7.8 Hz, 2H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 3.70 (t, J=4.5 Hz, 4H), 3.60 (s, 2H), 2.52-2.44 (m, 4H). HRMS (ESI+) calcd for C25H25D2N4O4 (M+H)+449.2152, found 449.2153.
  • Figure US20180194731A1-20180712-C00237
  • D11-6.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (s, 1H), 7.94-7.90 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.51 (d, J=7.2 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.2 Hz, 1H), 3.80 (s, 2H), 2.69-2.62 (m, 4H), 1.89-1.82 (m, 4H). HRMS (ESI+) calcd for C25H25D2N4O3 (M+H)+ 433.2203, found 433.2205.
  • Figure US20180194731A1-20180712-C00238
  • D11-7.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.46 (d, J=3.0 Hz, 1H), 7.95 (d, J=8.4 Hz, 2H), 7.92 (dd, J=2.1, 2.1 Hz, 1H), 7.87 (s, 1H), 7.68 (d, J=7.2 Hz, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 3.97 (s, 2H), 3.63 (t, J=7.5 Hz, 4H), 2.28 (q, J=7.8 Hz, 2H). HRMS (ESI+) calcd for C24H23D2N4O3 (M+H)+ 419.2047, found 419.2057.
  • Figure US20180194731A1-20180712-C00239
  • D11-8.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=2.4 Hz, 1H), 8.45 (d, J=3.0 Hz, 1H), 7.93-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.50 (d, J=7.8 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 3.73 (s, 2H), 2.62 (q, J=7.2 Hz, 4H), 1.11 (t, J=7.2 Hz, 6H). HRMS (ESI+) calcd for C25H27D2N4O3 (M+H)+435.2360, found 435.2366.
  • Figure US20180194731A1-20180712-C00240
  • D11-9.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 7.96-7.91 (m, 3H), 7.88 (s, 1H), 7.68 (dd, J=8.4, 1.2 Hz, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.40 (dd, J=8.1, 8.1 Hz, 1H), 7.27 (d, J=7.8 Hz, 1H), 3.68 (d, J=3.0 Hz, 2H), 2.36 (s, 6H). HRMS (ESI+) calcd for C23H23D2N4O3 (M+H)+ 407.2047, found 407.2053.
  • Figure US20180194731A1-20180712-C00241
  • D11-10.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (d, J=1.8 Hz, 1H), 7.93-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.49 (d, J=7.8 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 3.65 (s, 2H), 2.62-2.54 (m, 4H), 2.04-1.95 (m, 4H). HRMS (ESI+) calcd for C26H25D2F2N4O3 (M+H)+483.2171, found 483.2179.
  • Figure US20180194731A1-20180712-C00242
  • D11-11.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.93-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.48 (d, J=7.8 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 3.65 (s, 2H), 2.61 (t, J=11.4 Hz, 2H), 2.51-2.44 (m, 2H), 1.92-1.84 (m, 2H), 1.79-1.73 (m, 2H). HRMS (ESI+) calcd for C26H25D2F2N4O3 (M+H)+483.2171, found 483.2184.
  • Figure US20180194731A1-20180712-C00243
  • D11-12.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.8 Hz, 1H), 8.45 (d, J=2.4 Hz, 1H), 7.93-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=9.0 Hz, 1H), 7.49 (d, J=8.4 Hz, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 3.72 (s, 2H), 2.89 (t, J=13.2 Hz, 2H), 2.78 (t, J=6.9 Hz, 2H), 2.52-2.43 (m, 2H). HRMS (ESI+) calcd for C25H23D2F2N4O3 (M+H)+469.2015, found 469.2023.
  • Figure US20180194731A1-20180712-C00244
  • D11-13.
  • 1H NMR (CD3OD, 600 MHz) δ 8.62 (d, J=1.2 Hz, 1H), 8.45 (d, J=3.0 Hz, 1H), 7.94-7.89 (m, 3H), 7.87 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.47 (d, J=7.8 Hz, 2H), 7.39 (dd, J=8.1, 8.1 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 3.84 (s, 2H), 3.65 (t, J=12.0 Hz, 4H). HRMS (ESI+) calcd for C24H21D2F2N4O3 (M+H)+455.1858, found 455.1867.
    • Example 5
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00245
    • 6-((2-Chloro-5-nitrobenzyl)oxy)pyrazine-2-carboxamide (IE3)
  • An oven-dried seal tube was charged with Pd(OAc)2 (4.4 mg, 0.02 mmol, 1 mol %), t-Bu-Xphos (17 mg, 0.04 mmol, 2 mol %) and Cs2CO3 (980 mg, 3.0 mmol, 1.5 equiv). The seal tube was sealed with a septum, evacuated and back-filled with argon. Toluene (10 mL), methyl 6-chloro-2-pyrazinecarboxylate (IE2, 340 mg, 2.0 mmol), and 2-chloro-5-nitrobenzyl alcohol (IE1, 1.13 g, 6.0 mmol) were added via syringe. The reaction mixture was heated at 100° C. for 24 h, then cooled to room temperature, diluted with EtOAc (20 mL), filtered through a pad of Celite, and concentrated. The residue was purified by flash column chromatography (0-50% EtOAc/hexanes) to afford an inseparable mixture of E1 and the coupling product. This mixture in NH3/MeOH (ca. 7N, 20 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (150 mL) and the resulting solution was washed with H2O (150 mL) and brine (100 mL). After the organic layer was dried over Na2SO4 and filtered, the filtrate was concentrated and the residue was purified by flash column chromatography (0-15% MeOH/CH2Cl2) to afford compound IE3 as a light yellow solid (100 mg, 16% over two steps). 1H NMR (CDCl3, 600 MHz) δ 9.06 (s, 1H), 8.60 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.19 (dd, J=9.0, 2.4 Hz, 1H), 7.63 (d, J=9.0 Hz, 1H), 5.59 (s, 2H). HRMS (ESI+) calcd for C12H10ClN4O4 (M+H)+309.0385, found 309.0392.
    • 6-((5-Amino-2-chlorobenzyl)oxy)pyrazine-2-carboxamide (IE4)
  • A solution of IE3 (100 mg, 0.323 mmol) and SnCl2 (442 mg, 2.33 mmol) in MeOH (20 mL) was heated at 70° C. for 16 h. After the solvent was evaporated in vacuo, the residue was quenched with NaHCO3 (sat.) and EtOAc (50 mL) was added. The solid formed was filtered and the organic layer was washed with H2O (150 mL) and brine (100 mL) and then concentrated. The residue was purified by flash column chromatography (0-15% MeOH/CH2Cl2) to afford compound IE4 as a light yellow solid (25 mg, 25%). 1H NMR (DMSO-d6, 600 MHz) δ 8.75 (s, 1H), 8.53 (s, 1H), 8.20 (s, 1H), 7.85 (s, 1H), 7.10 (d, J=9.0 Hz, 1H), 6.76 (d, J=2.4 Hz, 1H), 6.56 (dd, J=8.4, 2.4 Hz, 1H), 5.45 (s, 2H), 5.31 (s, 2H). HRMS (ESI+) calcd for C12H12ClN4O2 (M+H)+279.0643, found 279.0639.
  • Figure US20180194731A1-20180712-C00246
    • 6-((2-Chloro-5-(nicotinamido)benzyl)oxy)pyrazine-2-carboxamide (E3-1)
  • Compound E3-1 was prepared from intermediate IE4 and nicotinic acid via an HBTU-mediated amide formation. Light yellow solid (10.7 mg, 87%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 9.07 (s, 1H), 8.78-8.71 (m, 2H), 8.55 (s, 1H), 8.25 (d, J=7.8 Hz, 1H), 8.19 (s, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.80 (d, J=7.8 Hz, 1H), 7.54 (dd, J=6.6 Hz, 1H), 7.51 (d, J=9.0 Hz, 1H), 5.60 (s, 2H). HRMS (ESI+) calcd for C18H15ClN5O11(M+H)+384.0858, found 384.0858.
  • Figure US20180194731A1-20180712-C00247
    • 6-((2-Chloro-5-(picolinamido)benzyl)oxy)pyrazine-2-carboxamide (E3-2)
  • Compound E3-2 was prepared from intermediate IE4 and picolinic acid via an HBTU-mediated amide formation. White solid (12.0 mg, 98%). 1H NMR (DMSO-d6, 600 MHz) δ 10.84 (s, 1H), 8.77 (s, 1H), 8.74 (d, J=4.2 Hz, 1H), 8.59 (s, 1H), 8.26-8.20 (m, 2H), 8.16 (d, J=7.8 Hz, 1H), 8.07 (dd, J=7.2, 7.2 Hz, 1H), 7.99 (dd, J=8.4, 3.0 Hz, 1H), 7.88 (s, 1H), 7.69 (dd, J=6.0, 6.0 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 5.62 (s, 2H). HRMS (ESI+) calcd for C18H15ClN5O11(M+H)+384.0858, found 384.0850.
  • The following compounds were prepared through a reaction sequence similar to that described for the preparation of compound E3-1.
  • Figure US20180194731A1-20180712-C00248
    • 6-((3-(Isonicotinamido)benzyl)oxy)pyrazine-2-carboxamide (E1-1)
  • 1H NMR (CD3OD, 600 MHz) δ 8.80 (s, 1H), 8.47 (s, 1H), 7.96 (s, 1H), 7.63 (d, J=7.8 Hz, 2H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 7.39-7.33 (m, 2H), 7.19 (d, J=7.2 Hz, 2H), 5.55 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1256.
  • Figure US20180194731A1-20180712-C00249
    • 6-((3-(Isonicotinamido)benzyl)oxy)pyridazine-4-carboxamide (E2-1)
  • 1H NMR (DMF-d7, 600 MHz) δ 10.64 (s, 1H), 9.33 (s, 1H), 8.84-8.78 (m, 2H), 8.53 (s, 1H), 8.08 (s, 1H), 7.98-7.95 (m, 3H), 7.92 (d, J=7.8 Hz, 1H), 7.68 (s, 1H), 7.46 (dd, J=7.8, 7.8 Hz, 1H), 7.36 (d, J=6.0 Hz, 1H), 5.67 (s, 2H). HRMS (ESI+) calcd for C15H16N5O3 (M+H)+350.1248, found 350.1252.
    • Example 6
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00250
  • IF2a.
  • To a mixture of carboxylic acid IF1a (1.81 g, 10.0 mmol) and N-methylmorpholine (1.11 g, 11.0 mmol) in THF (20 mL) at 0° C. was added ethyl chloroformate (1.19 g, 11.0 mmol). The mixture was allowed to stir at 0° C. for an additional 30 min and filtered. The insoluble salt was washed with THF (5 mL×3). To the filtrate was added NaBH4 (1.13 g, 30 mmol) and the resulting mixture was then stirred at rt for 2 h. The reaction mixture was quenched with saturated NH4Cl (50 mL) and extracted with EtOAc. The organic phase was washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford compound IF2a as a colorless oil (1.60 g, 94%). 1H NMR (CDCl3, 600 MHz) δ 8.31 (d, J=2.4 Hz, 1H), 8.06 (dd, J=8.1, 2.7 Hz, 1H), 7.32 (d, J=9.0 Hz, 1H), 4.79 (d, J=4.8 Hz, 2H), 1.57 (s, 3H).
  • IF2d.
  • In a manner similar to that described for the preparation of compound IF2a, IF1d (2.35 g, 10.0 mmol) was reduced to alcohol IF2d as a light yellow solid (1.70 g, 77%). 1H NMR (CDCl3, 600 MHz) δ 8.69 (s, 1H), 8.23 (d, J=7.2 Hz, 1H), 7.84 (d, J=9.0 Hz, 1H), 5.01 (d, J=4.8 Hz, 2H).
  • IF2e.
  • In a manner similar to that described for the preparation of compound IF2a, IF1e (1.97 g, 10.0 mmol) was reduced to alcohol IF2e as a white solid (1.60 g, 87%). 1H NMR (CDCl3, 600 MHz) δ 8.29 (d, J=3.0 Hz, 1H), 8.21 (dd, J=9.0, 3.0 Hz, 1H), 7.84 (d, J=9.0 Hz, 1H), 4.75 (s, 2H), 3.97 (s, 3H).
  • IF2g.
  • In a manner similar to that described for the preparation of compound IF2a, IF1g (1.85 g, 10.0 mmol) was reduced to alcohol IF2g as a light yellow oil (1.54 g, 90%). 1H NMR (CDCl3, 600 MHz) δ 7.97 (dd, J=7.8, 7.8 Hz, 1H), 7.80 (dd, J=7.2, 7.2 Hz, 1H), 7.31 (dd, J=7.8, 7.8 Hz, 1H), 4.86 (s, 2H).
  • IF2i.
  • In a manner similar to that described for the preparation of compound IF2a, IF1i (2.50 g, 13.5 mmol) was reduced to alcohol IF2i as a yellow oil (1.37 g, 59%). 1H NMR (CDCl3, 600 MHz) δ 8.08 (dd, J=7.0 Hz, J2=2.2 Hz, 1H), 7.66-7.62 (m, 1H), 7.29 (dd, J1=10.5 Hz, J2=8.6 Hz, 1H), 4.77 (d, J=5.7 Hz, 2H), 1.98 (t, J=5.7 Hz, 1H).
  • IF2k.
  • In a manner similar to that described for the preparation of compound IF2a, IF1k (1.00 g, 5.40 mmol) was reduced to alcohol IF2k as a yellow oil (346 mg, 37%). 1H NMR (CDCl3, 600 MHz) δ 8.05 (s, 1H), 7.84 (dt, J, =8.2 Hz, J2=2.1 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 4.84 (d, J=5.7 Hz, 2H), 1.98 (t, J=5.7 Hz, 1H).
  • IF2l.
  • In a manner similar to that described for the preparation of compound IF2a, IF1l (1.00 g, 5.78 mmol) was reduced to alcohol IF2l as a light yellow oil (700 mg, 76%). 1H NMR (CDCl3, 600 MHz) δ 8.14-8.08 (m, 1H), 7.10-7.05 (m, 1H), 4.84 (s, 2H).
  • IF3a.
  • A mixture of IF2a (1.60 g, 9.58 mmol), CBr4 (3.81 g, 11.50 mmol) and Ph3P (3.02 g, 11.50 mmol) in CH2Cl2 (100 mL) was allowed to stir at rt for 12 h. After removal of the solvent, the residue was purified by flash column chromatography (EtOAc/hexanes) to to afford IF3a as a white solid (1.22 g, 55%). 1H NMR (CDCl3, 600 MHz) δ 8.20 (d, J=1.2 Hz, 1H), 8.08 (dd, J=8.4, 2.4 Hz, 1H), 7.36 (d, J=9.0 Hz, 1H), 4.53 (s, 2H), 1.58 (s, 3H).
  • IF3b.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2b (1.71 g, 10.0 mmol) afforded IF3b as a white solid (2.00 g, 85%). 1H NMR (CDCl3, 600 MHz) δ 8.36 (dd, J1=6.4 Hz, J2=2.8 Hz, 1H), 8.25-8.21 (m, 1H), 7.25 (t, J=8.8 Hz, 1H), 4.54 (s, 2H).
  • IF3c.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2c (1.88 g, 10.0 mmol) afforded IF3b as a white solid (1.96 g, 78%). 1H NMR (CDCl3, 600 MHz) δ 8.35 (d, J=2.5 Hz, 1H), 8.13 (dd, J1=8.8 Hz, J2=2.5 Hz, 1H), 7.59 (d, J=8.8 Hz, 1H), 4.62 (s, 2H).
  • IF3d.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2d (1.70 g, 7.70 mmol) afforded IF3d as a colorless oil (1.50 g, 69%). 1H NMR (CDCl3, 600 MHz) δ 8.48 (s, 1H), 8.26 (d, J=9.0 Hz, 1H), 7.88 (d, J=8.4 Hz, 1H), 4.68 (s, 2H).
  • IF3e.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2e (1.60 g, 8.70 mmol) afforded IF3e as a white solid (1.50 g, 70%). 1H NMR (CDCl3, 600 MHz) δ 8.26 (d, J=3.0 Hz, 1H), 8.22 (dd, J=9.0, 3.0 Hz, 1H), 6.97 (d, J=9.0 Hz, 1H), 4.54 (s, 2H), 4.02 (s, 3H).
  • IF3g.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2g (1.54 g, 9.00 mmol) afforded IF3g as a brownish oil (1.54 g, 73%). 1H NMR (CDCl3, 600 MHz) δ 8.02 (dd, J=6.6, 6.6 Hz, 1H), 7.73 (dd, J=6.6, 6.6 Hz, 1H), 7.31 (dd, J=7.8, 7.8 Hz, 1H), 4.56 (s, 2H).
  • IF3j.
  • To a solution of 1,3-dimethyl-5-nitrobenzene (IF1j, 2.00 g, 13.2 mmol) and NBS (2.35 g, 13.2 mmol) in CCl4 (50 mL) was added AIBN (217 mg, 1.32 mmol) and the mixture was allowed to reflux overnight. The organic solvent was removed and the resulting residue was purified by flash column chromatography to give IF3j as a white solid (1.30 g, 43%). 1H NMR (CDCl3, 600 MHz) δ 8.06 (s, 1H), 7.98 (s, 1H), 7.53 (s, 1H), 4.50 (s, 2H), 2.47 (s, 3H).
  • IF3l.
  • In a manner similar to that described for the preparation of compound IF3a, bromination of IF2l (700 mg, 4.40 mmol) afforded IF3l as a colorless oil (700 mg, 72%). 1H NMR (CDCl3, 600 MHz) δ 8.16-8.10 (m, 1H), 7.09 (dd, J=8.4, 8.4 Hz, 1H), 4.54 (s, 2H).
  • IF4a.
  • A mixture of methyl 5-hydroxynicotinate (0.893 g, 5.83 mmol), CsCO3 (3.45 g, 10.6 mmol) and IF3a (1.22 g, 5.30 mmol) in DMF (80 mL) was allowed to stir at rt for 12 h. After water (200 mL) was added, the solid precipitate was filtered, washed with hexanes, and dried under vacuum to afford IF4a as a light yellow solid (1.14 g, 71%). 1H NMR (CDCl3, 600 MHz) δ 8.90 (d, J=1.8 Hz, 1H), 8.59 (d, J=3.0 Hz, 1H), 8.35 (d, J=2.4 Hz, 1H), 8.15 (dd, J=7.8, 2.4 Hz, 1H), 7.90 (dd, J=3.0, 1.8 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 5.18 (s, 2H), 3.98 (s, 3H), 2.49 (s, 3H). HRMS (ESI+) calcd for C15H15N2O5 (M+H)+303.0976, found 303.0985.
  • IF4b.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3b (2.00 g, 8.55 mmol) afforded IF4b as a light yellow solid (1.43 g, 55%). 1H NMR (CDCl3, 600 MHz) 8.91 (d, J=1.5 Hz, 1H), 8.60 (d, J=2.9 Hz, 1H), 8.50 (dd, J=6.0 Hz, J2=2.9 Hz, 1H), 8.31-8.27 (m, 1H), 7.90 (dd, J=2.9 Hz, J2=1.8 Hz, 1H), 7.30 (t, J=8.9 Hz, 1H), 5.27 (s, 2H), 3.98 (s, 3H). HRMS (ESI+) calcd for C14H12FN2O (M+H)+307.0725, found 307.0721.
  • IF4c.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3c (1.96 g, 7.82 mmol) afforded IF4c as a brownish solid (1.65 g, 65%). 1H NMR (CDCl3, 600 MHz) δ 8.92 (d, J=1.5 Hz, 1H), 8.63 (d, J=2.9 Hz, 1H), 8.50 (d, J=2.6 Hz, 1H), 8.20 (dd, J=8.8 Hz, 2=2.6 Hz, 1H), 7.92 (dd, J=2.9 Hz, 2=1.8 Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 5.29 (s, 2H), 3.98 (s, 3H). HRMS (ESI+) calcd for C14H12ClN2O (M+H)+323.0429, found 323.0433.
  • IF4d.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3d (1.50 g, 5.28 mmol) afforded IF4d as a light yellow solid (1.30 g, 69%). 1H NMR (CDCl3, 600 MHz) δ 8.92 (s, 1H), 8.66 (s, 1H), 8.61 (d, J=2.4 Hz, 1H), 8.33 (d, J=8.4 Hz, 1H), 7.95 (d, J=9.0 Hz, 1H), 7.89 (s, 1H), 5.41 (s, 2H), 3.98 (s, 3H). HRMS (ESI+) calcd for C15H12F3N2O5 (M+H)+357.0693, found 357.0695.
  • IF4e.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3e (1.50 g, 6.10 mmol) afforded IF4e as a light brownish solid (1.50 g, 77%). 1H NMR (CDCl3, 600 MHz) δ 8.88 (s, 1H), 8.59 (d, J=2.4 Hz, 1H), 8.41 (d, J=3.0 Hz, 1H), 8.27 (dd, J=9.0, 3.0 Hz, 1H), 7.90 (dd, J=3.0, 1.8 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.20 (s, 2H), 4.02 (s, 3H), 3.97 (s, 3H). HRMS (ESI+) calcd for C15H15N2O6 (M+H)+319.0925, found 319.0931.
  • IF4f.
  • To a solution of IF2f (700 mg, 4.19 mmol) and methyl 5-hydroxynicotinate (706 mg, 4.61 mmol) and Ph3P (1.65 g, 6.29 mmol) in anhydrous THF (40 mL) at rt was added DIAD (1.27 g, 6.29 mmol) dropwise. After the mixture was allowed to stir at rt for 12 h and the solvent removed, the resulting residue was purified by flash column chromatography (EtOAc/hexanes) to afford IF4f as a yellow solid (320 mg, 255). 1H NMR (CDCl3, 600 MHz) δ 7.88 (d, J=7.8 Hz, 1H), 7.82 (s, 1H), 7.61 (s, 1H), 7.45 (dd, J=7.8, 7.8 Hz, 1H), 7.40 (s, 1H), 7.35 (d, J=7.8 Hz, 1H), 5.40 (s, 2H), 3.93 (s, 3H), 2.42 (s, 3H). HRMS (ESI+) calcd for C15H15N2O5 (M+H)+303.0976, found 303.0980.
  • IF4g.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3g (1.54 g, 6.58 mmol) afforded IF4g as a light yellow solid (1.42 g, 70%). 1H NMR (CDCl3, 600 MHz) δ 8.90 (s, 1H), 8.57 (d, J=2.4 Hz, 1H), 8.08 (dd, J=7.8, 7.8 Hz, 1H), 8.89 (s, 1H), 7.85 (dd, J=6.6, 6.6 Hz, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 5.30 (s, 2H), 3.97 (s, 3H). HRMS (ESI+) calcd for C14H12FN2O5 (M+H)+307.0725, found 307.0733.
  • IF4 h.
  • In a manner similar to that described for the preparation of compound IF4f, a Mitsunobu reaction of IF2 h (500 mg, 3.00 mmol) afforded IF4 h as a light yellow solid (400 mg, 44%). 1H NMR (DMSO-d6, 600 MHz) δ 8.24 (s, 1H), 8.08 (s, 1H), 7.80 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.55 (d, J=8.4 Hz, 1H), 7.27 (s, 1H), 5.54 (s, 2H), 3.84 (s, 3H), 3.33 (s, 3H). HRMS (ESI+) calcd for C15H15N2O5 (M+H)+303.0976, found 303.0976.
  • IF4i.
  • In a manner similar to that described for the preparation of compound IF4f, a Mitsunobu reaction of IF2i (1.18 g, 6.88 mmol) afforded IF4i as a yellow solid (490 mg, 23%). 1H NMR (CDCl3, 600 MHz) δ8.89 (d, J=1.4 Hz, 1H), 8.56 (d, J=3.0 Hz, 1H), 8.18 (dd, J1=7.0 Hz, J2=2.3 Hz, 1H), 7.85 (dd, J1=2.9 Hz, J2=1.8 Hz, 1H), 7.74-7.71 (m, 1H), 7.36 (dd, J1=10.2 Hz, J2=8.7 Hz, 1H), 5.19 (s, 2H), 3.97 (s, 3H). HRMS (ESI+) calcd for C14H12FN2O5 (M+H)+307.0725, found 307.0731.
  • IF4j.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3j (1.28 g, 5.56 mmol) afforded IF4j as a white solid (540 mg, 32%). 1H NMR (CDCl3, 600 MHz) δ 8.88 (d, J=1.2 Hz, 1H), 8.57 (d, J=2.9 Hz, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 7.86 (dd, J1=2.9 Hz, J2=1.8 Hz, 1H), 7.59 (s, 1H), 5.20 (s, 2H), 3.97 (s, 3H), 2.51 (s, 3H). HRMS (ESI+) calcd for C15H15N2O5 (M+H)+303.0976, found 303.0967.
  • IF4k.
  • In a manner similar to that described for the preparation of compound IF4f, a Mitsunobu reaction of IF2k (322 mg, 1.88 mmol) afforded IF4k as a white solid (286 mg, 49%). 1H NMR (CDCl3, 600 MHz) δ 8.90 (d, J=1.4 Hz, 1H), 8.59 (d, J=2.9 Hz, 1H), 8.16 (s, 1H), 7.93 (dt, J, =8.1 Hz, J2=2.1 Hz, 1H), 7.87 (dd, J=2.9 Hz, J2=1.7 Hz, 1H), 7.56 (d, J=8.2 Hz, 1H), 5.25 (s, 2H), 3.97 (s, 3H). HRMS (ESI+) calcd for C14H12FN2O (M+H)+307.0725, found 307.0729.
  • IF4l.
  • In a manner similar to that described for the preparation of compound IF4a, coupling of IF3l (700 mg, 3.15 mmol) afforded IF4l as a light yellow solid (600 mg, 62%). 1H NMR (CDCl3, 600 MHz) δ 8.90 (s, 1H), 8.53 (d, J=3.0 Hz, 1H), 8.25-8.20 (m, 1H), 7.92 (dd, J=3.0, 1.8 Hz, 1H), 7.15 (dd, J=9.0, 9.0 Hz, 1H), 5.27 (s, 2H), 3.98 (s, 3H). HRMS (ESI+) calcd for C14H11F2N2O (M+H)+325.0631, found 325.0639.
  • IF5a.
  • To a solution of IF4a (1.14 g, 3.77 mmol) and NiCl2.6H2O (1.79 g, 7.54 mmol) in MeOH (150 mL) was slowly added NaBH4 (570 mg, 15.1 mmol) and the mixture was allowed to stir at rt for 3 h. After the reaction was quenched with saturated NH4Cl (50 ml), the mixture was extracted with EtOAc. The organic phase washed with water and brine, dried over anhydrous K2CO3, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford IF5a as a brownish solid (700 mg, 68%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.54 (d, J=3.0 Hz, 1H), 7.85 (d, J=1.8 Hz, 1H), 7.01 (d, J=7.8 Hz, 1H), 7.76 (d, J=2.4 Hz, 1H), 6.62 (dd, J=8.4, 2.4 Hz, 1H), 5.04 (s, 2H), 3.96 (s, 3H), 3.61 (brs, 2H), 2.26 (s, 3H). HRMS (ESI+) calcd for C15H17N2O3 (M+H)+273.1234, found 273.1236.
  • IF5b.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4b (1.43 g, 4.67 mmol) afforded IF5b as a light yellow solid (980 mg, 76%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.53 (d, J=2.6 Hz, 1H), 7.86 (s, 1H), 6.90 (t, J=9.2 Hz, 1H), 6.77 (dd, J1=5.6 Hz, J2=2.7 Hz, 1H), 6.64-6.59 (m, 1H), 5.13 (s, 2H), 3.95 (s, 3H), 3.63 (br s, 2H). HRMS (ESI+) calcd for C14H14FN2O3 (M+H)+277.0983, found 277.0980.
  • IF5c.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4c (1.65 g, 5.11 mmol) afforded IF5c as a light yellow solid (1.10 g, 74%). 1H NMR (CDCl3, 600 MHz) δ 8.85 (d, J=1.7 Hz, 1H), 8.55 (d, J=2.9 Hz, 1H), 7.86-7.84 (m, 1H), 7.16 (d, J=8.6 Hz, 1H), 6.83 (d, J=2.9 Hz, 1H), 6.59 (dd, J=8.6 Hz, J2=2.9 Hz, 1H), 5.15 (s, 2H), 3.95 (s, 3H), 3.75 (br s, 2H). HRMS (ESI+) calcd for C14H14ClN2O3 (M+H)+293.0687, found 293.0686.
  • IF5d.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4d (1.30 g, 3.65 mmol) afforded IF5d as a light yellow solid (800 mg, 67%). 1H NMR (CDCl3, 600 MHz) δ 8.86 (s, 1H), 8.54 (s, 1H), 7.83 (s, 1H), 7.47 (d, J=8.4 Hz, 1H), 6.91 (s, 1H), 6.63 (d, J=8.4 Hz, 1H), 5.25 (s, 2H), 4.02 (s, 2H), 3.95 (s, 3H). HRMS (ESI+) calcd for C15H14F3N2O3 (M+H)+327.0952, found 327.0961.
  • IF5e.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4e (1.50 g, 4.70 mmol) afforded IF5e as a light yellow solid (1.00 g, 74%). 1H NMR (CDCl3, 600 MHz) δ 8.82 (d, J=1.2 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 7.88 (dd, J=3.0, 1.8 Hz, 1H), 6.82 (d, J=3.0 Hz, 1H), 6.76 (d, J=9.0 Hz, 1H), 6.66 (dd, J=8.4, 3.0 Hz, 1H), 5.14 (s, 2H), 3.95 (s, 3H), 3.82 (s, 3H). HRMS (ESI+) calcd for C15H17N2O4 (M+H)+289.1183, found 289.1183.
  • IF5g.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4g (1.42 g, 4.64 mmol) afforded IF5g as a light yellow solid (1.00 g, 78%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (d, J=1.2 Hz, 1H), 8.54 (d, J=3.0 Hz, 1H), 7.87 (dd, J=1.8, 1.8 Hz, 1H), 6.96 (dd, J=7.2, 7.2 Hz, 1H), 6.84-6.77 (m, 2H), 5.17 (s, 2H), 3.96 (s, 3H). HRMS (ESI+) calcd for C14H14FN2O3 (M+H)+277.0983, found 277.0988.
  • IF5 h.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4 h (2.47 g, 8.18 mmol) afforded IF5 h as a light yellow oil (1.77 g, 80%). 1H NMR (DMSO-d6, 600 MHz) δ 7.86 (s, 1H), 7.63 (s, 1H), 7.25 (s, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.59 (s, 1H), 6.55 (d, J=7.2 Hz, 1H), 5.30 (s, 2H), 4.99 (s, 2H), 3.84 (s, 3H), 2.02 (s, 3H). HRMS (ESI+) calcd for C15H17N2O3 (M+H)+273.1234, found 273.1239.
  • IF5i.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4i (490 mg, 1.60 mmol) afforded IF5i as a white solid (150 mg, 34%). 1H NMR (CDCl3, 600 MHz) δ 8.83 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 7.83-7.81 (m, 1H), 6.99 (dd, J=10.9 Hz, J2=8.3 Hz, 1H), 6.85 (dd, J1=8.5 Hz, J2=2.0 Hz, 1H), 6.75-6.72 (m, 1H), 5.02 (s, 2H), 3.95 (s, 3H), 3.81 (br s, 2H). HRMS (ESI+) calcd for C14H14FN2O3 (M+H)+277.0983, found 277.0982.
  • IF5j.
  • A solution of IF4j (540 mg, 1.79 mmol) and SnCl2 (2.37 g, 12.5 mmol) in MeOH (10 mL) in a seal tube was heated at 75° C. for 2 h before it was quenched with saturated Na2CO3. The mixture was filtered and the filtrate was diluted with water. The resulting mixture was extracted with EtOAc and the organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc/hexanes) to afford IF5j as a white solid (103 mg, 21%). 1H NMR (CDCl3, 600 MHz) δ 8.82 (d, J=1.8 Hz, 1H), 8.53 (d, J=2.9 Hz, 1H), 7.83 (dd, J=2.9 Hz, J2=1.8 Hz, 1H), 6.63 (s, 1H), 6.55 (s, 1H), 6.48 (s, 1H), 5.01 (s, 2H), 3.94 (s, 3H), 3.68 (br s, 2H), 2.27 (s, 3H). HRMS (ESI+) calcd for C15H17N2O3 (M+H)+273.1234, found 273.1225.
  • IF5k.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4k (286 mg, 0.94 mmol) afforded IF5k as a white solid (92 mg, 35%). 1H NMR (CDCl3, 600 MHz) δ 8.84 (s, 1H), 8.52 (d, J=2.8 Hz, 1H), 7.82-7.80 (m, 1H), 6.52-6.49 (m, 2H), 6.34 (dt, J, =10.4 Hz, J2=2.0 Hz, 1H), 5.03 (s, 2H), 3.95 (s, 3H), 3.85 (br s, 2H). HRMS (ESI+) calcd for C14H14FN2O3 (M+H)+277.0983, found 277.0983.
  • IF5l.
  • In a manner similar to that described for the preparation of compound IF5a, reduction of IF4l (600 mg, 1.94 mmol) afforded IF5l as a light brownish oil (300 mg, 53%). 1H NMR (CDCl3, 600 MHz) δ 8.86 (d, J=1.2 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 7.92 (dd, J=2.4, 1.2 Hz, 1H), 6.81-6.76 (m, 2H), 5.20 (s, 2H), 3.96 (s, 3H). HRMS (ESI+) calcd for C14H13F2N2O3 (M+H)+295.0889, found 295.0893.
  • IF6a.
  • A solution of IF5a (700 mg, 2.57 mmol) in NH3/MeOH (ca. 7N, 10 mL) in a seal tube was heated at 70° C. for 24 h. After the solvent was evaporated in vacuo, the residue was dissolved in EtOAc (100 mL) and the solution was washed with H2O (150 mL) and then with brine (100 mL). The organic layer was dried over Na2SO4, concentrated, and the residue was purified by flash column chromatography (5% MeOH/CH2Cl2) to afford IF6a as a light brownish solid (250 mg, 38%). 1H NMR (DMSO-d6, 600 MHz) δ 8.64 (d, J=1.2 Hz, 1H), 8.46 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.83 (d, J=1.8 Hz, 1H), 7.61 (s, 1H), 6.87 (d, J=8.4 Hz, 1H), 6.64 (d, J=1.8 Hz, 1H), 6.46 (dd, J=7.8, 2.4 Hz, 1H), 5.06 (s, 2H), 4.89 (s, 2H), 2.15 (s, 3H). HRMS (ESI+) calcd for C14H16N3O2 (M+H)+258.1237, found 258.1239.
  • IF6b.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5b (980 mg, 3.55 mmol) afforded IF6b as a light yellow solid (600 mg, 65%). 1H NMR (DMSO-d6, 600 MHz) δ 8.65 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.84 (s, 1H), 7.61 (s, 1H), 6.90 (dd, J=9.0, 9.0 Hz, 1H), 6.69-6.65 (m, 1H), 6.57-6.52 (m, 1H), 5.13 (s, 2H), 5.03 (s, 2H). HRMS (ESI+) calcd for C13H13FN3O2 (M+H)+ 262.0986, found 262.0992.
  • IF6c.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5c (1.10 g, 3.76 mmol) afforded IF6b as an off-white solid (800 mg, 77%). 1H NMR (DMSO-d6, 600 MHz) δ 8.66 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 7.83 (s, 1H), 7.62 (s, 1H), 7.10 (d, J=9.0 Hz, 1H), 6.75 (d, J=3.0 Hz, 1H), 6.55 (dd, J=9.0, 3.0 Hz, 1H), 5.33 (s, 2H), 5.13 (s, 2H). HRMS (ESI+) calcd for C13H13ClN3O2 (M+H)+278.0691, found 278.0696.
  • IF6d.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5d (800 mg, 2.45 mmol) afforded IF6d as a light brownish solid (400 mg, 52%). 1H NMR (DMSO-d6, 600 MHz) δ 8.67 (s, 1H), 8.44 (s, 1H), 8.17 (s, 1H), 7.81 (s, 1H), 7.63 (s, 1H), 7.38 (d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.60 (d, J=8.4 Hz, 1H), 5.92 (s, 2H), 5.18 (s, 2H). HRMS (ESI+) calcd for C14H13F3N3O2 (M+H)+312.0954, found 312.0965.
  • IF6e.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5e (1.00 g, 3.47 mmol) afforded IF6e as a light brownish solid (400 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 8.63 (s, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.81 (s, 1H), 7.59 (s, 1H), 6.77 (d, J=9.0 Hz, 1H), 6.65 (d, J=3.0 Hz, 1H), 6.54 (dd, J=9.0, 3.0 Hz, 1H), 5.07 (s, 2H), 4.70 (s, 2H), 3.70 (s, 3H). HRMS (ESI+) calcd for C14H16N3O3 (M+H)+274.1186, found 274.1197.
  • IF6f.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5f (2.00 g, 7.34 mmol) afforded IF6f as a light yellow solid (1.60 g, 85%). 1H NMR (DMSO-d6, 600 MHz) δ 8.63 (s, 1H), 8.46 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.84 (s, 1H), 7.60 (s, 1H), 6.89 (dd, J=7.5. 7.5 Hz, 1H), 6.65 (d, J=7.8 Hz, 2H), 5.12 (s, 2H), 4.90 (s, 2H), 2.03 (s, 3H). HRMS (ESI+) calcd for C14H16N3O2 (M+H)+258.1237, found 258.1238.
  • IF6g.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5g (1.00 g, 3.62 mmol) afforded IF6G as a light yellow solid (600 mg, 64%). 1H NMR (DMSO-d6, 600 MHz) δ 8.65 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.14 (s, 1H), 7.86 (s, 1H), 7.61 (s, 1H), 6.88 (dd, J=7.2. 7.2 Hz, 1H), 6.77 (dd, J=8.4, 8.4 Hz, 1H), 6.65 (dd, J=6.6, 6.6 Hz, 1H) 5.20 (s, 2H), 5.18 (s, 2H). HRMS (ESI+) calcd for C13H13FN3O2 (M+H)+262.0986, found 262.0992.
  • IF6 h.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5 h (20 mg, 0.07 mmol) afforded IF6 h as a light yellow solid (15 mg, 83%). 1H NMR (DMSO-d6, 600 MHz) δ 8.05 (s, 1H), 7.73 (s, 1H), 7.59 (s, 1H), 7.51 (s, 1H), 7.33 (s, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.59 (s, 1H), 6.54 (d, J=6.0 Hz, 1H), 5.24 (s, 2H), 4.99 (s, 2H), 2.02 (s, 3H). HRMS (ESI+) calcd for C14H16N3O2 (M+H)+258.1237, found 258.1257.
  • IF6i.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5i (175 mg, 0.63 mmol) afforded IF6i as a white solid (141 mg, 85%). 1H NMR (CD3OD, 600 MHz) δ 8.60 (d, J=1.8 Hz, 1H), 8.38 (d, J=2.7 Hz, 1H), 7.85 (t, J=2.3 Hz, 1H), 6.94-6.90 (m, 2H), 6.71-6.67 (m, 1H), 5.04 (s, 2H). HRMS (ESI+) calcd for C13H13FN3O2 (M+H)+262.0986, found 262.0991.
  • IF6j.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5j (100 mg, 0.37 mmol) afforded IF6j as a white solid (77 mg, 81%). 1H NMR (CDCl3, 600 MHz) δ 8.58 (d, J=1.8 Hz, 1H), 8.44 (d, J=2.9 Hz, 1H), 7.73-7.71 (m, 1H), 6.73 (br s, 1H), 6.58 (s, 1H), 6.51 (s, 1H), 6.45 (s, 1H), 6.44 (br s, 1H), 4.96 (s, 2H), 3.67 (br s, 2H), 2.24 (s, 3H). HRMS (ESI+) calcd for C14H16N3O2 (M+H)+258.1237, found 258.1234.
  • IF6k.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5k (82 mg, 0.30 mmol) afforded IF6k as a white solid (75 mg, 96%). 1H NMR (CD3OD, 600 MHz) δ 8.61 (d, J=1.8 Hz, 1H), 8.41 (d, J=2.9 Hz, 1H), 7.86 (t, J=2.1 Hz, 1H), 6.56 (s, 1H), 6.42 (d, J=9.5 Hz, 1H), 6.34 (dt, J=11.2 Hz, J2=2.0 Hz, 1H), 5.08 (s, 2H). HRMS (ESI+) calcd for C13H13FN3O2 (M+H)+262.0986, found 262.0990.
  • IF6l.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IF5l (300 mg, 1.02 mmol) afforded IF6l as a brown solid (250 mg, 88%). 1H NMR (DMSO-d6, 600 MHz) δ 8.68 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.90 (s, 1H), 7.62 (s, 1H), 6.90-6.80 (m, 2H), 5.19 (s, 2H), 5.10 (s, 2H). HRMS (ESI+) calcd for C13H12F2N3O2 (M+H)+280.0892, found 280.0895.
  • Figure US20180194731A1-20180712-C00251
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)nicotinamide (F1-1)
  • A mixture of IF6a (39 mg, 0.15 mmol), nicotinic acid (23 mg, 0.18 mmol) and EDC-HCl (36 mg, 0.18 mmol) in CH2Cl2/DMF (1:1, 8 mL) was allowed to stir at rt for 12 h. After the reaction was quenched with saturated NH4Cl (10 mL), the mixture was extracted with EtOAc and the organic phase was washed with water and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (MeOH/CH2Cl2) to afford compound F1-1 as a white solid (36 mg, 65%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 9.10 (s, 1H), 8.75 (d, J=4.2 Hz, 1H), 8.67 (s, 1H), 8.52 (s, 1H), 8.28 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 7.89 (s, 1H), 7.83 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.58-7.52 (m, 1H), 7.24 (d, J=7.8 Hz, 1H), 5.23 (s, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1460.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for the preparation of compound F1-1.
  • Figure US20180194731A1-20180712-C00252
    • 5-((5-(Isonicotinamido)-2-methylbenzyl)oxy)nicotinamide (F1-2)
  • White solid (35 mg, 62%). 1H NMR (DMSO-d6, 600 MHz) δ 10.49 (s, 1H), 8.78 (d, J=6.0 Hz, 2H), 8.67 (d, J=1.8 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 7.88 (dd, J=2.4, 2.4 Hz, 1H), 7.85 (d, J=5.4 Hz, 2H), 7.83 (d, J=1.8 Hz, 1H), 7.69 (dd, J=8.4, 1.8 Hz, 1H), 7.63 (s, 1H), 7.25 (d, J=7.8, 1H), 5.23 (s, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+ 363.1452, found 363. 1457.
  • Figure US20180194731A1-20180712-C00253
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)pyridazine-4-carboxamide (F1-3)
  • White solid (43 mg, 76%). 1H NMR (DMSO-d6, 600 MHz) δ 10.70 (s, 1H), 9.64 (s, 1H), 9.48 (d, J=5.4 Hz, 1H), 8.67 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 8.11 (d, J=3.0 Hz, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.27 (d, J=8.4 Hz, 1H), 5.24 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C19H15N5O3 (M+H)+364.1404, found 364. 1413.
  • Figure US20180194731A1-20180712-C00254
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-fluoronicotinamide (F1-4)
  • White solid (50 mg, 85%). 1H NMR (DMSO-d6, 600 MHz) δ 10.47 (s, 1H), 8.81 (s, 1H), 8.67 (s, 1H), 8.54-8.46 (m, 2H), 8.17 (s, 1H), 7.89 (s, 1H), 7.82 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C20H18FN4O3 (M+H)+381.1357, found 381. 1368.
  • Figure US20180194731A1-20180712-C00255
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-methylnicotinamide (F1-5)
  • White solid (32 mg, 55%). 1H NMR (DMSO-d6, 600 MHz) δ 10.33 (s, 1H), 8.99 (d, J=2.8 Hz, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.19 (dd, J=8.1, 2.1 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.82 (d, J=1.8 Hz, 1H), 7.67 (dd, J=7.8, 2.4 Hz, 1H), 7.63 (s, 1H), 7.41 (d, J=8.4, 1H), 7.24 (d, J=8.4 Hz, 1H), 5.22 (s, 2H), 2.55 (s, 3H), 2.32 (s, 3H). HRMS (ESI+) calcd for C21H21N4O3 (M+H)+377.1608, found 377. 1617.
  • Figure US20180194731A1-20180712-C00256
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-ethoxynicotinamide (F1-6)
  • White solid (10 mg, 17%). 1H NMR (DMSO-d6, 600 MHz) δ 10.21 (s, 1H), 8.76 (d, J=2.4 Hz, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.21 (dd, J=2.4, 8.4 Hz, 1H), 8.15 (s, 1H), 7.88 (dd, J=2.1, 2.1 Hz, 1H), 7.81 (d, J=1.8 Hz, 1H), 7.66 (dd, J=1.8, 7.8 Hz, 1H), 7.62 (s, 1H), 7.22 (d, J=8.4 Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 5.22 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 2.31 (s, 3H), 1.34 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C22H23N4O4 (M+H)+407.1714, found 407.1721.
  • Figure US20180194731A1-20180712-C00257
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-phenylnicotinamide (F1-7)
  • White solid (40 mg, 59%). 1H NMR (DMSO-d6, 600 MHz) δ 10.45 (s, 1H), 9.19 (s, 1H), 8.67 (s, 1H), 8.52 (s, 1H), 8.39 (d, J=10.2 Hz, 1H), 8.20-8.12 (m, 4H), 7.89 (s, 1H), 7.86 (s, 1H), 7.72 (d, J=6.6 Hz, 1H), 7.63 (s, 1H), 7.57-7.47 (m, 3H), 7.26 (d, J=7.2 Hz, 1H), 5.24 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C26H23N4O3 (M+H)+439.1765, found 439. 1775.
  • Figure US20180194731A1-20180712-C00258
    • N-(3-(((5-carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(thiophen-2-yl)nicotinamide (F1-8)
  • White solid (50 mg, 74%). 1H NMR (DMSO-d6, 600 MHz) δ 10.39 (s, 1H), 9.04 (d, J=1.2 Hz, 1H), 8.67 (s, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.33 (dd, J=2.4, 8.4 Hz, 1H), 8.15 (s, 1H), 8.07 (d, J=7.8 Hz, 1H), 7.95 (d, J=2.4 Hz, 1H), 7.89 (s, 1H), 7.84 (s, 1H), 7.74 (d, J=5.4 Hz, 1H), 7.72-7.67 (m, 1H), 7.63 (s, 1H), 7.25 (d, J=7.8 Hz, 1H), 7.22 (dd, J=4.5, 4.5 Hz, 1H), 5.24 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C24H21N4O3S (M+H)+445.1329, found 445.1336.
  • Figure US20180194731A1-20180712-C00259
    • 5-((5-(2-Fluoroisonicotinamido)-2-methylbenzyl)oxy)nicotinamide (F1-9)
  • White solid (50 mg, 85%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.44 (d, J=4.8 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.84-7.80 (m, 2H), 7.69 (d, J=8.4 Hz, 1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.26 (d, J=8.4 Hz, 1H), 5.24 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C20H18FN4O3 (M+H)+381.1357, found 381. 1367.
  • Figure US20180194731A1-20180712-C00260
    • 5-((5-([1,1′-Biphenyl]-4-ylcarboxamido)-2-methylbenzyl)oxy)nicotinamide (F1-10)
  • White solid (25 mg, 37%). 1H NMR (DMSO-d6, 600 MHz) δ 10.28 (s, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 8.06 (d, J=8.4, 2H), 7.89 (s, 1H), 7.87 (d, J=1.8 Hz, 1H), 7.83 (d, J=9.0 Hz, 2H), 7.76 (d, J=6.6 Hz, 2H), 7.72 (dd, J=8.4, 1.8 Hz, 1H), 7.63 (s, 1H), 7.51 (dd, J=7.8, 7.8 Hz, 2H), 7.43 (dd, J=7.2, 7.2 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C27H24N3O3 (M+H)+438.1812, found 438. 1821.
  • Figure US20180194731A1-20180712-C00261
    • 5-((2-Methyl-5-(4-(thiophen-2-yl)benzamido)benzyl)oxy)nicotinamide (F1-1)
  • White solid (30 mg, 44%). 1H NMR (DMSO-d6, 600 MHz) δ 10.26 (s, 1H), 8.67 (s, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 8.01 (d, J=8.4 Hz, 2H), 7.89 (s, 1H), 7.85 (s, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.70 (d, J=8.4 Hz, 1H), 7.68 (d, J=3.6 Hz, 1H), 7.65 (d, J=5.4 Hz, 1H), 7.63 (s, 1H), 7.23 (d, J=8.4 Hz, 1H), 7.19 (dd, J=4.2 Hz, 1H), 5.23 (s, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C25H22N3O3S (M+H)+444.1376, found 444. 1382.
  • Figure US20180194731A1-20180712-C00262
    • 5-((5-(3-Fluoro-4-(trifluoromethoxy)benzamido)-2-methylbenzyl)oxy)nicotinamide (F1-12)
  • White solid (52 mg, 73%). 1H NMR (DMSO-d6, 600 MHz) δ 10.39 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 8.08-8.04 (m, 1H), 7.92-7.86 (m, 2H), 7.81 (s, 1H), 7.75 (dd, J=8.1, 8.1 Hz, 1H), 7.68 (dd, J=1.8, 8.4 Hz, 1H), 7.63 (s, 1H), 7.25 (d, J=7.8 Hz, 1H), 5.23 (s, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C22H18F4N3O4 (M+H)+464.1228, found 464.1236.
  • Figure US20180194731A1-20180712-C00263
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-ethynylnicotinamide (F1-13)
  • Pale solid (17 mg, 37%). 1H NMR (DMSO-d6, 600 MHz) δ 10.47 (s, 1H), 9.07 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.31 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.69 (d, J=9.0 Hz, 1H), 7.63 (s, 1H), 7.25 (d, J=7.8 Hz, 1H), 5.23 (s, 2H), 4.55 (s, 1H), 2.32 (s, 3H). HRMS (ESI+) calcd for C22H19N4O3 (M+H)+387.1452, found 387.1454.
  • Figure US20180194731A1-20180712-C00264
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-ethylnicotinamide (F1-14)
  • White solid (30 mg, 66%). 1H NMR (DMSO-d6, 600 MHz) δ 10.33 (s, 1H), 9.00 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.20 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.68 (d, J=9.9 Hz, 1H), 7.63 (s, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 2.83 (q, J=7.8 Hz, 2H), 2.32 (s, 3H), 1.26 (t, J=7.8 Hz, 3H). HRMS (ESI+) calcd for C22H23N4O3 (M+H)+391.1765, found 391.1765.
  • Figure US20180194731A1-20180712-C00265
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(prop-1-yn-1-yl)nicotinamide (F1-15)
  • Pale solid (21 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 9.03 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.26 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.59 (d, J=8.4 Hz, 1H), 7.24 (d, J=9.0 Hz, 1H), 5.23 (s, 2H), 2.32 (s, 3H), 2.12 (s, 3H). HRMS (ESI+) calcd for C23H21N4O3 (M+H)+401.1608, found 401.1612.
  • Figure US20180194731A1-20180712-C00266
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-propynicotinamide (F1-16)
  • White solid (21 mg, 43%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 9.00 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.19 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.40 (d, J=8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 2.78 (t, J=8.1 Hz, 2H), 2.32 (s, 3H), 1.76-1.67 (m, 2H), 0.91 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C23H25N4O3 (M+H)+405.1921, found 405.1929.
  • Figure US20180194731A1-20180712-C00267
    • 5-((2-Methyl-5-(4-(3-methyl-1H-pyrazol-1-yl)benzamido)benzyl)oxy)nicotinamide (F1-17)
  • White solid (33 mg, 64%). 1H NMR (DMSO-d6, 600 MHz) δ 10.25 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=7.8 Hz, 2H), 8.15 (s, 1H), 8.07 (d, J=7.8 Hz, 2H), 7.94 (d, J=7.2 Hz, 2H), 7.89 (s, 1H), 7.85 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.23 (d, J=8.4 Hz, 1H), 6.40 (s, 1H), 5.23 (s, 2H), 2.32 (s, 3H), 2.29 (s, 3H). HRMS (ESI+) calcd for C25H24N5O3 (M+H)+442.1874, found 442.1883.
  • Figure US20180194731A1-20180712-C00268
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(3-methyl-1H-pyrazol-1-yl)nicotinamide (F1-18)
  • White solid (28 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.97 (s, 1H), 8.67 (s, 1H), 8.58 (s, 1H), 8.52 (s, 1H), 8.47 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.96 (d, J=9.0 Hz, 1H), 7.89 (s, 1H), 7.83 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.25 (d, J=7.8 Hz, 1H), 6.45 (s, 1H), 5.24 (s, 2H), 2.33 (s, 3H), 2.32 (s, 3H). HRMS (ESI+) calcd for C24H23N6O3 (M+H)+443.1826, found 443.1829.
  • Figure US20180194731A1-20180712-C00269
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(fluoromethyl)nicotinamide (F1-19)
  • White solid (14 mg, 36%). 1H NMR (CD3OD, 600 MHz) δ 9.07 (s, 1H), 8.64 (s, 1H), 8.48 (s, 1H), 8.39 (d, J=8.4 Hz, 1H), 7.96 (s, 1H), 7.82 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 5.54 (d, J=46.8 Hz, 2H), 5.26 (s, 2H), 2.40 (s, 3H). HRMS (ESI+) calcd for C21H20FN4O3 (M+H)+395.1514, found 395.1512.
  • Figure US20180194731A1-20180712-C00270
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(difluoromethyl)nicotinamide (F1-20)
  • White solid (32 mg, 77%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 9.17 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=1.8 Hz, 1H), 8.48 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 7.89 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.83 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.26 (d, J=8.4 Hz, 1H), 7.07 (t, J=54.9 Hz, 1H), 5.76 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C21H19F2N4O3 (M+H)+413.1420, found 413.1428.
  • Figure US20180194731A1-20180712-C00271
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(trifluoromethyl)nicotinamide (F1-21)
  • White solid (20 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 10.62 (s, 1H), 9.24 (s, 1H), 8.67 (s, 1H), 8.56 (d, J=8.4 Hz, 1H), 8.52 (s, 1H), 8.15 (s, 1H), 8.10 (d, J=8.4 Hz, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.70 (d, J=9.0 Hz, 1H), 7.63 (s, 1H), 7.27 (d, J=8.4 Hz, 1H), 5.24 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C21H18F3N4O3 (M+H)+431.1326, found 431.1326.
  • Figure US20180194731A1-20180712-C00272
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-5-phenylpicolinamide (F1-22)
  • White solid (25 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.65 (s, 1H), 9.02 (d, J=2.4 Hz, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.53 (d, J=3.0 Hz, 1H), 8.35 (dd, J=2.4, 7.8 Hz, 1H), 8.22 (d, J=7.8 Hz, 1H), 8.16 (s, 1H), 8.30 (d, J=1.8 Hz, 1H), 7.90 (dd, J=2.4, 2.4 Hz, 1H), 7.86-7.81 (m, 3H), 7.63 (s, 1H), 7.57 (dd, J=7.5, 7.5 Hz, 2H), 7.50 (dd, J=7.5, 7.5 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 5.23 (s, 2H), 2.33 (s, 3H). HRMS (ESI+) calcd for C26H23N4O3 (M+H)+439.1765, found 439.1775.
  • Figure US20180194731A1-20180712-C00273
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-5-(prop-1-yn-1-yl)picolinamide (F1-23)
  • White solid (22 mg, 55%). 1H NMR (DMSO-d6, 600 MHz) δ 10.61 (s, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 8.10 (d, J=8.4 Hz, 1H), 8.05 (dd, J=1.8, 8.4 Hz, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.79 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.22 (s, 2H), 2.32 (s, 3H), 2.14 (s, 3H). HRMS (ESI+) calcd for C23H21N4O3 (M+H)+401.1608, found 401.1612.
  • Figure US20180194731A1-20180712-C00274
    • 5-((2-Methyl-5-(4-morpholinobenzamido)benzyl)oxy)nicotinamide (F1-24)
  • Pale solid (20 mg, 38%). 1H NMR (DMSO-d6, 600 MHz) δ 9.94 (s, 1H), 8.72 (s, 1H), 8.58 (s, 1H), 8.15 (s, 1H), 7.93-7.85 (m, 3H), 7.83 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.63 (s, 1H), 7.19 (d, J=8.4 Hz, 1H), 7.01 (d, J=9.0 Hz, 2H), 5.21 (s, 2H), 3.74 (t, J=4.2 Hz, 4H), 3.25 (t, J=4.2 Hz, 4H), 2.30 (s, 3H). HRMS (ESI+) calcd for C25H27N4O4 (M+H)+447.2027, found 447.2035.
  • Figure US20180194731A1-20180712-C00275
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-cyclopropylnicotinamide (F1-25)
  • Yellow solid (6.0 mg, 27%). 1H NMR (MeOH-d4, 600 MHz) δ 8.90 (s, 1H), 8.64 (s, 1H), 8.48 (s, 1H), 8.20-8.15 (m, 1H), 7.95 (s, 1H), 7.79 (s, 1H), 7.60 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 5.25 (s, 2H), 2.39 (s, 3H), 2.20-2.14 (m, 1H), 1.13-1.02 (m, 4H). HRMS (ESI+) calcd for C23H23N4O3 (M+H)+403.1765, found 403.1765.
  • Figure US20180194731A1-20180712-C00276
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methylphenyl)-6-(2,2,2-trifluoroethoxy)nicotinamide (F1-26)
  • Yellow solid (8.4 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 10.31 (s, 1H), 8.79 (s, 1H), 8.67 (s, 1H), 8.51 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.88 (s, 1H), 7.81 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.63 (s, 1H), 7.24 (d, J=8.4 Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 5.23 (s, 2H), 5.09 (q, J=9.0 Hz, 2H), 2.32 (s, 3H). HRMS (ESI+) calcd for C22H20F3N4O4 (M+H)+461.1431, found 461.1436.
  • Figure US20180194731A1-20180712-C00277
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)nicotinamide (F2-1)
  • White solid (25 mg, 36%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 9.13 (s, 1H), 8.78 (s, 1H), 8.69 (s, 1H), 8.53 (s, 1H), 8.29 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 7.98 (d, J=4.8 Hz, 1H), 7.90 (s, 1H), 7.83-7.78 (m, 1H), 7.63 (s, 1H), 7.60-7.54 (m, 1H), 7.30 (dd, J=9.0, 9.0 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1208.
  • Figure US20180194731A1-20180712-C00278
    • 5-((2-Fluoro-5-(isonicotinamido)benzyl)oxy)nicotinamide (F2-2)
  • White solid (23 mg, 41%). 1H NMR (DMSO-d6, 600 MHz) δ 10.61 (s, 1H), 8.79 (d, J=6.0 Hz, 2H), 8.67 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J=4.2 Hz, 1H), 7.89 (s, 1H), 7.86 (d, J=6.0 Hz, 2H), 7.83-7.79 (m, 1H), 7.63 (s, 1H), 7.31 (dd, J=9.6, 9.6 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367. 1212.
  • Figure US20180194731A1-20180712-C00279
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)pyridazine-4-carboxamide (F2-3)
  • White solid (30 mg, 53%). 1H NMR (DMSO-d6, 600 MHz) δ 10.82 (s, 1H), 9.64 (s, 1H), 9.49 (d, J=5.4 Hz, 1H), 8.68 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.15 (s, 1H), 8.11 (dd, J=5.4, 1.8 Hz, 1H), 7.98-7.93 (m, 1H), 7.89 (s, 1H), 7.83-7.79 (m, 1H), 7.63 (s, 1H), 7.33 (dd, J=9.3, 9.3 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C18H15FN5O3 (M+H)+368.1153, found 368. 1162.
  • Figure US20180194731A1-20180712-C00280
    • N-(3-((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)-6-fluoronicotinamide (F2-4)
  • White solid (38 mg, 66%). 1H NMR (DMSO-d6, 600 MHz) δ 10.55 (s, 1H), 8.81 (d, J=2.4 Hz, 1H), 8.67 (d, J=1.8 Hz, 1H), 8.52-8.46 (m, 2H), 8.15 (s, 1H), 7.94 (dd, J=6.0, 1.8 Hz, 1H), 7.89 (dd, J=2.1, 2.1 Hz, 1H), 7.81-7.78 (m, 1H), 7.63 (s, 1H), 7.37 (dd, J=8.4, 2.4 Hz, 1H), 7.31 (dd, J=9.6, 9.6 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C19H15F2N4O3 (M+H)+385.1107, found 385. 1111.
  • Figure US20180194731A1-20180712-C00281
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)-6-methylnicotinamide (F2-5)
  • White solid (35 mg, 60%). 1H NMR (DMSO-d6, 600 MHz) δ 10.45 (s, 1H), 8.99 (d, J=2.4 Hz, 1H), 8.67 (d, J=1.8 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.19 (dd, J=8.4, 2.4 Hz, 1H), 8.15 (s, 1H), 7.96 (dd, J=6.6, 2.4 Hz, 1H), 7.92-7.88 (m, 1H), 7.82-7.78 (m, 1H), 7.63 (s, 1H), 7.42 (d, J=8.4, 1H), 7.29 (dd, J=9.3, 9.3 Hz, 1H), 5.30 (s, 2H), 2.55 (s, 3H). HRMS (ESI+) calcd for C20H18FN4O3 (M+H)+ 381.1357, found 381. 1366.
  • Figure US20180194731A1-20180712-C00282
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)-6-ethoxynicotinamide (F2-6)
  • White solid (23 mg, 37%). 1H NMR (DMSO-d6, 600 MHz) δ 10.34 (s, 1H), 8.76 (s, 1H), 8.67 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.21 (dd, J=1.8, 8.1 Hz, 1H), 8.15 (s, 1H), 7.95 (d, J=4.2 Hz, 1H), 7.89 (s, 1H), 7.78 (d, J=3.9, 3.9 Hz, 1H), 7.63 (s, 1H), 7.28 (dd, J=9.3, 9.3, Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 5.29 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 1.34 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C21H20FN4O4 (M+H)+411.1463, found 411.1467.
  • Figure US20180194731A1-20180712-C00283
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)-6-phenylnicotinamide (F2-7)
  • White solid (43 mg, 64%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 9.19 (d, J=2.4 Hz, 1H), 8.68 (d, J=0.6 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.39 (dd, J=8.1, 2.1 Hz, 1H), 8.20-8.13 (m, 4H), 8.00 (dd, J=6.6, 2.4 Hz, 1H), 7.91-7.89 (m, 1H), 7.86-7.82 (m, 1H), 7.63 (s, 1H), 7.57-7.49 (m, 3H), 7.31 (dd, J=9.3, 9.3 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C25H20FN4O3 (M+H)+443.1514, found 443. 1511.
  • Figure US20180194731A1-20180712-C00284
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-fluorophenyl)-6-(thiophen-2-yl)nicotinamide (F2-8)
  • Pale solid (23 mg, 34%). 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 9.04 (s, 1H), 8.68 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.33 (dd, J=1.8, 8.4 Hz, 1H), 8.16 (s, 1H), 8.08 (d, J=8.4 Hz, 1H), 7.98 (d, J=4.2 Hz, 1H), 7.95 (d, J=3.6 Hz, 1H), 7.90 (s, 1H), 7.84-7.79 (m, 1H), 7.74 (d, J=5.4 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, J=9.3, 9.3 Hz, 1H), 7.22 (dd, J=4.2, 4.2 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C23H18FN4O3S (M+H)+449.1078, found 449.1088.
  • Figure US20180194731A1-20180712-C00285
    • 5-((2-Fluoro-5-(2-fluoroisonicotinamido)benzyl)oxy)nicotinamide (F2-9)
  • Pale solid (40 mg, 68%). 1H NMR (DMSO-d6, 600 MHz) δ 10.67 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.45 (d, J=5.4 Hz, 1H), 8.15 (s, 1H), 7.96 (dd, J=6.6, 2.4 Hz, 1H), 7.89 (s, 1H), 7.84-7.79 (m, 2H), 7.66 (s, 1H), 7.63 (s, 1H), 7.32 (dd, J=9.3, 9.3 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C19H15F2N4O3 (M+H)+385.1107, found 385. 1113.
  • Figure US20180194731A1-20180712-C00286
    • 5-((5-([1,1′-Biphenyl]-4-ylcarboxamido)-2-fluorobenzyl)oxy)nicotinamide (F2-10)
  • White solid (13 mg, 20%/). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.68 (s, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 8.07 (d, J=8.4 Hz, 2H), 8.02 (d, J=4.2 Hz, 1H), 7.91 (s, 1H), 7.84 (d, J=8.4 Hz, 3H), 7.76 (d, J=7.2 Hz, 2H), 7.63 (s, 1H), 7.51 (dd, J=7.8, 7.8 Hz, 2H), 7.43 (dd, J=7.2, 7.2 Hz, 1H), 7.29 (dd, J=9.0 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C26H21FN3O3 (M+H)+442.1561, found 442.1570.
  • Figure US20180194731A1-20180712-C00287
    • 5-((2-Fluoro-5-(4-(thiophen-2-yl)benzamido)benzyl)oxy)nicotinamide (F2-11)
  • White solid (42 mg, 61%). 1H NMR (DMSO-d6, 600 MHz) δ 10.38 (s, 1H), 8.68 (d, J=1.2 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 8.02-7.97 (m, 3H), 7.90 (dd, J=1.8, 1.8 Hz, 1H), 7.84-7.80 (m, 3H), 7.68 (d, J=3.6 Hz, 1H), 7.65 (d, J=5.4 Hz, 1H), 7.63 (s, 1H), 7.29 (dd, J=9.3, 9.3 Hz, 1H), 7.20 (dd, J=5.1, 3.9 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C24H19FN3O3S (M+H)+448.1126, found 448. 1138.
  • Figure US20180194731A1-20180712-C00288
    • 5-((2-Fluoro-5-(3-fluoro-4-(trifluoromethoxy)benzamido)benzyl)oxy)nicotinamide (F2-12)
  • White solid (32 mg, 45%). 1H NMR (DMSO-d6, 600 MHz) δ 10.51 (s, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.15 (s, 1H), 8.07 (dd, J=1.8, 10.5 Hz, 1H), 7.95 (dd, J=2.4, 6.6 Hz, 1H), 7.93-7.87 (m, 2H), 7.82-7.74 (m, 2H), 7.63 (s, 1H), 7.30 (d, J=9.0 Hz, 1H), 5.30 (s, 2H). HRMS (ESI+) calcd for C21H15F5N3O4 (M+H)+468.0977, found 468.0986.
  • Figure US20180194731A1-20180712-C00289
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)nicotinamide (F3-1)
  • White solid (18 mg, 26%). 1H NMR (DMSO-d6, 600 MHz) δ 10.62 (s, 1H), 9.10 (s, 1H), 8.77 (d, J=4.8 Hz, 1H), 8.69 (s, 1H), 8.52 (s, 1H), 8.29 (d, J=8.4 Hz, 1H), 8.17 (s, 1H), 8.04 (s, 1H), 7.89 (s, 1H), 7.86 (d, J=9.0 Hz, 1H), 7.64 (s, 1H), 7.57 (dd, J=5.7, 5.7 Hz, 1H), 7.54 (d, J=9.0 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C19H16ClN4O3 (M+H)+383.0905, found 383.0913.
  • Figure US20180194731A1-20180712-C00290
    • 5-((2-Chloro-5-(isonicotinamido)benzyl)oxy)nicotinamide (F3-2)
  • White solid (9.7 mg, 32%). 1H NMR (DMSO-d6, 600 MHz) δ 10.68 (s, 1H), 8.79 (d, J=5.4 Hz, 2H), 8.69 (s, 1H), 8.52 (s, 1H), 8.17 (s, 1H), 8.03 (s, 1H), 7.91-7.83 (m, 4H), 7.64 (s, 1H), 7.55 (d, J=9.0 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C19H16ClN4O3 (M+H)+383.0905, found 383.0904.
  • Figure US20180194731A1-20180712-C00291
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-ethoxynicotinamide (F3-3)
  • White solid (21 mg, 32%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 8.76 (d, J=1.2 Hz, 1H), 8.68 (s, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.21 (dd, J=2.7, 8.1 Hz, 1H), 8.17 (s, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.83 (dd, J=2.4, 9.0 Hz, 1H), 7.63 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 5.30 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 1.34 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C21H20ClN4O4 (M+H)+427.1168, found 427.1175.
  • Figure US20180194731A1-20180712-C00292
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-(thiophen-2-yl)nicotinamide (F3-4)
  • White solid (57 mg, 42%). 1H NMR (DMSO-d6, 600 MHz) δ 10.58 (s, 1H), 9.04 (d, J=2.4 Hz, 1H), 8.69 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.33 (dd, J=2.4, 8.4 Hz, 1H), 8.18 (s, 1H), 8.08 (d, J=8.4 Hz, 1H), 8.04 (d, J=2.4 Hz, 1H), 7.95 (d, J=3.6 Hz, 1H), 7.89 (s, 1H), 7.86 (dd, J=2.4, 8.4 Hz, 1H), 7.75 (d, J=5.4 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.23 (dd, J=4.5, 4.5 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C23H15ClN4O3S(M+H)+465.0783, found 465.0788.
  • Figure US20180194731A1-20180712-C00293
    • 5-((2-Chloro-5-(3-fluoro-4-(trifluoromethoxy)benzamido)benzyl)oxy)nicotinamide (F3-5)
  • White solid (42 mg, 57%). 1H NMR (DMSO-d6, 600 MHz) δ 10.57 (s, 1H), 8.67 (s, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.17 (s, 1H), 8.07 (dd, J=1.8, 10.8 Hz, 1H), 8.01 (d, J=2.4 Hz, 1H), 7.92-7.87 (m, 2H), 7.84 (dd, J=2.4, 8.4 Hz, 1H), 7.77 (d, J=8.1, 8.1 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J=9.0 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C21H15ClF4N3O4 (M+H)+484.0682, found 484.0689.
  • Figure US20180194731A1-20180712-C00294
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-(prop-1-yn-1-yl)nicotinamide (F3-6)
  • Pale solid (2 mg, 5%). 1H NMR (CD3OD, 600 MHz) δ 8.98 (d, J=2.4 Hz, 1H), 8.66 (d, J=1.8 Hz, 1H), 8.49 (d, J=3.0 Hz, 1H), 8.27 (dd, J=2.4, 7.8 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 7.95 (dd, J=1.8, 3.0 Hz, 1H), 7.76 (dd, J=2.4, 3.0 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.47 (d, J=9.0 Hz, 1H), 5.34 (s, 2H), 2.12 (s, 3H). HRMS (ESI+) calcd for C22H15ClN4O3 (M+H)+421.1062, found 421.1062.
  • Figure US20180194731A1-20180712-C00295
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-5-(prop-1-yn-1-yl)picolinamide (F3-7)
  • White solid (23 mg, 55%). 1H NMR (DMSO-d6, 600 MHz) δ 10.88 (s, 1H), 8.72 (d, J=1.8 Hz, 1H), 8.68 (d, J=1.8 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.22 (d, J=2.4 Hz, 1H), 8.17 (s, 1H), 8.11 (d, J=7.8 Hz, 1H), 8.05 (dd, J=2.4, 8.4 Hz, 1H), 7.98 (dd, J=2.4, 8.4 Hz, 1H), 7.89 (dd, J=1.8, 1.8 Hz, 1H), 7.63 (s, 1H), 7.52 (d, J=9.0 Hz, 1H), 5.29 (s, 2H), 2.14 (s, 3H). HRMS (ESI+) calcd for C22H15ClN4O3 (M+H)+421.1062, found 421.1060.
  • Figure US20180194731A1-20180712-C00296
    • 5-((2-Chloro-5-(4-morpholinobenzamido)benzyl)oxy)nicotinamide (F3-8)
  • White solid (6.3 mg, 13%). 1H NMR (DMSO-d6, 600 MHz) δ 10.14 (s, 1H), 8.68 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.17 (s, 1H), 8.06-8.03 (m, 1H), 7.91-7.84 (m, 4H), 7.63 (s, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.03 (d, J=8.4 Hz, 2H), 5.28 (s, 2H), 3.75 (t, J=4.8 Hz, 4H), 3.26 (t, J=4.8 Hz, 4H). HRMS (ESI+) calcd for C24H24ClN4O4 (M+H)+467.1481, found 467.1478.
  • Figure US20180194731A1-20180712-C00297
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)picolinamide (F3-9)
  • White solid (14.0 mg, 51%). 1H NMR (MeOH-d4, 600 MHz) δ 8.71 (d, J=4.2 Hz, 1H), 8.66 (s, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.21 (d, J=7.8 Hz, 1H), 8.13 (d, J=3.0 Hz, 1H), 8.02 (dd, J=7.8, 7.8 Hz, 1H), 7.98 (s, 1H), 8.84 (dd, J=8.4, 2.4 Hz, 1H), 7.62 (dd, J=7.8, 4.8 Hz, 1H), 7.49 (d, J=9.0 Hz, 1H), 5.35 (s, 2H). HRMS (ESI+) calcd for C19H15ClN4O3 (M+H)+383.0905, found 383.0909.
  • Figure US20180194731A1-20180712-C00298
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-fluoronicotinamide (F3-10)
  • White solid (7.3 mg, 25%). 1H NMR (MeOH-d4, 600 MHz) δ 8.66 (d, J=1.8 Hz, 1H), 8.60 (d, J=3.0 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.28 (dd, J=9.0, 4.8 Hz, 1H), 8.11 (d, J=2.4 Hz, 1H), 7.98 (dd, J=2.4, 2.4 Hz, 1H), 7.84-7.78 (m, 2H), 7.48 (d, J=9.0 Hz, 1H), 5.35 (s, 2H). HRMS (ESI+) calcd for C19H15ClFN4O3 (M+H)+401.0811, found 401.0813.
  • Figure US20180194731A1-20180712-C00299
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-phenylnicotinamide (F3-11)
  • White solid (16.0 mg, 49%). 1H NMR (DMSO-d6, 600 MHz) δ 10.65 (s, 1H), 9.19 (d, J=2.4 Hz, 1H), 8.69 (s, 1H), 8.53 (s, 1H), 8.40 (dd, J=7.8, 1.8 Hz, 1H), 8.20-8.14 (m, 4H), 8.07 (d, J=2.4 Hz, 1H), 7.91-7.87 (m, 2H), 7.64 (s, 1H), 7.57-7.52 (m 3H), 7.51 (d, J=7.2 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C25H20ClN4O3 (M+H)+459.1218, found 459.1227.
  • Figure US20180194731A1-20180712-C00300
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-methylnicotinamide (F3-12)
  • White solid (13.0 mg, 46%). 1H NMR (MeOH-d4, 600 MHz) δ 8.94 (d, J=1.8 Hz, 1H), 8.65 (s, 1H), 8.48 (s, 1H), 8.23 (dd, J=8.4, 2.4 Hz, 1H), 8.00 (d, J=1.8 Hz, 1H), 7.95 (s, 1H), 7.74 (dd, J=8.4, 2.4 Hz, 1H), 7.46-7.42 (m, 2H), 5.31 (s, 2H), 2.61 (s, 3H). HRMS (ESI+) calcd for C20H15ClN4O3 (M+H)+397.1062, found 397.1068.
  • Figure US20180194731A1-20180712-C00301
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-5-phenylpicolinamide (F3-13)
  • White solid (7.0 mg, 21%). 1H NMR (DMSO-d6, 600 MHz) δ 10.92 (s, 1H), 9.03 (s, 1H), 8.69 (s, 1H), 8.54 (d, J=1.8 Hz, 1H), 8.36 (dd, J=8.4, 1.8 Hz, 1H), 8.26 (s, 1H), 8.23 (d, J=8.4 Hz, 1H), 8.17 (s, 1H), 8.02 (dd, J=8.4, 3.0 Hz, 1H), 7.90 (s, 1H), 7.84 (d, J=7.8 Hz, 2H), 7.63 (s, 1H), 7.59-7.48 (m, 4H), 5.31 (s, 2H). HRMS (ESI+) calcd for C25H20ClN4O3 (M+H)+459.1218, found 459.1225.
  • Figure US20180194731A1-20180712-C00302
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-cyclopropylnicotinamide (F3-14)
  • Yellow solid (7.0 mg, 27%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.92 (s, 1H), 8.69 (s, 1H), 8.52 (s, 1H), 8.20-8.12 (m, 2H), 8.02 (s, 1H), 7.88 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.64 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 5.30 (s, 2H), 2.23-2.17 (m, 1H), 1.08-0.97 (m, 4H). HRMS (ESI+) calcd for C22H20ClN4O3 (M+H)+423.1218, found 423.1222.
  • Figure US20180194731A1-20180712-C00303
    • N-(3-(((5-carbamoylpyridin-3-yl)oxy)methyl)-4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)nicotinamide (F3-15)
  • Yellow solid (7.0 mg, 27%). 1H NMR (DMSO-d6, 600 MHz) δ 10.50 (s, 1H), 8.79 (s, 1H), 8.70 (s, 1H), 8.53 (s, 1H), 8.32 (d, J=8.4 Hz, 1H), 8.17 (s, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.64 (s, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 5.30 (s, 2H), 5.10 (q, J=9.0 Hz, 2H). HRMS (ESI+) calcd for C21H17ClF3N4O4 (M+H)+481.0885, found 481.0888.
  • Figure US20180194731A1-20180712-C00304
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-(trifluoromethyl)phenyl)nicotinamide (F4-1)
  • White solid (8 mg, 20%). 1H NMR (DMSO-d6, 600 MHz) δ 10.83 (s, 1H), 9.12 (s, 1H), 8.78 (d, J=4.8 Hz, 1H), 8.69 (s, 1H), 8.50 (d, J=3.0 Hz, 1H), 8.31 (d, J=7.8 Hz, 1H), 8.18 (s, 2H), 8.05 (d, J=9.0 Hz, 1H), 7.87 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.64 (s, 1H), 7.59 (dd, J=7.8, 4.8 Hz, 1H), 5.37 (s, 2H). HRMS (ESI+) calcd for C20H16F3N4O3 (M+H)+417.1169, found 417.1171.
  • Figure US20180194731A1-20180712-C00305
    • 5-((5-(Isonicotinamido)-2-(trifluoromethyl)benzyl)oxy)nicotinamide (F4-2)
  • White solid (10 mg, 25%). 1H NMR (DMSO-d6, 600 MHz)) δ 10.88 (s, 1H), 8.81 (d, J=6.0 Hz, 2H), 8.63 (d, J=1.2 Hz, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.18 (s, 2H), 8.06 (d, J=9.0 Hz, 1H), 7.89-7.85 (m, 3H), 7.85 (d, J=8.4 Hz, 1H), 7.64 (s, 1H), 5.37 (s, 2H). HRMS (ESI+) calcd for C20H16F3N4O3 (M+H)+417.1169, found 417.1176.
  • Figure US20180194731A1-20180712-C00306
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-(trifluoromethyl)phenyl)-6-ethoxynicotinamide (F4-3)
  • Pale solid (7 mg, 15%). 1H NMR (CD3OD, 600 MHz) δ 8.75 (s, 1H), 8.67 (s, 1H), 8.48 (s, 1H), 8.20 (d, J=7.8 Hz, 1H), 8.16 (s, 1H), 7.98-7.92 (m, 2H), 7.76 (d, J=9.0 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 5.41 (s, 2H), 4.43 (q, J=7.2 Hz, 2H), 1.40 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C22H20F3N4O4 (M+H)+461.1431, found 461.1439.
  • Figure US20180194731A1-20180712-C00307
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methoxyphenyl)nicotinamide (F5-1)
  • Light yellow solid (19 mg, 46%). 1H NMR (CD3OD, 600 MHz) δ 9.07 (s, 1H), 8.71 (d, J=4.2 Hz, 1H), 8.62 (s, 1H), 8.44 (d, J=2.4 Hz, 1H), 8.34 (d, J=7.2 Hz, 1H), 7.94 (s, 1H), 7.78 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.58 (dd, J=8.1, 5.1 Hz, 1H), 7.06 (d, J=9.0, 1H), 5.27 (s, 2H), 3.91 (s, 3H). HRMS (ESI+) calcd for C20H19N4O4 (M+H)+379.1401, found 379. 1407.
  • Figure US20180194731A1-20180712-C00308
    • 5-((5-(Isonicotinamido)-2-methoxybenzyl)oxy)nicotinamide (F5-2)
  • Light brown solid (14 mg, 34%) 1H NMR (DMSO-d6, 600 MHz) δ 10.43 (s, 1H), 8.77 (d, J=4.2 Hz, 2H), 8.65 (s, 1H), 8.47 (d, J=1.8 Hz, 1H), 8.15 (s, 1H), 7.87-7.82 (m, 3H), 7.81 (s, 1H), 7.77 (d, J=9.0 Hz, 1H), 7.61 (s, 1H), 7.10 (d, J=8.4, 1H), 5.21 (s, 2H), 3.85 (s, 3H). HRMS (ESI+) calcd for C20H19N4O4 (M+H)+379.1401, found 379. 1401.
  • Figure US20180194731A1-20180712-C00309
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-4-methoxyphenyl)-6-ethoxynicotinamide (F5-3)
  • White solid (22 mg, 47%). 1H NMR (DMSO-d6, 600 MHz) δ 10.15 (s, 1H), 8.75 (d, J=2.4 Hz, 1H), 8.65 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.21 (dd, J=9.0, 2.4 Hz, 1H), 8.15 (s, 1H), 7.85 (s, 1H), 7.78 (s, 1H), 7.74 (dd, J=8.7, 2.1 Hz, 1H), 7.61 (s, 1H), 7.08 (d, J=8.4 Hz, 1H), 7.90 (d, J=9.0 Hz, 1H), 5.20 (s, 2H), 4.38 (q, J=7.2 Hz, 2H), 3.32 (s, 3H), 1.34 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C22H23N4O0 (M+H)+423.1663, found 423. 1667.
  • Figure US20180194731A1-20180712-C00310
    • 5-((5-([1,1′-Biphenyl]-4-ylcarboxamido)-2-methoxybenzyl)oxy)nicotinamide (F5-4)
  • White solid (70 mg, 95%). 1H NMR (DMSO-d6, 600 MHz) δ 10.27 (s, 1H), 8.66 (s, 1H), 8.47 (d, J=2.4 Hz, 1H), 8.20 (s, 1H), 8.07 (d, J=8.4 Hz, 2H), 7.87 (d, J=10.8 Hz, 2H), 7.84-7.78 (m, 3H), 7.76 (d, J=7.2 Hz, 2H), 7.61 (s, 1H), 7.51 (dd, J=7.8 Hz, 2H), 7.42 (dd, J=7.2 Hz, 1H), 7.08 (d, J=9.0 Hz, 1H), 5.21 (s, 2H), 3.85 (s, 3H). HRMS (ESI+) calcd for C27H24N3O4 (M+H)+454.1761, found 454. 1767.
  • Figure US20180194731A1-20180712-C00311
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2-methylphenyl)nicotinamide (F6-1)
  • White solid (23 mg, 54%). 1H NMR (DMSO-d6, 600 MHz) δ 10.19 (s, 1H), 9.16 (s, 1H), 8.77 (d, J=4.5 Hz, 1H), 8.66 (s, 1H), 8.52 (d, J=2.4 Hz, 1H), 8.33 (d, J=7.6 Hz, 1H), 8.15 (br s, 1H), 7.91 (s, 1H), 7.63 (br s, 1H), 7.58 (dd, J=7.7 Hz, J2=5.0 Hz, 1H), 7.42 (d, J=7.7 Hz, 1H), 7.36 (d, J=7.7 Hz, 1H), 7.28 (t, J=7.7 Hz, 1H), 5.29 (s, 2H), 2.24 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1445.
  • Figure US20180194731A1-20180712-C00312
    • 5-((3-(Isonicotinamido)-2-methylbenzyl)oxy)nicotinamide (F6-2)
  • White solid (17 mg, 40%). 1H NMR (DMSO-d6, 600 MHz) δ 10.27 (s, 1H), 8.80 (d, J=5.0 Hz, 2H), 8.66 (s, 1H), 8.52 (d, J=2.5 Hz, 1H), 8.15 (br s, 1H), 7.91-7.88 (m, 3H), 7.63 (br s, 1H), 7.43 (d, J=7.4 Hz, 1H), 7.36 (d, J=7.7 Hz, 1H), 7.28 (t, J=7.7 Hz, 1H), 5.29 (s, 2H), 2.23 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1459.
  • Figure US20180194731A1-20180712-C00313
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2-fluorophenyl)nicotinamide (F7-1)
  • White solid (10 mg, 19%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 9.13 (d, J=1.8 Hz, 1H), 8.78 (dd, J=1.8, 4.8 Hz, 1H), 8.67 (d, J=1.2 Hz, 1H), 8.51 (d, J=2.4 Hz, 1H), 8.32 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 7.91 (s, 1H), 7.68 (dd, J=7.8, 7.8 Hz, 1H), 7.63 (s, 1H), 7.58 (dd, J=4.8, 7.8 Hz, 1H), 7.48 (dd, J=6.6, 6.6 Hz, 1H), 7.29 (dd, J=7.8, 7.8 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1202.
  • Figure US20180194731A1-20180712-C00314
    • 5-((2-Fluoro-3-(isonicotinamido)benzyl)oxy)nicotinamide (F7-2)
  • White solid (8 mg, 19%). 1H NMR (CD3OD, 600 MHz) δ 7.76 (d, J=5.4 Hz, 2H), 8.65 (s, 1H), 8.48 (d, J=2.4 Hz, 1H), 7.96 (s, 1H), 7.92 (d, J=6.0 Hz, 2H), 7.80 (dd, J=7.8, 7.8 Hz, 1H), 7.47 (dd, J=6.6, 6.6 Hz, 1H), 7.28 (dd, J=7.8, 7.8 Hz, 1H), 5.35 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1207.
  • Figure US20180194731A1-20180712-C00315
    • N-(5-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2-methylphenyl)nicotinamide (F8-1)
  • White solid (17 mg, 39%). 1H NMR (DMSO-d6, 600 MHz) δ 10.13 (s, 1H), 9.14 (s, 1H), 8.77 (d, J=4.5 Hz, 1H), 8.64 (s, 1H), 8.48 (d, J=2.4 Hz, 1H), 8.31 (d, J=7.6 Hz, 1H), 8.13 (br s, 1H), 7.85 (s, 1H), 7.61 (br s, 1H), 7.57 (dd, J=7.5 Hz, J2=5.0 Hz, 1H), 7.50 (s, 1H), 7.33 (d, J=7.7 Hz, 1H), 7.30 (d, J=7.7 Hz, 1H), 5.23 (s, 2H), 2.26 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+ 363.1452, found 363.1451.
  • Figure US20180194731A1-20180712-C00316
    • 5-((3-(Isonicotinamido)-4-methylbenzyl)oxy)nicotinamide (F8-2)
  • White solid (22 mg, 52%). 1H NMR (DMSO-d6, 600 MHz) δ 10.22 (s, 1H), 8.79 (d, J=5.6 Hz, 2H), 8.64 (d, J=1.2 Hz, 1H), 8.48 (d, J=2.7 Hz, 1H), 8.13 (br s, 1H), 7.88 (d, J=5.3 Hz, 2H), 7.85 (t, J=1.8 Hz, 1H), 7.61 (br s, 1H), 7.48 (s, 1H), 7.34 (d, J=7.9 Hz, 1H), 7.31 (d, J=7.9 Hz, 1H), 5.23 (s, 2H), 2.25 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1445.
  • Figure US20180194731A1-20180712-C00317
    • N-(5-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2-fluorophenyl)nicotinamide (F9-1)
  • White solid (10 mg, 33%). 1H NMR (DMSO-d6, 600 MHz) δ 10.41 (s, 1H), 9.12 (s, 1H), 8.78 (d, J=4.4 Hz, 1H), 8.66 (s, 1H), 8.49 (d, J=2.4 Hz, 1H), 8.31 (d, J=8.0 Hz, 1H), 8.14 (br s, 1H), 7.87 (s, 1H), 7.78 (d, J=6.8 Hz, 1H), 7.62 (br s, 1H), 7.58 (dt, J=7.9 Hz, J2=4.8 Hz, 1H), 7.43-7.39 (m, 1H), 7.36 (t, J=9.2 Hz, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1202.
  • Figure US20180194731A1-20180712-C00318
    • 5-((4-Fluoro-3-(isonicotinamido)benzyl)oxy)nicotinamide (F9-2)
  • White solid (12 mg, 40%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.80 (d, J=5.9 Hz, 2H), 8.66 (d, J=1.2 Hz, 1H), 8.49 (d, J=2.9 Hz, 1H), 8.13 (s, 1H), 7.89-7.85 (m, 3H), 7.76 (d, J=7.2 Hz, 1H), 7.62 (s, 1H), 7.44-7.41 (m, 1H), 7.39-7.35 (m, 1H), 5.25 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1208.
  • Figure US20180194731A1-20180712-C00319
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-5-methylphenyl)nicotinamide (F10-1)
  • White solid (32 mg, 76%). 1H NMR (DMSO-d6, 600 MHz) δ 10.43 (s, 1H), 9.10 (d, J=2.2 Hz, 1H), 8.76 (dd, J, =4.7 Hz, J2=1.5 Hz, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.49 (d, J=2.9 Hz, 1H), 8.29 (dt, J, =8.0 Hz, J2=2.0 Hz, 1H), 8.14 (br s, 1H), 7.86-7.85 (m, 1H), 7.71 (s, 1H), 7.61 (br s, 1H), 7.60 (s, 1H), 7.57 (dd, J=7.8 Hz, J2=4.8 Hz, 1H), 7.07 (s, 1H), 5.21 (s, 2H), 2.34 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1448.
  • Figure US20180194731A1-20180712-C00320
    • 5-((3-(Isonicotinamido)-5-methylbenzyl)oxy)nicotinamide (F10-2)
  • White solid (33 mg, 78%). 1H NMR (DMSO-d6, 600 MHz) δ 10.48 (s, 1H), 8.78 (d, J=5.5 Hz, 2H), 8.65 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 8.14 (br s, 1H), 7.86-7.84 (m, 3H), 7.70 (s, 1H), 7.61 (br s, 1H), 7.60 (s, 1H), 7.08 (s, 1H), 5.22 (s, 2H), 2.34 (s, 3H). HRMS (ESI+) calcd for C20H19N4O3 (M+H)+363.1452, found 363.1450.
  • Figure US20180194731A1-20180712-C00321
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-5-fluorophenyl)nicotinamide (F11-1)
  • White solid (35 mg, 79%). 1H NMR (DMSO-d6, 600 MHz) δ 10.68 (s, 1H), 9.10 (s, 1H), 8.78 (d, J=4.5 Hz, 1H), 8.67 (s, 1H), 8.51 (d, J=2.6 Hz, 1H), 8.29 (d, J=8.2 Hz, 1H), 8.14 (br s, 1H), 7.86 (s, 1H), 7.72 (d, J=11.3 Hz, 1H), 7.70 (s, 1H), 7.63 (br s, 1H), 7.58 (dd, J=7.7 Hz, J2=4.8 Hz, 1H), 7.10 (d, J=9.0 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1195.
  • Figure US20180194731A1-20180712-C00322
    • 5-((3-Fluoro-5-(isonicotinamido)benzyl)oxy)nicotinamide (F11-2)
  • White solid (39 mg, 87%). 1H NMR (DMSO-d6, 600 MHz) δ 10.74 (s, 1H), 8.80 (d, J=5.9 Hz, 2H), 8.67 (s, 1H), 8.51 (d, J=2.6 Hz, 1H), 8.14 (br s, 1H), 7.87-7.85 (m, 3H), 7.74-7.69 (m, 2H), 7.63 (s, 1H), 7.11 (d, J=9.0 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C19H16FN4O3 (M+H)+367.1201, found 367.1198.
  • Figure US20180194731A1-20180712-C00323
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2,4-difluorophenyl)nicotinamide (F12-1)
  • White solid (7.8 mg, 13%). 1H NMR (DMSO-d6, 600 MHz) δ 10.44 (s, 1H), 9.13 (s, 1H), 8.78 (d, J=4.2 Hz, 1H), 8.68 (s, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.31 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.73 (d, J=9.0, 15.6 Hz, 1H), 7.64 (s, 1H), 7.59 (dd, J=7.2, 8.4 Hz, 1H), 7.27 (dd, J=9.0, 9.0 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C19H15F2N4O3 (M+H)+ 385.1107, found 385.1114.
  • Figure US20180194731A1-20180712-C00324
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2,4-difluorophenyl)-6-ethoxynicotinamide (F12-2)
  • White solid (5.7 mg, 8.7%). 1H NMR (DMSO-d6, 600 MHz) δ 10.21 (s, 1H), 8.72 (s, 1H), 8.68 (d, J=1.2 Hz, 1H), 8.50 (d, J=2.4 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 7.93 (s, 1H), 7.69 (dd, J=7.8, 14.4 Hz, 1H), 7.63 (s, 1H), 7.25 (dd, J=9.0, 9.0 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 5.30 (s, 2H), 4.39 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H). HRMS (ESI+) calcd for C21H9F2N4O4 (M+H)+429.1369, found 429.1379.
  • Figure US20180194731A1-20180712-C00325
    • N-(3-(((5-Carbamoylpyridin-3-yl)oxy)methyl)-2,4-difluorophenyl)-6-(thiophen-2-yl)nicotinamide (F12-3)
  • White solid (18 mg, 25%). 1H NMR (DMSO-d6, 600 MHz) δ 10.40 (s, 1H), 9.06 (s, 1H), 8.35 (d, J=9.0 Hz, 1H), 8.15 (s, 1H), 8.09 (d, J=8.4 Hz, 1H), 7.98-7.93 (m, 2H), 7.78-7.72 (m, 2H), 7.64 (s, 1H), 7.27 (dd, J=8.7, 8.7 Hz, 1H), 7.23 (dd, J=4.2, 4.2 Hz, 1H), 5.32 (s, 2H). HRMS (ESI+) calcd for C23H17F2N4O3S (M+H)+ 467.0984, found 467.0985.
  • Figure US20180194731A1-20180712-C00326
    • 5-((2,6-Difluoro-3-(3-fluoro-4-(trifluoromethoxy)benzamido)benzyl)oxy)nicotinamide (F12-4)
  • White solid (16 mg, 21%). 1H NMR (DMSO-d6, 600 MHz) δ 10.42 (s, 1H), 8.69 (s, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J=10.8 Hz, 1H), 7.96-7.90 (m, 2H), 7.78 (dd, J=8.4, 8.4 Hz, 1H), 7.70 (dd, J=7.8, 14.4 Hz, 1H), 7.64 (s, 1H), 7.27 (dd, J=9.0 Hz, 1H), 5.31 (s, 2H). HRMS (ESI+) calcd for C21H14F6N3O4 (M+H)+486.0883, found 486.0881.
    • Example 7
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00327
  • IG2a.
  • In a manner similar to that described for the preparation of compound IF4f, a Mitsunobu reaction of IG1a (124 mg, 1.00 mmol) and methyl 5-hydroxy-3-pyridinecarboxylate (153 mg, 1.00 mmol) afforded IG2a as a yellow solid (49 mg, 19%). 1H NMR (CDCl3, 600 MHz) δ 8.86 (d, J=1.8 Hz, 1H), 8.54 (d, J=2.9 Hz, 1H), 8.09 (d, J=5.3 Hz, 1H), 7.81-7.80 (m, 1H), 6.68 (d, J=5.3 Hz, 1H), 6.57 (s, 1H), 5.07 (s, 2H), 4.50 (br s, 2H), 3.96 (s, 3H). HRMS (ESI+) calcd for C13H14N3O3 (M+H)+260.1030, found 260.1038.
  • IG2b.
  • In a manner similar to that described for the preparation of compound IF4f, a Mitsunobu reaction of IG1b (621 mg, 5.00 mmol) and methyl 5-hydroxy-3-pyridinecarboxylate (766 mg, 5.00 mmol) afforded IG2b as a brown solid (362 mg, 14%). 1H NMR (CDCl3, 600 MHz) δ 8.78 (s, 1H), 8.27 (d, J=2.4 Hz, 1H), 7.83-7.75 (m, 6H), 7.65 (s, 1H), 7.51-7.47 (m, 3H), 7.43-7.33 (m, 7H), 6.86 (d, J=8.2 Hz, 1H), 6.59 (d, J=7.2 Hz, 1H), 4.71 (s, 2H), 3.94 (s, 3H). HRMS (ESI+) calcd for C31H27N3O3P (M+H)+520.1785, found 520.1780.
  • IG3a.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IG2a (46 mg, 0.18 mmol) afforded IG3a as a yellow solid (21 mg, 48%). 1H NMR (CD3OD, 600 MHz) δ 8.63 (s, 1H), 8.45 (d, J=2.7 Hz, 1H), 7.89-7.87 (m, 2H), 6.67-6.65 (m, 2H), 5.15 (s, 2H). HRMS (ESI+) calcd for C12H13N4O2 (M+H)+245.1033, found 245.1028.
  • IG3b.
  • In a manner similar to that described for the preparation of compound IF6a, aminolysis of IG2b (362 mg, 0.70 mmol) afforded IG3b as a white solid (120 mg, 70%). 1H NMR (CD3OD, 600 MHz) δ 8.62 (s, 1H), 8.44 (d, J=2.9 Hz, 1H), 7.90-7.88 (m, 1H), 7.46 (t, J=7.9 Hz, 1H), 6.75 (d, J=7.3 Hz, 1H), 6.52 (d, J=8.3 Hz, 1H), 5.07 (s, 2H). HRMS (ESI+) calcd for C12H13N4O2 (M+H)+245.1033, found 245.1035.
  • The following compounds were prepared through an amide formation reaction in a manner similar to that described for the preparation of compound F1-1.
  • Figure US20180194731A1-20180712-C00328
    • N-(4-(((5-Carbamoylpyridin-3-yl)oxy)methyl)pyridin-2-yl)nicotinamide (G1-1)
  • White solid (4 mg, 29%). 1H NMR (DMSO-d6, 600 MHz) δ 11.15 (s, 1H), 9.13 (s, 1H), 8.76 (d, J=4.1 Hz, 1H), 8.68 (s, 1H), 8.53 (d, J=2.7 Hz, 1H), 8.43 (d, J=5.0 Hz, 1H), 8.35 (d, J=7.9 Hz, 1H), 8.33 (s, 1H), 8.15 (br s, 1H), 7.87 (s, 1H), 7.63 (br s, 1H), 7.55 (dd, J1=7.9 Hz, J2=4.9 Hz, 1H), 7.27 (d, J=4.7 Hz, 1H), 5.38 (s, 2H). HRMS (ESI+) calcd for C15H16N5O3 (M+H)+350.1248, found 350.1254.
  • Figure US20180194731A1-20180712-C00329
    • 5-((2-(Isonicotinamido)pyridin-4-yl)methoxy)nicotinamide (G1-2)
  • White solid (5 mg, 41%). 1H NMR (DMSO-d6, 600 MHz) δ 11.19 (s, 1H), 8.77 (d, J=5.0 Hz, 2H), 8.68 (s, 1H), 8.53 (d, J=2.3 Hz, 1H), 8.43 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 8.15 (br s, 1H), 7.91 (d, J=5.0 Hz, 2H), 7.87 (s, 1H), 7.63 (br s, 1H), 7.29 (d, J=5.0 Hz, 1H), 5.39 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1256.
  • Figure US20180194731A1-20180712-C00330
    • N-(6-(((5-Carbamoylpyridin-3-yl)oxy)methyl)pyridin-2-yl)nicotinamide (G2-1)
  • White solid (10 mg, 26%). 1H NMR (DMSO-d6, 600 MHz) δ 11.20 (s, 1H), 9.14 (s, 1H), 8.75 (d, J=5.0 Hz, 1H), 8.67 (s, 1H), 8.53 (s, 1H), 8.35 (d, J=7.9 Hz, 1H), 8.17 (d, J=8.3 Hz, 1H), 8.14 (br s, 1H), 7.93 (t, J=7.8 Hz, 1H), 7.86 (s, 1H), 7.63 (br s, 1H), 7.56-7.53 (m, 1H), 7.35 (d, J=7.6 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1246.
  • Figure US20180194731A1-20180712-C00331
    • 5-((6-(Isonicotinamido)pyridin-2-yl)methoxy)nicotinamide (G2-2)
  • White solid (12 mg, 30%). 1H NMR (DMSO-d6, 600 MHz) δ 11.23 (s, 1H), 8.77 (d, J=5.2 Hz, 2H), 8.67 (s, 1H), 8.53 (d, J=2.4 Hz, 1H), 8.17 (d, J=8.4 Hz, 1H), 8.14 (br s, 1H), 7.94 (t, J=7.9 Hz, 1H), 7.92 (d, J=5.2 Hz, 2H), 7.86 (s, 1H), 7.63 (br s, 1H), 7.37 (d, J=7.4 Hz, 1H), 5.28 (s, 2H). HRMS (ESI+) calcd for C18H16N5O3 (M+H)+350.1248, found 350.1254.
    • Example 8
  • Representative compounds of formula (I) can be prepared as described below.
  • Figure US20180194731A1-20180712-C00332
    • (S)-2-((tert-Butoxycarbonyl)amino)-3-(4-((4-((3-(((5-carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamoyl)benzyl)oxy)phenyl)propanoic acid (IH3)
  • To a solution of A-135 (6.0 mg, 0.015 mmol) in DMF (2 mL) was added Cs2CO3 (10.0 mg, 0.030 mmol) and Boc-Tyr-OMe (IH2, 5.0 mg, 0.017 mmol) and the reaction mixture was allowed to stir at rt for 12 h. The reaction mixture was diluted with saturated NH4Cl and extracted with EtOAc. The organic phase was washed with water, brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was then dissolved in MeOH (5 mL) and 1N NaOH (2 mL). The reaction mixture was allowed to stir at rt for 12 h. Upon removal of MeOH, aqueous phase was acidified with 1N HCl to pH=5. Aqueous solution was extracted with EtOAc, The organic phase was washed with water, brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by flash column chromatography (0-30% MeOH/CH2Cl2) to afford acid IH3 as a white solid (8.0 mg, 83% over two steps). 1H NMR (MeOH-d4, 600 MHz) δ 8.65 (bs, 1H), 8.49 (bs, 1H), 7.99-7.90 (m, 3H), 7.88 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.58 (d, J=7.8 Hz, 2H), 7.40 (dd, J=8.4 Hz, 1H), 7.27 (d, J=7.2 Hz, 1H), 7.15 (d, J=7.8 Hz, 2H), 6.92 (d, J=7.8 Hz, 2H), 5.25 (s, 2H), 5.15 (s, 2H), 4.31-4.25 (m, 1H), 3.12-3.05 (m, 1H), 2.88-2.80 (m, 1H), 1.38 (s, 9H). HRMS (ESI+) calcd for C35H37N4O8 (M+H)+641.2606, found 641.2606.
    • (S)-2-Amino-3-(4-((4-((3-(((5-carbamoylpyridin-3-yl)oxy)methyl)phenyl)carbamoyl)-benzyl)oxy)phenyl)propanoic acid (H-1)
  • To a solution of IH3 (8.0 mg, 0.015 mmol) in DCM (2 mL) was added TFA (0.5 mL) and the reaction mixture was allowed to stir at rt for 2 h. The reaction mixture was concentrated in vacuo to afford acid H-1 as a white solid (7.2 mg, 78%). 1H NMR (MeOH-d4, 600 MHz) δ 8.70 (bs, 1H), 8.55 (bs, 1H), 8.07 (s, 1H), 7.96 (d, J=8.4 Hz, 2H), 7.90 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.41 (dd, J=8.4 Hz, 1H), 7.28 (d, J=7.2 Hz, 1H), 7.22 (d, J=8.4 Hz, 2H), 7.02 (d, J=9.0 Hz, 2H), 5.29 (s, 2H), 5.19 (s, 2H), 4.20 (dd, J=7.2, 5.4 Hz, 1H), 3.28-3.21 (m, 1H), 3.12-3.05 (m, 1H). HRMS (ESI+) calcd for C30H29N4O6 (M+H)+541.2082, found 541.2077.
    • Example 9. Biological Assays and Data
  • SIRT1-3 Biochemical Assays (I).
  • Full length human SIRT1 (GenBank Accession No. NM_012238, MW=82 kDa), full length human SIRT2 (GenBank Accession No. NM_012237, MW=43 kDa), and catalytically active human SIRT3 (GenBank Accession No. NM_012239, amino acids 102-399, MW=32.7 kDa) were expressed in E. coli and purified. The peptide substrate for SIRT1-3 was a fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide Ac-Arg-His-Lys-Lys(Ac)-AMC. The assays were performed in a buffer of 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 and 1 mg/ml BSA, which was added before use. The testing involved a two-step reaction. First, 50 μM AMC-labeled substrate with an acetylated lysine side chain was incubated with 91 nM SIRT1 (6 μL reaction volume) for 2 hours at 30° C. to produce the deacetylated substrate. The concentrations of SIRT2 and SIRT3 were 233 and 917 nM, respectively. Second, the deacetylated substrate was digested by a mixture of developer (6 μL) to release AMC that was detected at 360/460 Ex/Em. Each compound was dissolved in DMSO (1% or less final concentration, which does not significantly affect the enzymatic assay), sequentially diluted, and used for testing. Background fluorescence produced by compounds if detected was subtracted. The percentages of enzyme activity (relative to DMSO controls) were calculated. To determine the IC50 values, compounds were tested in a 10-dose mode with a 3-fold serial dilution starting at 200 μM (200 μM-10.2 nM) in singlet. The IC50 values were calculated from the resulting sigmoidal dose-response curves using GraphPad Prism. Suramin was used as a reference compound for SIRT1 as well as SIRT2, and nicotinamide for SIRT3.
  • SIRT1-3 Biochemical Assays (II).
  • The full length human SIRT2 gene (Accession No. NM_012237) was cloned into the expression vector pReceiver-B01 (GeneCopoeia). The recombinant human SIRT2 contains a hiss-affinity purification tag at the N terminal of the protein. The plasmid was transformed into E. coli BL21 (DE3) cells, and cultured to an OD600 of 0.6. The E. coli was induced with 0.4 mM isopropyl β-D-thiogalactoside (IPTG) and cultured for 16 h at 18° C. The cultures were harvested by centrifugation and the cell pellets were stored at −80° C. The cell pellets were resuspended in 40 ml binding buffer (50 mM HEPES pH 8.0, 300 mM NaCl, 10 mM imidazole). Cells were sonicated 4 times on ice using a Branson Sonifier 250 (power 8, 30% duty cycle, 2 min) and centrifuged at 45,000 g for 10 min at 4° C. The protein was recovered from the cleared lysate by the addition of 0.5 mL His60 resin (Clontech) followed by incubation at 4° C. for 1 hr with constant rotation. The resin was recovered by pouring the lysate into a gravity column. The column was washed using 15 mL wash buffer (50 mM HEPES pH 8.0, 300 mM NaCl, 20 mM imidazole) to remove all of the unbound proteins. Then the bound protein was eluted with 2.5 mL elution buffer (50 mM HEPES pH 8.0, 300 mM NaCl, 500 mM imidazole). The SIRT2 protein was desalted into storage buffer (25 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 10% glycerol) using PD-10 columns (GE Healthcare) and stored at −80° C. The yield of the protein was approximately 5.7 mg/L. Plasmids for the expression of SIRT1 (SIRT1.1, plasmid 13735) and SIRT3 (SIRT3L-12, plasmid 13736) were obtained from Addgene and transformed into E. coli BL21 (DE3). Expression and purification were performed as for SIRT2 and yielded 3.6 and 8.1 mg/L of culture for SIRT1 and SIRT3, respectively.
  • Compounds were aliquoted (0.5 μL) in duplicate into black 384 well non-binding surface plates (Corning). A master mix containing assay buffer (50 mM Tris pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2), NAD, 1 mM DTT, and 1 mg/mL BSA, was added to 2 wells to serve as a negative control. Enzyme was added to the remaining master mix, which was then aliquoted into all remaining wells. The plate was mixed for 30 s at 15000 RPM on a MixMate (Eppendorf) and left at 25° C. for 10 min. The reactions were initiated by the addition of peptide (to a final volume of 50 μL) followed by mixing of the plate as described above. The reaction was allowed to proceed at 37° C. for the desired time and then quenched by the addition of 10 μL developing buffer (12 mM nicotinamide, 30000 U/mL trypsin). The plates were once again mixed and then developed for 20 min at 37° C. before analyzing the plate by exciting at 355 nm and reading the emission at 460 nm.
  • Enzyme specific conditions for assays (II)
    Enzyme SIRT1 SIRT2 SIRT3
    NAD, mM 0.26 0.2 0.344
    Peptide, mM 0.453 0.297 0.255
    Enzyme, μM 0.25 0.1(titrated) 1.5
    Reaction time, min 20 20 60
  • TABLE 1
    Activities against SIRT1-3.
    IC50 or Ki app (μM)
    Compound Assays SIRT1 SIRT2 SIRT3
    A-1 I 7.14 0.107 6.39
    A-2 I >200 15.1 22.3
    A-3 I 42.4 2.05 28.4
    A-4 I >200 0.505 >200
    A-5 I 21.8 0.546 17.9
    A-6 I 12.5 0.252 11.5
    A-7 I 9.50 0.235 7.86
    A-8 I 50.8 4.80 6.03
    A-9 I 44.6 1.37 4.08
    A-10 I 19.7 0.156 18.5
    A-11 I 192 0.572 1.08
    A-12 I 52.1 0.0234 1.59
    A-13 I 1.62 0.0331 3.29
    A-14 I 9.93 0.0647 2.37
    A-15 I 7.33 0.0714 1.77
    A-16 I 65.2 0.437 36.2
    A-17 I 8.09 0.313 2.71
    A-18 I 1.81 0.0831 1.56
    A-19 I 2.23 0.0354 1.39
    A-20 I 0.483 0.0157 1.22
    A-21 I 192 4.15 19.5
    A-22 I 30.4 0.580 9.06
    A-23 I 8.54 0.111 5.84
    A-24 I 53.2 3.49 8.55
    A-25 I 29.5 0.841 9.93
    A-26 I 13.0 0.173 7.12
    A-27 I 53.2 3.82 11.6
    A-28 I 10.5 0.293 20.9
    A-29 I 2.96 0.113 8.05
    A-30 I 97.8 6.01 17.9
    A-31 I 26.3 0.273 8.04
    A-32 I 8.37 0.174 7.27
    A-33 I 194 7.04 12.6
    A-34 I 15.2 0.280 11.8
    A-35 I 1.64 0.0916 4.60
    A-36 I 30.2 0.288 2.94
    A-37 I 10.1 0.0754 3.39
    A-38 I 4.19 0.0368 2.57
    A-39 I 31.4 0.277 15.5
    A-40 I 7.97 0.0418 1.56
    A-41 I 16.5 0.474 5.79
    A-42 I 16.3 0.0954 13.0
    A-43 I 16.6 0.384 4.32
    A-44 I 19.9 0.0353 15.1
    A-45 I 71.8 0.109 1.33
    A-46 I 9.26 0.0217 1.60
    A-47 I 21.0 0.151 8.24
    A-48 I 13.5 0.0947 2.50
    A-49 I 15.3 0.113 4.89
    A-50 I 71.5 0.133 3.50
    A-51 I 15.6 0.0135 >200
    A-52 I 106 0.0263 66.4
    A-53 I 13.4 0.0460 8.15
    A-54 I 14.7 0.476 6.50
    A-55 I 3.51 0.0447 4.18
    A-56 I 0.237 0.251 0.827
    A-57 I 0.367 0.0190 0.843
    A-58 I 2.55 0.0227 0.503
    A-59 I 1.55 0.0281 0.829
    A-60 I 0.974 0.0229 0.697
    A-61 I 3.01 0.0415 3.20
    A-62 I 8.02 0.102 8.90
    A-63 I 142 2.58 106
    A-64 I 1.88 0.0478 7.35
    A-65 I 1.39 0.0281 2.64
    A-66 I 6.27 0.519 5.58
    A-67 I 0.672 0.0486 1.88
    A-68 I 24.1 0.465 17.7
    A-69 I >200 0.196 85.8
    A-70 I >200 0.138 >200
    A-71 I 2.82 0.216 5.62
    A-72 I 3.03 0.104 5.59
    A-73 I 10.5 0.0267 7.51
    A-74 I 11.5 0.366 8.19
    A-75 I 5.66 0.0982 0.910
    A-76 I 6.32 0.251 3.33
    A-77 I 6.56 0.0167 1.87
    A-78 I 2.08 0.112 0.580
    A-79 I 9.02 0.282 16.6
    A-80 I 5.54 0.268 5.40
    A-81 I 13.0 0.775 14.2
    A-82 I 10.7 0.865 11.5
    A-83 I 8.34 0.242 5.16
    A-84 I 3.89 0.711 6.01
    A-85 I 8.04 0.0914 9.02
    A-86 I 40.3 0.751 38.3
    A-87 I 2.95 0.186 6.78
    A-88 I 5.23 0.194 11.8
    A-89 I 5.78 0.159 9.51
    A-90 I 2.19 0.0422 5.06
    A-91 I 20.3 1.54 4.79
    A-92 I 18.7 0.193 13.4
    A-93 I 2.46 0.0341 2.40
    A-94 I 15.5 0.500 9.66
    A-95 I 7.92 0.171 6.86
    A-96 I 33.3 1.95 9.04
    A-97 I 90.9 4.46 7.32
    A-98 I 48.5 0.450 1.81
    A-99 I 11.3 0.157 2.70
    A-100 I 3.47 0.0436 0.723
    A-101 I 18.8 0.0468 5.85
    A-102 I 145 0.0419 >200
    A-103 I 14.9 0.0289 7.12
    A-104 I 1.23 0.0224 1.62
    A-105 I 11.3 0.0333 4.11
    A-106 I 115 0.0293 11.4
    A-107 I 2.27 0.0297 0.776
    A-108 I 2.23 0.0460 5.02
    A-109 I 1.45 0.0552 0.940
    A-110 I 146 0.0776 15.9
    A-111 I 2.87 0.0473 12.6
    A-112 I 13.1 0.206 14.6
    A-113 I 256 0.0764 164
    A-114 I 241 0.0342 6.87
    A-115 I 8.77 0.411 5.08
    A-116 I 9.96 0.161 7.55
    A-117 I 44.8 0.444 7.59
    A-118 I 10.5 0.0747 4.51
    A-119 I 24.6 0.136 12.5
    A-120 I 20.6 0.124 10.3
    A-121 I 17.3 0.0683 14.9
    A-122 I 132 0.464 7.41
    A-123 I 11.4 0.0639 11.0
    A-124 I 42.0 0.353 16.0
    A-125 I 2.07 0.0687 7.23
    A-126 II >100 4.39 >100
    A-127 II >100 2.49 47.2
    A-128 II 2.1 0.513 6.7
    A-129 II 3.8 0.925 10.2
    A-130 II 4.8 0.864 11.2
    A-131 II 18.1 0.902 5.7
    A-132 II 47.8 8.19 45.1
    A-133 II 26 1.30 2.9
    B1-1 I 64.0 9.36 2.56
    B1-2 I 43.2 3.36 0.760
    B1-3 I 20.7 2.59 0.535
    B1-4 I 94.9 3.28 3.01
    B1-5 I 104 3.28 1.45
    B1-6 I 85.6 6.14 7.53
    B1-7 I 52.1 3.84 3.09
    B1-8 I 37.3 5.04 2.77
    B1-9 I 46.6 4.96 2.63
    B1-10 I 86.9 5.99 14.7
    B1-11 I 13.9 0.666 1.23
    B1-12 I 41.0 3.12 1.80
    B1-13 I 124 1.17 8.45
    B2-1 I 15.7 0.763 1.57
    B3-1 I 9.71 0.488 16.9
    B3-2 I 43.4 0.193 6.77
    B4-1 I 41.4 0.436 9.77
    B4-2 I 15.0 0.572 2.15
    C1-1 I 25.6 0.281 4.36
    C1-2 I 8.51 0.163 5.28
    C1-3 I 14.4 0.144 4.34
    C1-4 I 15.3 0.0480 2.73
    C1-5 I 19.8 0.120 3.40
    C1-6 I 9.99 0.0503 0.856
    C4-1 I 23.6 0.540 16.0
    C4-2 I 69.8 0.166 19.5
    C4-3 I 41.5 0.212 10.7
    C4-4 I 29.9 0.0710 5.43
    C4-5 I 50.2 0.216 12.8
    C4-6 I 36.6 0.109 11.6
    C2-1 I 10.6 0.0343 1.46
    C2-2 I 1.18 0.0576 0.495
    C2-3 I 101 0.0634 6.00
    C3-1 I 25.1 0.105 0.709
    C3-2 I 18.3 0.0957 5.13
    C3-3 I 76.3 0.0286 13.9
    C5-1 I 73.2 0.269 18.6
    C5-2 I 113 0.152 5.79
    C5-3 I 78.2 0.0540 51.4
    C6-1 I 37.2 0.163 53.1
    C6-2 I 66.7 0.178 9.84
    C6-3 I 79.7 0.197 31.1
    C7-1 I 23.9 3.28 15.0
    C7-2 I 34.8 1.33 22.8
    C7-3 I 38.5 1.49 24.8
    C7-4 I 52.3 1.43 29.5
    C8-1 I 266 3.00 32.8
    C8-2 I 194 1.44 20.8
    C8-3 I 252 1.98 37.6
    C8-4 I 225 1.28 11.8
    C8-5 I 227 2.81 37.4
    D1-1 I 591 0.736 18.7
    D2-1 I 3.52 0.282 2.48
    D3-1 I 9.84 0.535 13.7
    D4-1 I 0.305 0.0477 1.85
    D4-2 I 1.41 0.0290 1.04
    D5-1 I 6.70 0.935 17.1
    D6-1 I 221 1.14 13.6
    D7-1 I 14.4 0.369 20.7
    D8-1 I 16.6 0.863 14.1
    D9-1 I 61.2 0.0704 1.14
    D10-1 I 32.3 1.78 24.9
    D11-1 I 17.3 0.397 14.2
    D11-2 I 3.34 0.191 5.81
    D11-4 I 9.89 0.581 11.9
    D11-5 I 5.35 0.158 13.1
    D11-6 I 8.54 0.381 10.7
    D11-7 I 4.72 0.359 5.88
    D11-8 I 7.67 0.751 11.4
    D11-9 I 8.34 0.277 12.0
    D11-10 I 3.71 0.136 8.22
    D11-11 I 3.01 0.152 8.72
    D11-12 I 3.60 0.152 12.1
    D11-13 I 6.76 0.341 13.1
    E1-1 I 2.27 0.0905 11.6
    E2-1 I 14.7 0.110 13.4
    E3-1 II >100 0.738 >100
    E3-2 II >100 7.31 >100
    F1-1 II 22.0 0.0440 20.5
    F1-2 II 9.8 0.0752 17.2
    F1-3 II >100 0.141 >100
    F1-4 II 77.4 0.131 36.7
    F1-5 II 30.6 0.0962 25.6
    F1-6 II >100 0.0996 >100
    F1-7 II >100 0.0198 >100
    F1-8 II >100 0.0404 >100
    F1-9 II 29 0.180 27
    F1-10 II >100 0.0394 >100
    F1-11 II >100 0.0416 >100
    F1-12 II >100 0.300 >100
    F1-13 II 22.9 0.0432 11.6
    F1-14 II 51.6 0.0950 26.7
    F1-15 II 24 0.0110 9.6
    F1-16 II 59.9 0.0630 24.3
    F1-17 II >100 0.0169 7.2
    F1-18 II >100 0.0338 >100
    F1-19 II 28.5 0.166 30.4
    F1-20 II 43.3 0.150 26.6
    F1-21 II >100 0.221 53.6
    F1-22 II >100 0.879 >100
    F1-23 II >100 0.790 >100
    F1-24 II 21.4 0.130 11.5
    F1-25 II 59.6 0.201 46.3
    F2-1 II 8.21 0.0530 1.92
    F2-2 II 1.51 0.0653 7
    F2-3 II 41.9 0.183 12.1
    F2-4 II 10 0.113 12.4
    F2-5 II 7.8 0.0849 9.9
    F2-6 II 20.7 0.111 8.3
    F2-7 II >100 0.0242 >100
    F2-8 II >100 0.0455 >100
    F2-9 II 4 0.124 7.6
    F2-10 II >100 0.0396 >100
    F2-11 II >100 0.0532 >100
    F2-12 II 99.2 0.218 21.4
    F3-1 II 23.0 0.0290 4.79
    F3-2 II 3.4 0.0687 5.9
    F3-3 II >100 0.0813 >100
    F3-4 II >100 0.0455 >100
    F3-5 II >100 0.214 >100
    F3-6 II 90 0.031 5.2
    F3-7 II >100 0.450 >100
    F3-8 II 9.0 0.0641 6.6
    F3-9 II >100 1.48 14.8
    F3-10 II >100 0.870 28.5
    F3-11 II >100 0.0489 >100
    F3-12 II 20 0.126 7.8
    F3-13 II >100 0.475 >100
    F3-14 II 49.8 0.139 18
    F4-1 II 93 0.163 19.3
    F4-2 II 23.5 0.0683 13.1
    F4-3 II >100 0.523 28.2
    F5-1 II 53.2 0.186 29.1
    F5-2 II 8.0 0.0643 17.2
    F5-3 II >100 0.0952 51.6
    F5-4 II >100 0.0724 >100
    F6-1 II >100 2.557 >100
    F6-2 II >100 1.634 >100
    F7-1 II >100 1.242 >100
    F7-2 II 19.9 0.532 33.3
    F8-1 II 47 0.352 27.2
    F8-2 II 10.3 0.147 17.5
    F9-1 II 25.1 0.268 46.7
    F9-2 II 4.8 0.121 23.1
    F10-1 II 47.8 0.342 22.7
    F10-2 II 14.7 0.122 10.9
    F11-1 II 23.5 0.484 18.5
    F11-2 II 4.7 0.153 13.6
    F12-1 II 3.68 0.0770 7.39
    F12-2 II >100 0.361 20.4
    F12-3 II >100 0.148 >100
    F12-4 II >100 0.730 91.4
    G1-1 II >100 21.3 >100
    G1-2 II >100 6.29 >100
    G2-1 II >100 22.7 >100
    G2-2 II >100 8.03 >100
    Note:
    For the inhibitory activity against SIRT2, Ki app was usually determined when the assays (II) were used.
    • Example 10
  • The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I (‘Compound X’), for therapeutic or prophylactic use in humans.
  • (i) Tablet 1 mg/tablet
    Compound X = 100.0
    Lactose 77.5
    Povidone 15.0
    Croscarmellose sodium 12.0
    Microcrystalline cellulose 92.5
    Magnesium stearate 3.0
    300.0
  • (ii) Tablet 2 mg/tablet
    Compound X = 20.0
    Microcrystalline cellulose 410.0
    Starch 50.0
    Sodium starch glycolate 15.0
    Magnesium stearate 5.0
    500.0
  • (iii) Capsule ms/capsule
    Compound X = 10.0
    Colloidal silicon dioxide 1.5
    Lactose 465.5
    Pregelatinized starch 120.0
    Magnesium stearate 3.0
    600.0
  • (iv) Injection 1 (1 mg/ml) mg/ml
    Compound X = (free acid form) 1.0
    Dibasic sodium phosphate 12.0
    Monobasic sodium phosphate 0.7
    Sodium chloride 4.5
    1.0N Sodium hydroxide solution
    (pH adjustment to 7.0-7.5) q.s.
    Water for injection q.s. ad 1 mL
  • (v) Injection 2 (10 mg/ml) mg/ml
    Compound X = (free acid form) 10.0
    Monobasic sodium phosphate 0.3
    Dibasic sodium phosphate 1.1
    Polyethylene glycol 400 200.0
    1.0N Sodium hydroxide solution
    (pH adjustment to 7.0-7.5) q.s.
    Water for injection q.s. ad 1 mL
  • (vi) Aerosol mg/can
    Compound X = 20.0
    Oleic acid 10.0
    Trichloromonofluoromethane 5,000.0
    Dichlorodifluoromethane 10,000.0
    Dichlorotetrafluoroethane 5,000.0

    The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims (24)

1. A compound of formula (I):
Figure US20180194731A1-20180712-C00333
wherein:
X is CH;
Y is CH;
A is -A′-B′—,
A′ is
Figure US20180194731A1-20180712-C00334
B′ is phenyl,
C is selected from the group consisting of:
Figure US20180194731A1-20180712-C00335
D is phenyl that is substituted with —NRaRb, or D is pyridyl that is optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NRaRb, —C(═O)NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C3-C15)carbocycle, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C3-C15)carbocycle, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, aryloxy, and heteroaryl, wherein any aryl, aryloxy, and heteroaryl of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, Rx, and (C1-C4)haloalkoxy,
each Ra and Rb is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, and heteroaryl, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, hydroxy, (C3-C15)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, oxo (═O), aryl, and heteroaryl, and wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, nitro, cyano, carboxy, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C15)carbocycle, —NRcRd, —C(═O)NRcRd, (C1-C4)alkoxycarbonyl, (C1-C4)haloalkyl, aryl, heteroaryl, and ReO—; or Ra and Rb together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino, 1,1-(dioxido)thio-morpholino and piperidino is optionally substituted with one or more groups independently selected from halo, oxo, and (C1-C4)alkyl;
each Rc and Rd is independently selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkoxy, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, (C3-C15)carbocycle, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, and oxo (═O); or Rc and Rd together with the nitrogen to which they are attached form a morpholino, piperazino, pyrrolidino or piperidino;
Re is selected from the group consisting of H, (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, aryl, and (C1-C4)alkanoyl, wherein any (C1-C4)alkyl, (C3-C8)cycloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, and (C1-C4)alkanoyl is optionally substituted with one or more groups independently selected from halo and aryl, and wherein any aryl is optionally substituted with one or more groups independently selected from halo deuterium, nitro, cyano, hydroxy, carboxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, and (C1-C4)alkanoyloxy; and
each Rx is (C1-C4)alkyl that is substituted with one or more groups independently selected from oxo, carboxy, (C1-C4)alkoxycarbonyl, and amino; or a salt thereof.
2. (canceled)
3. The compound of claim 1 which is a compound of formula (Ia):
Figure US20180194731A1-20180712-C00336
or a salt thereof.
4. The compound of claim 1 which is a compound of formula (Ib):
Figure US20180194731A1-20180712-C00337
or a salt thereof.
5. The compound of claim 1 which is a compound of formula (Ic):
Figure US20180194731A1-20180712-C00338
or a salt thereof.
6. The compound of claim 1 which is a compound of formula (Id):
Figure US20180194731A1-20180712-C00339
or a salt thereof.
7-9. (canceled)
10. The compound of claim 1 which is a compound of formula (Ig):
Figure US20180194731A1-20180712-C00340
wherein:
R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
11. The compound of claim 1 which is a compound of formula (Ih):
Figure US20180194731A1-20180712-C00341
wherein:
R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
12. The compound of claim 1 which is a compound of formula (Ii):
Figure US20180194731A1-20180712-C00342
wherein:
R is selected from F, Cl, deuterium, methyl, trifluoromethyl, methoxy, and trifluoromethoxy; or a salt thereof.
13-17. (canceled)
18. A pharmaceutical composition comprising a compound as described in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
19. (canceled)
20. A method for inhibiting the activity of SIRT2 in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in claim 1.
21-28. (canceled)
29. The compound of claim 1 wherein D is phenyl that is substituted with —NRaRb.
30. The compound of claim 29 wherein Ra and Rb together with the nitrogen to which they are attached form an azetidinyl, morpholino, piperazino, pyrrolidino or piperidino, wherein any a azetidinyl, morpholino, piperazino, pyrrolidino, 1,1-(dioxido)thio-morpholino and piperidino is optionally substituted with one or more groups independently selected from halo, oxo, and (C1-C4)alkyl.
31. The compound of claim 29 wherein Ra and Rb together with the nitrogen to which they are attached form an morpholino, piperazino, pyrrolidino or piperidino, 2-oxomorpholino, 2-oxopyrrolidino, 2-oxopiperidino, 4-methylpiperazino, or 1,1-(dioxido)thio-morpholino.
32. The compound of claim 1 wherein D is pyridyl that is optionally substituted with one or more groups Rz independently selected from halo, deuterium, nitro, hydroxy, cyano, carboxy, —NRaRb, —C(═O)NRaRb, —N—S(O)2Ra, —NRaC(═O)NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C3-C15)carbocycle, aryl, aryloxy, and heteroaryl, wherein any (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkanoyl, (C1-C4)alkoxycarbonyl, (C3-C15)carbocycle, and (C1-C4)alkanoyloxy of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, deuterium, —NRaRb, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, aryl, aryloxy, and heteroaryl, wherein any aryl, aryloxy, and heteroaryl of Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, halo, nitro, cyano, hydroxy, —NRaRb, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C4)haloalkyl, Rx, and (C1-C4)haloalkoxy.
33. The compound of claim 1 wherein D is pyridyl that is optionally substituted with one or more groups Rz independently selected from aryl and heteroaryl, wherein any aryl and heteroaryl is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, (C1-C4)alkyl, (C1-C4)alkoxy, and (C1-C4)haloalkyl.
34. The compound of claim 1 wherein D is pyridyl that is substituted with one or more groups Rz independently selected from phenyl, furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) and quinolyl (or its N-oxide), wherein any Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, (C1-C4)alkyl, (C1-C4)alkoxy, and (C1-C4)haloalkyl.
35. The compound of claim 1 wherein D is pyridyl that is substituted with one or more groups Rz independently selected from phenyl, furyl, pyrazolyl, pyrrolyl, and thienyl, wherein any Rz is optionally substituted with one or more groups independently selected from the group consisting of halo, deuterium, (C1-C4)alkyl, (C1-C4)alkoxy, and (C1-C4)haloalkyl.
36. A compound selected from the group consisting of:
Figure US20180194731A1-20180712-C00343
Figure US20180194731A1-20180712-C00344
Figure US20180194731A1-20180712-C00345
or a salt thereof.
37. A compound selected from the group consisting of:
Figure US20180194731A1-20180712-C00346
Figure US20180194731A1-20180712-C00347
Figure US20180194731A1-20180712-C00348
Figure US20180194731A1-20180712-C00349
or a salt thereof.
US15/811,490 2015-06-26 2017-11-13 Therapeutic compounds Abandoned US20180194731A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/811,490 US20180194731A1 (en) 2015-06-26 2017-11-13 Therapeutic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185417P 2015-06-26 2015-06-26
US15/192,728 US9951019B2 (en) 2015-06-26 2016-06-24 Therapeutic compounds
US15/811,490 US20180194731A1 (en) 2015-06-26 2017-11-13 Therapeutic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/192,728 Continuation US9951019B2 (en) 2015-06-26 2016-06-24 Therapeutic compounds

Publications (1)

Publication Number Publication Date
US20180194731A1 true US20180194731A1 (en) 2018-07-12

Family

ID=57601879

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/192,728 Active US9951019B2 (en) 2015-06-26 2016-06-24 Therapeutic compounds
US15/811,490 Abandoned US20180194731A1 (en) 2015-06-26 2017-11-13 Therapeutic compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/192,728 Active US9951019B2 (en) 2015-06-26 2016-06-24 Therapeutic compounds

Country Status (1)

Country Link
US (2) US9951019B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872243B (en) * 2018-08-31 2023-03-31 四川科伦博泰生物医药股份有限公司 Sulfonamide compound, preparation method and application thereof
CN112110829B (en) * 2019-06-19 2023-08-01 复旦大学 A small molecular compound capable of binding to α-synuclein aggregates, its preparation method and use
CN116829542A (en) * 2021-01-29 2023-09-29 韩国化学研究院 Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient
GB202215290D0 (en) * 2022-10-17 2022-11-30 Univ Durham Treatment of leishmaniasis
CN119039104A (en) * 2024-06-07 2024-11-29 四川奥邦古得药业有限公司 Preparation method of high-purity dexbornyl alcohol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000008A (en) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
US20080221195A1 (en) * 2006-12-13 2008-09-11 Lars Wortmann 1,2-diarylacetylene derivatives of acyltryptophanols

Also Published As

Publication number Publication date
US9951019B2 (en) 2018-04-24
US20160376238A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
US9951019B2 (en) Therapeutic compounds
US10494355B2 (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US9944589B2 (en) Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A
US10538498B2 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP5575646B2 (en) 4- (4-Pyridinyl) -benzamide and their use as ROCK activity modulators
RU2571414C2 (en) Cyclopropane compounds
US11530213B2 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
EA037257B1 (en) Novel apelin receptor agonists and methods of use
NZ509310A (en) N,N-substituted cyclic amine derivatives as calcium channel antagonists
EP2760443A1 (en) Sulfonamide compounds and their use in the modulation retinoid - related orphan receptor
WO2013106761A2 (en) Antimicrobial agents
EP2906539B1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
US12459899B2 (en) Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
US10882837B2 (en) Amide compounds and use thereof
JP6869571B2 (en) Pyridinone compounds and their uses
US20140350024A1 (en) Antimicrobial agents
WO2021247921A1 (en) Benzothiazole compounds and uses thereof
TW201811760A (en) Novel cyclopropyl derivatives
WO2022003712A1 (en) Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION